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Abstract
The anilinoquinazoline compounds have proven to be effective in current cancer treatment
as EGF and VEGF RTK inhibitors. They were also excellent candidates for
radiopharmaceutical development (with 18F, 123I and 11C) due to the precedence of halogen
substituents present in active compounds and the ease of synthesis.

A series of chemical precursors and standards were synthesized in preparation for
radiochemical synthesis and biological evaluation. The Series I synthesis yielded the
fluorine standards [36], [37] and their tosylate precursors [39], [40] in eleven steps, while
the iodine standard [47] and stannane precursor [48] were obtained through the five step
Series II synthesis. The carbon precursors and standards [13], [42] - [46] were also
produced during Series I and Series II syntheses respectively.

Radiolabelling of the fluorine-18 derivatives [26], [27] using Kryptofix 222 was achieved
in 30-38% RCY. These yields had improved significantly with changes to solvent (DMA),
base (K2C2O4) and higher reaction temperature (150 °C). The iodine-123 derivative [27]
was also successfully synthesised using electrophilic radioiodination, giving both cis and
trans isomers in 71% RCY (E:Z = 8:1).

In vitro evaluation of the fluorine derivatives [36], [37] in a kinase assay (including EGFR,
VEGFR (KDR and Flt1), FGFR, PDGFR, IGFR and Akt) showed significant activity and
selectivity for EGFR and VEGFR. Since EGFR had a strong inhibition profile, an IC50 was
obtained for this RTK, revealing IC50 values of 1.2 nM [36] and 3.4 nM [37]. In vivo
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imaging and biodistribution studies of the radioiodinated compound [30] were performed in
rats expressing a mammary adenocarcinoma EGFR tumour model. There was some uptake
of [30] in the tumour, but also signs of in vivo metabolism and deiodination.

In addition, structure-based drug design was used to investigate the EGF and VEGF
receptor

targets,

gaining

further

insight

into

developing

RTK

inhibitors

as

radiopharmaceuticals. The crystal structures of each receptor were analysed, to find both
conserved regions within the binding pockets and the differences which could provide
selectivity in drug design. AutoDock studies also revealed key binding patterns within each
receptor. For example, the anilinoquinazoline compounds docked into EGFR with the
aniline group reaching into the hydrophobic pocket, while the 6,7-alkoxy chains stretched
along

the

edge

of

the

binding

pocket,

interacting

with

residues

such

as

Lys721/Asp831/Phe832 (hydrophobic pocket) and Gly772/Cys773 (edge). Preliminary
VEGFR docking studies showed a more diverse binding pattern throughout the open
channel-like binding area with key binding residues, Glu915 and Cys917.

Docking analysis was also performed for the target molecules, including the fluorine and
iodine derivatives. Very good results were obtained for both fluorine compounds [36], [37]
in the EGFR, which was consistent with initial in vitro evaluation. The iodine derivative
was not as well suited to the EGFR due to the bulkier iodoethenyl substituent on the
aniline, with slightly better results obtained in VEGFR. Therefore, the fluorine derivatives
may have greater potential as radiopharmaceuticals.

xvi

Chapter 1: Introduction

1.1 Targeting Growth Factor Receptor Tyrosine Kinases in Cancer
Treatment
Cancer is a disease which arises as a consequence of an imbalance between the rate of cell
proliferation and the rate of apoptosis (programmed cell death). Abnormal cellular signal
transduction pathways play a vital role in this imbalance and therefore contribute to
malignant transformation.1 It is the receptor tyrosine kinases (RTKs) that govern these
signaling pathways for cellular processes such as proliferation, migration, metabolism,
differentiation and survival.2 Altered RTKs contribute to signaling pathway deregulation
through:3-6
(a)

Overexpression of normal growth factor RTKs

(b)

Overproduction of growth factor ligands (causing activation of normal receptors)

(c)

Development of RTK mutants (receptors constitutively active without ligands)

This has been shown to cause the development and progression of human cancers, giving
rise to RTKs and their growth factor ligands becoming rational drug design targets.7

Consequently, the growth factor RTKs represent an ideal molecular target as they are firstly
differentially expressed and secondly differentially functional in tumour and non tumour
tissues,8 as outlined below.
1. Growth factor RTKs are overexpressed in many different cancer cell lines. For example:
1

•

Epidermal Growth Factor Receptor (EGFR) overexpression occurs in cancers such
as breast, lung, colorectal, pancreatic, renal, ovarian, cervical, hepato-cellular,
gastric, oesophageal, head and neck, prostate and gliomas;8-12

•

Vascular Endothelial Growth Factor Receptor (VEGFR) overexpression occurs in
cancers such as colon adenocarcinomas, multiple myelomas and glioblastomas13-15

2. While phosphorylation is used throughout the body as a key step in cellular regulation,
this is mostly carried out on serine/threonine residues, as opposed to the regulation of
growth factor RTKs which is characterized by tyrosine phosphorylation.16 This specificity
means that the growth factor RTKs provide an excellent target to stop the uncontrolled
cellular signaling that signifies cancer.

1.2 Growth Factor Receptor Tyrosine Kinases and Cell Signaling
The crucial role of growth factors and their receptors (RTKs) in oncogenesis involves the
regulation of cell growth and differentiation, which is maintained through the initiation of
cell signaling.7,16-19

Growth factors are polypeptide ligands which bind to the transmembrane RTKs to
transduce extracellular signals into intracellular responses using a cell signaling cascade
(Figure 1.1).4

2

3

Figure 1.1: Growth Factor Receptor Tyrosine Kinase Cell Signaling: A) Inactive transmembrane growth factor receptor tyrosine kinase (RTK) before ligand
binding; B) Once the growth factor ligand binds (1), receptor dimerisation is initiated (2) which activates the tyrosine kinase region and allows ATP binding to
occur (3). This leads to the process of phosphorylation (4) followed by signal transduction (through the interaction of adapter proteins with the receptor docking
sites and other components further downstream) to the cell nucleus (5) which instigates cell growth and/or differentiation. Adapted from refs4,6,20.

Growth factor RTKs consist of an extracellular domain containing a ligand binding site, a
single hydrophobic transmembrane alpha helix and an intracellular (cytosolic) domain. It is
this intracellular domain which includes the tyrosine kinase region (Figure 1.1A).1

The process of growth factor RTK cell signaling is demonstrated in Figure 1.1B, with step
1 involving stimulation of tyrosine kinase activity by ligand (e.g. growth factor) binding
and subsequent receptor dimerisation (Figure 1.1B, Step 2).7 This results in the binding of
an ATP molecule (Figure 1.1B, Step 3) which the receptor utilises to incorporate phosphate
into several key tyrosine residues in the activation loops of their catalytic domain, a process
called autophosphorylation (Figure 1.1B, Step 4).4,7 This leads to other sites in the cytosolic
domain becoming phosphorylated, such that the resulting phosphotyrosines can serve as
docking sites for adapter proteins.1 Finally, signal transduction is completed as the adapter
proteins either phosphorylate effector molecules or couple the receptors of other
components of the pathway (Figure 1.1B, part 5).1 This entire process relays signals of
growth and differentiation to the cell nucleus.

1.2.1 Types of Growth Factors and their Receptors
The existence of growth factors was implied in experimental work of the early 1900s, but
the nerve growth factor (NGF) was the first to be identified in the 1950s.7,21 Since the initial
discovery, this family has been constantly expanding with the identification of numerous
structurally related, yet role-specific growth factors.

4

Each growth factor (GF) has corresponding receptors which belong to the receptor tyrosine
kinase (RTK) family. While there are approximately 20 known classes of RTKs,9,22-23 the
main GF RTKs are summarised in Figure 1.2. The Epidermal Growth Factor/Receptor
(EGF/R) and Vascular Endothelial Growth Factor/Receptor (VEGF/R) families are
highlighted due to their particular roles in oncogenesis and will be discussed in the
following sections (1.3.1.1 and 1.3.1.2).

Figure 1.2: Simplified Growth Factor Receptor Tyrosine Kinase Family Tree: Major branches represent
Growth Factor/Receptor families: Nerve Growth Factor (NGF), Insulin Growth Factor (IGF), Epidermal
Growth Factor (EGF), Vascular Endothelial Growth Factor (VEGF), Platelet Derived Growth Factor (PDGF)
and Fibroblast Growth Factor (FGF). Each family consists of a number of different receptors, e.g. EGF has 4
known receptors: EGFR, Neu, ErbB3, ErbB4 and VEGF has 3 known receptors: Flt1, KDR, Flt4. Adapted
from refs23-25.
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1.2.1.1 Epidermal Growth Factor/ Receptor
The Epidermal Growth Factor (EGF) was the first growth factor to be purified16 and is well
characterized.7,21,26 It is a 6 kDa polypeptide which consists of 53 amino acid residues.26
The interaction between EGF and its transmembrane receptor, EGFR, gives rise to several
important cellular functions such as proliferation, differentiation, survival and metastasis.2730

The transmembrane EGFR is a family of receptor tyrosine kinases, consisting of fourϒ

different receptor members:7-8,27,31
(i) EGFR
(ii) Neu
(iii) ErbB3
(iv) ErbB4

All of these receptors have a similar structure, sharing homology in their kinase domain,
but differ slightly in their extracellular domains and carboxy-terminal end tails.1 The EGFR
structure can be defined as a 170 kDa transmembrane protein with a single polypeptide
chain consisting of 1186 amino acids.10 The hydrophobic transmembrane segment (23
amino acids) is attached to the intracellular tyrosine kinase region that is common to all GF
receptors.1,26,32

ϒ

The common names for each Epidermal Growth Factor Receptor are listed above. They can also be referred
to as (i) ErbB1 or HER1; (ii) ErbB2 or HER2; (iii) HER3; (iv) HER4.
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1.2.1.2 Vascular Endothelial Growth Factor/ Receptor
The discovery of Vascular Endothelial Growth Factor (VEGF) occurred decades later while
performing an analysis of vascular endothelial cell proliferation.16 VEGF, a 45 kDa
glycoprotein, interacts with the 220 kDa transmembrane protein VEGFR to induce its
distinctive biological response.33 This interaction is known to stimulate mitogenesis,
enhance vascular permeability and its most important role is in the regulation of
angiogenesis.34-41 Pathological angiogenesis in tumours is mediated by VEGF/R.37,42 Like
EGFR, VEGFR is a family of receptor tyrosine kinases, in this case consisting of three
different receptor members:1,7,43
(i) Flt1
(ii) KDR
(iii) Flt4

Of these receptors, KDR (VEGFR2) performs the major role in mediating angiogenesis and
likewise, EGFR (HER1) is the most predominant in cell growth and survival.31,42,44,45 Due
to these key roles, the EGF and VEGF receptors have become promising targets in cancer
research. This has lead to the discovery and development of EGF/VEGF receptor tyrosine
kinase inhibitors.

1.3 Current Cancer Research
Current research into the treatment of cancer has evolved from cytotoxic, non specific
drugs to molecularly targeted therapy. This is due to an increased understanding of the


The common names for each Vascular Endothelial Growth Factor Receptor are listed above. They can also
be referred to as (i) VEGFR1; (ii) Flk1 or VEGFR2; (iii) VEGFR3.
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molecular mechasisms involved, including cell proliferation, motility, invasion, metastasis
and angiogenesis.46

The receptor tyrosine kinases (RTKs) are one of the more effective molecular targets
investigated in recent years. They normally regulate cellular processes, however, once
altered, they contribute to the development of numerous cancers.3,4 Furthermore, in vitro
and in vivo studies show that inhibition of these kinases retards cancer cell growth.1,8

RTK inhibition can be targeted either at their extracellular ligand-binding domain, e.g.
monoclonal antibodies (MAbs), or at the intracellular ATP binding site e.g. small molecule
tyrosine kinase inhibitors (TKIs).7 Many of these types of inhibitors have undergone
clinical trials with some receiving FDA approval for cancer treatment in the last few years,
e.g. Gefitinib/Iressa and Erlotinib (small molecule EGFR TKIs) and Bevacizumab
(MAb).8,47,48

However, these clinical studies and other supporting research show that problems still need
to be addressed. For example, only some patients treated with TKIs are likely to benefit or
could have limited effectiveness.49 It is thought that both genetic mutations in the receptor
tyrosine kinases and upregulation of alternative molecular pathways8,20,50 contribute to an
individual’s insensitivity or resistance to TKIs.

To overcome these difficulties, the focus is now on multitargeted therapy, either through
multiple RTK targets20,22,51,52 or combining TKIs with chemo/radiotherapy.53,54,55
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Additionally, there is a need for the development of biomarkers to determine which patients
will benefit from therapy.47,48,56

1.4 Known Growth Factor Receptor Tyrosine Kinase Inhibitors
Small molecules capable of selective inhibition of receptor tyrosine kinase (RTK)
activation in the cell signalling cascade have been the target of intense research. The focus
has been on ATP competitive inhibitors57 due to ATP’s key role in the signaling pathway
(see Figure 1.1B, step 2). While it was initially thought that the structural homology of
growth factor ATP binding sites would lead to decreased selectivity, the discovery process
resulted in the identification of numerous ATP competitive, selective GF RTK inhibitors.58
The development of these inhibitors progressed from natural products to various small
molecule GF RTK inhibitors.

1.4.1 Natural Product Inhibitors
The first RTK inhibitors identified were the non-selective, weakly binding natural products
such as Staurosporine [1], Genistein [2] and Erbstatin [3] (Figure 1.3), which act as
reversible competitive inhibitors at the ATP substrate binding site.58,59
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Figure 1.3: Identification of the first RTK inhibitors: natural products Staurosporine [1], Genistein [2] and
Erbstatin [3] and staurosporine derivative, CGP-52411 [4].

Of the subsequent natural product derivatives developed, the most notable was CGP-52411
[4] (Figure 1.3), which showed reversible competitive ATP site inhibition at 0.3 μM and
was selective for the EGFR. More importantly, CGP-52411 [4] showed good inhibition of
tumour growth.58

1.4.2 Small Molecule Growth Factor Receptor Tyrosine Kinase
Inhibitors
Mass screenings followed by structure-activity relationship (SAR) studies also resulted in
the discovery of many small molecule RTK inhibitors including pyridopyrimidine based
structures e.g. [5] and [6], and oxindole based structures e.g. [7] (Figure 1.4).58,59 More
recently, further derivatives such as SU-6668 [8] and SU-11248 [9] (both derived from
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initial oxindole based structure), the phthalazine based PTK787 [10] and the
pyrrolopyrimidine based AEE788 [11] (see Figure 1.4) have been ascertained.
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Figure 1.4: Small molecule RTK Inhibitors discovered from mass screenings and SAR studies: [5] PD069896 – EGFR inhibitor, [6] PD-158780 – EGFR inhibitor, [7] SU-5416 – VEGFR inhibitor, [8] SU-6668 –
VEGFR inhibitor, [9] SU-11248 – VEGFR inhibitor, [10] PTK787 – VEGFR inhibitor, [11] AEE788 –
inhibits both EGFR and VEGFR.

PD-069896 [5] exhibited selective inhibition of EGFR at a concentration of 1 μM and was
seen to be ATP competitive.59 From studies based on the general pyridopyrimidine
structure, the potent (IC50 = 8 pM) EGFR selective compound PD-158780 [6] was
discovered. This compound was tested in vivo showing delayed tumour growth for 12-15
days.58
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SU-5416 [7] was one of the first RTK inhibitors that was found to be selective for VEGFR.
Inhibition by this indole based compound was seen at 40-70 nM, but most importantly this
compound effectively blocked tumour growth in mice.60,61 While initial results appeared
promising, SU-5416 has not progressed beyond Phase II-III clinical studies, due to
inadequate efficacy and the presence of severe side effects.62-66 SU-6668 [8] showed a
similar activity and selectivity profile to [7], however clinical trials also discontinued due to
toxicity.62-63

SU-11248 [9] has undergone significant clinical testing, receiving FDA approval in January
2006 for treatment of advanced renal cell carcinoma (RCC) and gastrointestinal stromal
tumors.67-69 Evaluation of SU-11248 in metastatic breast cancer patients has also begun.62

Another type of VEGFR inhibitor which is active in the submicromolar range is the
phthalazine PTK787 [10]. This inhibitor is currently in Phase III clinical trials.69,70 The dual
inhibitor, AEE788 [11], shows nanomolar activity against both EGFR and VEGFR (2 nM
and 77 nM respectively) and is currently in phase I clinical trials.62,71

1.4.3 Anilinoquinazolines
The initial discovery of the potent anilinoquinazoline class of compounds was through
CAQ [12] and PD-153035 [13] (Figure 1.5) showing inhibition of 27 nM and 29 pM
respectively. Both were ATP competitive and showed selectivity for the EGFR.58,59,72
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This discovery was followed by extensive SAR studies of the 4-anilinoquinazolines by
synthesising a series of compounds with varied substituents on the quinazoline and aniline
groups.73 The results indicated that maximum activity against EGFR was obtained with 6,7alkoxy substituents on the quinazoline structure and the substitution of halogens on the
aniline group, with meta substitution showing the highest activity. The highest selectivity
was seen in the compound that contained 6,7-diethoxy and 3'-bromo substituents [14]
(Figure 1.5).73
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Figure 1.5: Discovery and SAR of 4-anilinoquinazolines: CAQ [12], PD153035 [13], [14] - EGFR selective,
[15] - VEGFR selective, [16] - General SAR structure of EGFR/VEGFR inhibitors (where R1=R2=alkoxy
groups, R3=halogen/alkyl substituents).

Subsequently, the 4-anilinoquinazolines have also been studied as potent VEGFR tyrosine
kinase inhibitors. SAR studies for the anilinoquinazoline inhibitors against the VEGFR
showed that while the 6,7-substitution was still important in the quinazoline, changing the
methoxy group to a methoxyethoxy group in the 7-position significantly increased
activity.74 Further, 2',4'-disubstitution of halogens in the aniline group was more favourable
13

and the addition of a meta hydroxyl group also improved activity. The most potent
compound in this study contained 6-methoxy-7-methoxyethoxy and 4'-chloro-2'-fluoro-5'hydroxy substituents [15].74 Combining these studies, a general structure for small
molecule inhibitors of EGFR/VEGFR is summarized by compound [16] (Figure 1.5).

1.4.3.1 Clinical Development of the Anilinoquinazolines
In more recent years, examples from the anilinoquinazoline class of compounds have
entered clinical trials.75-77 The most successful to date being Iressa (ZD1839) [17] and
Erlotinib (CP-358774/OSI774) [18] (Figure 1.6), which received FDA approval for the
second and third-line treatment of non-small cell lung cancer (NSCLC).8 Both are potent
EGFR inhibitors having IC50 values of 5 nM and 2 nM respectively.58,78-80

Some other noteworthy inhibitors are CI1033 [19], ZD6474 [20], ZD4190 [21] and
AZD2171 [22] (Figure 1.6). The former is a potent, selective inhibitor of the EGFR
tyrosine kinase family with studies showing not only significant antitumour activity but
increased sensitivity when used in combination with radiation therapy.77,81-83
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Figure 1.6: Anilinoquinazolines in clinical development: [17] Iressa (ZD1839) - EGFR inhibitor, [18]
Erlotinib (CP-358774/OSI774) - EGFR inhibitor, [19] CI1033 - EGFR inhibitor, [20] ZD6474 – inhibits both
VEGFR and EGFR, [21] ZD4190 - VEGFR inhibitor, [22] AZD2171 – VEGFR inhibitor.

ZD6474 [20] is an effective VEGFR inhibitor (KDR IC50 40 nM) with additional activity
against EGFR (IC50 500 nM).84 Since this is a multitargeted GF RTK inhibitor, it may lead
to increased antitumour activity through the inhibition of both pathways.53,85 Some
preliminary studies have already revealed improved outcome using ZD6474 [20] over first
generation EGFR (that often form resistance).77

The VEGF RTK inhibitor ZD4190 [21] (Figure 1.6), has shown both in vitro activity (KDR
IC50 0.03 μM) and in vivo activity in tumour cells such as breast lung, prostate and
15

ovarian.84,86 AZD2171 [22] is a potent ATP-competitive VEGF RTK inhibitor (KDR IC50
1

nM)

that

has

shown

inhibition of

VEGF-induced

proliferation,

VEGFR-2

phosphorylation in HUVEC and also angiogenesis inhibition in vivo.62,63,70,87

Therefore it can be seen that the 4-anilinoquinazolines are effective as inhibitors of both the
EGF and VEGF receptor tyrosine kinases. Since current cancer research is moving towards
dual inhibition of these kinases,51-53 further development and optimisation of 4anilinoquinazoline derivatives could be beneficial. They are also an appealing
pharmaceutical target due to their synthetic accessibility.

1.5 Radiopharmaceuticals and their Use in Cancer Research/Drug Design
One of the key issues in current cancer research lies in being able to predict which patients
will benefit from treatments (see Section 1.1).47,48 Most approved drugs (e.g. Iressa,
Erlotinib) will only be effective in a small percentage of patients and others may develop
resistance.49 Therefore, determining the biological/biochemical features of an individual’s
tumour cells through tools such as biomarkers could optimise treatment by establishing
patients who will benefit from a particular therapy.47,48,88 Radiopharmaceuticals and
molecular imaging have the ability to perform this role among others and truly provide
personalised medicine.89-91

Radiopharmaceuticals are drugs that contain a radionuclide♣ with suitable emission
properties for in vivo tracking.92 They have specific characteristics (e.g. the ability to bind

♣

an unstable atom that undergoes radioactive decay to regain its stability 92
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to a specific receptor or mimic a metabolite used in the body) which make them useful in
the diagnosis, treatment and study of diseases.93 Since growth factor receptors are
overexpressed in tumour cells,94,95 targeting of the GF RTK with radiopharmaceuticals not
only provides potential therapeutics for cancer, but also a promising avenue for diagnostic
tools through the use of imaging. This is due to their unique ability to evaluate alterations in
the metabolism of tumour cells before any anatomical or structural changes are detected.96

The distinguishing feature of whether a radiopharmaceutical is used for diagnosis or
therapy is the type of radiation emitted from the radionuclide present.92 For therapeutic
purposes, the radionuclide emits radiation capable of destroying the diseased tissue.
Diagnosis involves radionuclides emitting radiation that can be measured externally to give
information about the disease.97 Therefore radiolabelled GF RTK inhibitors cannot only be
used to detect tumour growth and metastasis but also assist with disease monitoring or
evaluation of upcoming novel GF RTK therapies developed by the pharmaceutical
industry.89 Furthermore, this will impact upon patient management and improve our
understanding and evaluation of the disease process over time.96

1.5.1 Diagnostic Radiopharmaceuticals
Diagnostic imaging involves the detection and spatial mapping of the radiation emitted by a
radiopharmaceutical. Most imaging systems for nuclear medicine use the principle of
scintillation detection (Figure 1.7) which consists of a crystal, typically sodium iodide with
traces of thallium, that can absorb a gamma photon and as a result emits light photons.98,99
A coupled photomultiplier tube (PMT) then converts the brief pulse of light to a pulse of
17

electricity. After the position and energy of the gamma ray source has been determined by
analysis of the electrical output signals, a projectional or planar image can be produced.99

Figure 1.7: Scintillation Detection. The source (organ/tissue) emits gamma photons, some of which enter the
collimator and are detected by the scintillation crystal. After absorption of a gamma photon, the crystal emits
a light photon. This is converted to an electrical signal by photomultiplier tubes (PMTs). Position and energy
analysis is determined through the output signal sent to a computer. Adapted from ref 99.

Scintillation cameras can be used for imaging, but they are limited because they depict
images of 3D radiopharmaceutical distributions in a 2D display. Consequently the images
obtained are obscured in the third dimension.99

Emission computed tomography (ECT) is a technique which attempts to give an improved
3D representation of the target tissue. It reconstructs a set of two dimensional projections,
based on rigorous mathematical algorithms, acquired at many different angles around the
18

patient.

99

This process achieves greater resolution and delineation of the structural and

functional information. Furthermore, important physiological and pathological processes
may be measured non-invasively by ECT as it has the potential to give quantitative
measurements of pharmaceutical concentrations.99 There are two types of ECT that have
been developed: positron emission tomography (PET) and single photon emission
computed tomography (SPECT).

1.5.1.1 PET
The most commonly used radionuclides for PET are

11

C,

13

N,

15

O and

18

F (Table 1.1).90

Carbon, nitrogen and oxygen are the most appealing as they are elements of life and can be
directly substituted for their stable counterparts without influencing the bioactivity of the
molecule.96 However due to the short half lives of these radionuclides (see Table 1.1) they
are not always practical in radiopharmaceutical development. This leads to the use of
radionuclides which have longer half lives e.g. fluorine.99 Since halogens are not usually
present in biological compounds or pharmaceuticals, they must be incorporated into the
target structure such that its overall affinity and selectivity is not altered significantly. For
example, bioisosteres such as H or OH groups in the active target molecule can be
substituted with 18F.100
Table 1.1: Physical Properties of Positron Emitters used in PET.

Radionuclide
Fluorine-18
Carbon-11
Nitrogen-13
Oxygen-15

Half-Life
(min)
110
20.4
9.96
2.1

Maximum Energy
(MeV)
0.635
0.96
1.19
1.72

Positron Range in
Water (mm)
2.4
4.1
5.4
8.2
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PET utilises positrons which are positively charged electrons and when emitted from a
radionuclide they only travel a few millimetres in tissue before losing kinetic energy and
colliding with an electron. This collision causes both particles to be annihilated,
transforming their mass into two 511 keV photons (gamma rays) which move in opposite
directions to one another (Figure 1.8).99

Figure 1.8: Basis of PET detection: positron – electron annihilation causes the release of two 511 keV
photons (gamma rays) which move in opposite directions (180o) to each other.

The pair of gamma rays are collected simultaneously by a circular array of detectors. The
origin of the gamma rays must be on a line joining the two detection points and can be
determined by reading their relative intensities.99,101 Computer analysis enables the
reconstruction of the data to produce images of the distribution of the positron emitter in
the tissue.

1.5.1.2 SPECT
SPECT uses gamma emitting radionuclides such as

99m

Tc and

123

I. These isotopes emit a

single photon with gamma energies between 70-250 keV resulting in high detection
20

efficiency.99 In particular,

123

I is ideally suited for use in gamma camera imaging with

gamma ray energy of 159 keV and a longer half life of 13.1 hours.96 When designing
SPECT radiopharmaceuticals where the target compounds do not contain iodine,

123

I can

act as a bioisostere and replace OH or CH3 groups.100

The detection system of a typical SPECT gamma camera consists of one to three detector
heads mounted on a gantry, and an on-line computer system for acquisition and data
display. The detector head rotates around the patient in small angle increments for either
180o or 360o angular sampling. The collected data can produce transverseℵ, sagittal# and
coronal∗ images.92

Superior image resolution is most often achieved with PET due to the simultaneous
collection of gamma ray pairs,89,101 however the longer half lives associated with SPECT
radionuclides provide a different advantage. It allows the radiopharmaceuticals to be
produced in centralised radiopharmacies and transported to the hospital for use, as
compared to PET where there is a necessity for a cyclotron∝ near the hospital for onsite
production.99

ℵ

A horizontal plane that separates the superior from the inferior, or put another way, the head from the feet
(also known as axial or horizontal) 102
#
A vertical plane (in a front to back direction) that separates the body into left and right halves (also known as
median) 102
∗
A vertical plane that separates the anterior from the posterior, the front from the back (also known as frontal)
102
∝

a type of particle accelerator - Cyclotron beams can be used to bombard other atoms to produce short-lived
positron-emitting isotopes
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1.5.2 Therapeutic Radiopharmaceuticals
Radiopharmaceutical therapy is achieved using a radionuclide with appropriate
physical/chemical properties, which can be attached to the targeting molecules with
effective biological properties.96 Current radionuclide therapy in humans is almost entirely
based on beta particle emitting isotopes, such as the radionuclide

131

I which emits high

energy beta particles (as well as gamma photons) making it useful for cancer therapy.96,97
This is due to the ionising radiation of the beta particles being able to disrupt the vital cell
processes, resulting in cell death.93 Another important feature of the beta particle is that its
path length is only millimetres (maximum of 2.3 mm for

131

I), so the toxic effects can be

limited to the target tissue.96,97

Since the development of the target molecule for therapy depends on the same factors (such
as target specificity/affinity and molecule stability)96 as those required for a diagnostic, the
same

target

molecules

can

be

integrated

into

radiopharmaceuticals incorporating the radionuclide

123

both.

Therefore,

if

effective

I are developed for use in the

diagnostic study of cancer, then substitution with the therapeutic radionuclide 131I could be
potentially employed in therapy. This would prove useful in cancer treatment if the
radiopharmaceutical containing

131

I is selectively taken up by the tumour in high

concentration ratios to destroy the diseased tissue.
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1.5.3 Growth Factor Receptor Tyrosine Kinase Inhibitors as
Radiopharmaceuticals
Many of the GF RTK inhibitors described earlier (section 1.4) were shown to have high
affinity and selectivity for the EGF and VEGF receptors in vitro, but it is their in vivo
action that ultimately determines their potential as diagnostic or therapeutic agents. That is,
the inhibitor must bind effectively to the target (within the tumour cells) while minimizing
binding to non-target organs and tissues.99 Other factors to be considered in vivo are the
metabolic fate and clearance of the compound from non-target tissues and blood. The
development of an effective diagnostic or therapeutic agent requires the optimisation of all
of these factors.

There has been some research into

18

F,

11

C and

124

I radiolabelled analogues of known

inhibitors such as Iressa [23], and PD153035 [24] (Figure 1.9).103-111 In the reported studies,
many of the radiolabelled derivatives displayed good biochemical properties and high
inhibitory potency in vitro, however they were unsuitable for in vivo imaging, either due to
low tumour uptake or rapid metabolism.110 One of the more recent studies used healthy
human volunteers to investigate the biodistribution and metabolism of [C-11] PD153035
[24]. Low uptake of [24] in the lungs of healthy humans suggested that it may be a useful
radiotracer for lung cancer, however widespread distribution in the abdominal region may
limit its usefulness in the imaging of abdominal tumours and liver/lymph metatasis.112
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Figure 1.9: Previously developed radiolabelled anilinoquinazolines: [F-18] Iressa [23], [C-11] PD153035
[24], [I-124] ML08 [25].

Some attempts had been made to enhance tumour uptake through greater in vivo
optimisation for EGFR and VEGFR via derivatisation of these compounds, such as
employing acrolein or acetamide substituents (e.g. ML08 [25], Figure 1.9) to promote
irreversible intracellular binding. However, these compounds also displayed average in vivo
pharmacokinetic properties, primarily due to considerably high non-specific binding and
low clearance of radiometabolites.105,113

Further derivatisation and investigation may result in a more effective in vivo imaging
agent. The presence of the methoxy/ethoxy substituents on the 6 and 7 positions of the
quinazoline core (SAR structure [16], Figure 1.5) allows for the incorporation of
radionuclides such as

11

C. These substituents also provide an enormous potential for not

only a rapid and convenient incorporation of

18

F but opportunities to modify the overall

molecule’s pharmacokinetics with respect to lipophilicity and metabolic profile. The
halogens and alkyne substituent on the aniline ring also make it ideal for iodine-123 and F18 radiolabelling with little change to the inhibitor’s bioactivity. Previous studies have also
utilized this key fact, developing a number of 18F labelled derivatives of anilinoquinazoline
GF RTK inhibitors.9,105-107 However the incorporation of F-18 on this unactivated aniline
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ring system required complex multi-step syntheses from the initial F-18 incorporation,
resulting in low yields and difficult processing.104,106,107,114 Optimisation of the
radiochemical synthesis involving the aniline substituent could also contribute to the
success of the radiopharmaceutical. Therefore, the anilinoquinazoline GF RTK inhibitors
can be seen as a prospective area for novel radiopharmaceutical development using 11C, 18F
and 123I.

1.6 Structure-Based Drug Design & Computer Aided Modeling
Techniques
Structure-based drug design currently forms an integral part of the drug discovery process,
due to the improvement of structural determination techniques in recent years.115,116 X-ray
crystallographic methods provide the most common source of structural information for
drug design, in the form of crystal structures.115

Numerous crystal structures have been publicly available since the inception of the RCSBφ
database in the early 1970’s.118,119 These include the tyrosine kinase domains of EGFR and
VEGFR which have been elucidated in more recent years.120-125 Greater understanding
about the binding site and mode of binding for inhibitors of the EGF and VEGF receptors
can be provided by these structures. For example, the crystal structure of the EGFR kinase
domain in complex with Erlotinib [18], 1M17♦ reveals the binding position within the
cleft/pocket and some of the key hydrogen bond interactions involved (Figure 1.10).120

φ
♦

Research Collaboratory for Structural Biology117
Each crystal structure has a 4 character pdb reference code on the RCSB database
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(a)

(b)

Figure 1.10: Crystal Structure of EGFR kinase domain with Erlotinib [18] bound: 1M17 (a) Full view of
receptor (ribbon) with inhibitor (line/stick) in binding pocket, (b) detailed view outlining some of the key
hydrogen bond interactions (orange dotted lines).

It is also noted that while sequence alignments of some growth factors have highlighted
conservation amongst the receptor tyrosine kinases, comparative analysis of the EGFR and
VEGFR amino acid sequence and 3D structure is still required. This analysis combined
with binding site information from the EGFR and VEGFR crystal structures could aid in
the development of inhibitors with better affinity and selectivity.

1.6.1 Computer-Aided Drug Design (CADD)
Computational methodologies have become a crucial component of drug design,116
particularly when the structure of the target receptor/protein is known. These computeraided techniques can examine the steric and chemical compatibility of inhibitors with the
receptor binding site.126 Docking is a key computational technique that predicts the bound
conformation of ligands (inhibitors) to the macromolecular target (receptor),119,127
providing tools in hit identification and lead optimisation.116 There are a number of
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applications of these techniques during the development of the radiopharmaceutical targets.
These include the assessment of the key binding areas for EGFR and VEGFR, which
inhibitors show the strongest interaction and would the predicted binding be improved or
impaired if inhibitor structures need to be altered to incorporate a radiolabel (e.g.
18

123

I or

F). Therefore, utilisation of CADD methods could facilitate the refinement of current

target compounds to develop superior inhibitors.

1.7 Project aims
This project aims to develop potential radiotracers based on the known EGFR/VEGFR
quinazoline SAR structure, alongside further investigation into the EGFR/VEGFR binding
sites through CADD methods. To achieve this, the following components are outlined:
•

Synthesise

18

F,

123

I or

11

C radiolabelled 4-anilinoquinazoline derivatives (see Figure

1.11), via their chemical precursors and standards.

HN
O
R1O

R2
N

N

Figure 1.11: General Structure for Radiolabelled Target Compounds (based on the EGFR/VEGFR
quinazoline SAR). 4-Anilinoquinazolines to be synthesized with either fluorine-18/carbon-11 incorporated
into alkyl chains in the R1 position or fluorine-18/iodine-123 incorporated as substituents in the R2 position.

•

Undertake biological evaluation of these compounds, including in vitro testing, in vivo
imaging and biodistribution studies.
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•

Use the biological data to determine their affinity and selectivity for the EGF/VEGF
RTKs and assess their potential as a radiopharmaceutical for cancer.

•

Carry out comparative analysis of the EGF and VEGF receptor sequence/tertiary
structure using computer-aided techniques.

•

Perform inhibitor docking studies, utilising the crystal structures of both the EGFR and
VEGFR kinase domain, with known inhibitors and also testing the current target
compounds.

•

Use the results obtained from CADD studies to refine key features necessary for
binding specificity and affinity in target compounds.

Chapter 2 will summarise the synthesis of the chemical precursors and standards, followed
by subsequent radiolabeling in Chapter 3. The biological evaluation of these compounds
will be discussed in Chapter 4. Finally, structure-based drug design incorporating
computer-aided studies will be covered in Chapter 5.
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Chapter 2: Synthesis of Anilinoquinazoline
Standards and Precursors

2.1 General Synthetic Strategy
The preparation of anilinoquinazoline standards and precursors were required to attain the
target radiolabelled compounds (Figure 2.1), as outlined in Section 1.7.

HN
O
R1O

R2
N

N

Compoundϒ

Radiolabel

R1

[26]

Fluorine-18

CH2CH2 F

R2
18

Br

18

Cl

18

[27]

Fluorine-18

CH2CH2 F

[28]

Fluorine-18

CH2CH2 F

C≡CH

[29]

Fluorine-18

CH3

OCH2CH2 F

[30]

Iodine-123



CH3

18

123

CHCH

Carbon-11

11

CH3

[31]

Carbon-11

11

CH3

Cl

[32]

Carbon-11

11

CH3

C≡CH

[24]

I

Br

Figure 2.1: Target Radiolabelled Compounds [26] – [32]. 4-Anilinoquinazolines to be synthesized with either
fluorine-18/iodine-123/carbon-11 incorporated into the R1 or R2 position, derived from the SAR studies (see
Section 1.4.3, Figure 5).

These could be synthesised via two separate pathways, Series I and II, to yield both the 7alkoxy-6-methoxy- and 6,7-dimethoxyquinazoline derivatives respectively. Both series
ϒ

Throughout this chapter all radiolabelled compounds or syntheses are shown in green, as Chapter 3
provides the radiochemistry discussion.

This derivative has already been developed as a radiotracer,128 however only limited biology studies were
completed until recently.108 Synthetic routes utilised for the other target compounds also provided easy access.
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utilised the key step involving nucleophilic displacement of the chloroquinazoline with
different substituted anilines (eg 3-chloro, 3-bromo, 3-hydroxy and 3-ethynyl) as outlined
in Scheme 2.1.

Cl
N

O

N

R1O

H 2N

R2

R 2 = Br, Cl, OH,
ethynyl

HN
O
R1 O

R2
N

N

key intermediate

anilinoquinazoline product

[33]

[34] Series I: R 1 = benzyl
[35] Series II: R1 = methyl

Scheme 2.1: Key synthetic step for anilinoquinazoline derivatives. Series I is represented by [34] where R1=
benzyl (which is later converted to fluoroethyl); Series II is represented by [35] where R1= methyl. Each
series incorporates different substituted anilines, 3-Br, 3-Cl, 3-OH and 3-ethynyl.

Series I involved the 11 step synthetic pathway, through the 7-benzyloxy-6methoxyquinazoline key intermediate [33] (R1= benzyl), to reach the desired fluoro
substituted anilinoquinazolines and tosylate precursors (see Section 2.2). Series II could be
initiated by a 3 step synthesis, followed by divergent synthetic routes to integrate iodine or
fluorine into the aniline portion of the 6,7-dimethoxy derivatives (see Section 2.3). Also,
some of the Series I and II synthetic intermediates could be used as carbon-11 precursors
and standards (Sections 2.2 and 2.3). All of the anilinoquinazoline targets (Figure 2.2),
which act as standards and precursors for subsequent fluorine/iodine/carbon radiolabelling,
were accessible through the Series I and II synthetic pathways.
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Series I/II
Carbon-11

Series I
Fluorine-18

HN
O
R1

R2

HN
O

N

O

N

Standard

R2
N

R1O

N

Standard

Precursor

[39] R 1=OTs, R 2=Br
[36] R 1=F, R 2=Br
[37] R 1=F, R 2=Cl
[40] R 1=OTs, R 2=Cl
[38] R 1=F, R 2=C ≡CH [41] R 1=OTs, R 2=C ≡CH

Precursor

[44] R 1=H, R2 =Br
[13] R 1=CH 3 , R2 =Br
[42] R 1=CH 3 , R2 =Cl
[45] R 1=H, R2 =Cl
[43] R 1=CH 3 , R2 =C≡ CH [46] R 1=H, R2 =C≡ CH

Series II
Iodine-123 & Fluorine-18

HN
O
O

O

N
N

O
Precursor

Standard
[47] R=I

HN

R

[48] R=Sn(Bu) 3

O

R

N
N

Standard

Precursor

[49] R=F

[50] R=OTs

Figure 2.2: Target Standard and Precursor anilinoquinazoline derivatives. These are accessed through the
Series I & II syntheses.

2.2 Series I Synthesis
The synthesis of the Series I fluorine derivatives [36] and [37], can be accessed through the
key intermediate 7-benzyloxy-4-chloro-6-methoxyquinazoline [51] (Scheme 2.2).74,129 The
coupling of either 3-bromo or 3-chloroaniline∗ to [51] results in the anilinoquinazolines
[52] and [53], which can be cleaved at the C-7 position using TFA, to afford the 7-hydroxy
derivatives [44] and [45].

∗

3-Ethynylaniline was also used towards the synthesis of [38] & [41], however this synthesis will be
discussed separately in Section 2.2.8.1
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[39] R=Br
[40] R=Cl

R
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R2

HN

H[18F], K2.2.2

O
R1

O

F

N
N

[36] R1 =F, R2 =Br / [26] R1 = 18 F, R 2=Br
[37] R 1=F, R2 =Cl / [27] R 1 =18F, R2 =Cl

Scheme 2.2: Proposed synthesis for Series I. Fluorine standards [36] and [37] and their tosylate precursors
([39] and [40]) from the key chloroquinazoline intermediate [51].

The deprotected anilinoquinazolines [44] and [45] can undergo alkylation with
bromoethanol or bromofluoroethane to yield the hydroxyethoxy derivatives [54] and [55]
as well as the fluorine standards [36] and [37]. Conversion of the hydroxyethoxy
derivatives [54] and [55] to their corresponding tosylates can be achieved using
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toluenesulfonyl chloride to give [39] and [40] (Scheme 2.2). These tosylate precursors
allow access to the fluorine-18 radiolabelled derivatives, [26] and [27], through
nucleophilic substitution reactions.

While there have been reports of the synthesis of [36] (Scheme 2.2), no details of the
synthetic route utilised or characterisation data were provided.104,130,131 Therefore, the
complete synthesis of [36] was developed based on available information and incorporated
into the overall synthetic strategy for the anilinoquinazoline target compounds.

2.2.1 Synthesis of 7-Benzyloxy-4-chloro-6-methoxyquinazoline [51]
The key intermediate [51], required for the total synthesis of the fluorine derivatives, was
prepared using the literature procedures74,129 with some modifications (Scheme 2.3).
Briefly, nitration of the commercially available protected benzylvanillin [56] in nitric acid
resulted in 99% yield of the nitrobenzaldehyde [57]. Subsequent oxidation with potassium
permanganate yielded the nitrobenzoic acid [58] in 67% yield, which was converted to the
nitrobenzamide [59] via the acid chloride in 80% yield (Scheme 2.3). The aminobenzamide
[60] was afforded through reduction of the nitrobenzamide [59]. This step proved to be
problematic and will be discussed further in Section 2.2.2.

33

O

O
O

O

H

H

(a)

O

O

99%
[56]

O

NO2

O

(b)

OH

O

67%

[57]

NO2
[58]

(c)

80%

O
O

O

NH2
NH2

O

(d)

O

65%

O

[60]

(e)

NO2
[59]

90%

O

OH
N

(f)

O

N

69%

[61]

NH2

O

Cl
N

O

N

[51]

Scheme 2.3: Synthesis of key intermediate [51]; (a) HNO3, 0 °C, 30 min, 15 °C, 1 hr; (b) KMnO4, acetone, rt,
1 hr; (c) i) SOCl2, reflux, 22 hr, ii) NH3, dioxane, rt, 2 hr; (d) Fe, acetic acid, 90 °C, 45 min; (e) i) Gold’s
Reagent ((CH3)2NCH=NCH=N(CH3)2Cl), dioxane, reflux, 24 hr, ii) NaOAc, acetic acid, reflux, 3 hr; (f)
POCl3, reflux, 4 hr.

Cyclisation of the aminobenzamide [60] to the quinazoline core unit was achieved using the
imminium salt, Gold’s reagent, giving a 90% yield of [61] (Scheme 2.3). Gold's Reagent
has been utilised previously74 and proves advantageous in this cyclisation due to ease of
preparation, mild reaction conditions & long term stability of the hydroxyquinazoline
product.132,133 Subsequent chlorination with phosphorus oxychloride provided the key
intermediate 7-benzyloxy-4-chloro-6-methoxyquinazoline [51] (Scheme 2.3) in 69% yield.
Initially thionyl chloride was the chlorinating agent used, however due to degradation
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problems arising from this method, phosphorus oxychloride was found to be superior for
the production of [51].

2.2.2 Synthesis of 2-Amino-4-benzyloxy-5-methoxybenzamide [60]
While the reported iron reduction for the aminobenzamide [60] states reasonable yields
(69%),129 it was felt that palladium catalysed hydrogenation might provide better yields
with a simple, cleaner work-up.134,135 Initial results utilising the hydrogenation method
supported these expectations with a significant increase in yield to 97% (Method 1, Scheme
2.4). However, further attempts of the hydrogenation reaction were not as successful, only
yielding an indistinguishable product. These problems encountered with reproducibility
were most likely due to poisoning of the palladium catalyst, which lead to the exploration
of other methods (Scheme 2.4).

O
O

O
O

NH2

O

NH2
NH2

O

NO2
[59]

[60]

Method

Reagents

Temp (°°C)

Time

Product/Result

1
2
3
4

H2/Pd/C
SnCl2/HCl
H2/PtO2
Fe/CH3COOH

rt
60-70
rt
90

o/n
4.5 hr
2 hr
45 min

97% [60]
Multiple products
Mixture (~ 20% [59]; 45% [60])
65% [60]

Scheme 2.4: Reduction of nitrobenzamide [59]. Method was changed from the high yielding H2/Pd/C
(Method 1) due to problems with reproducibility. After little success with SnCl2/HCl (2) or H2/PtO2 (3), the
Fe/CH3COOH method (4) provided consistent results.

Methods using tin chloride, platinum oxide as well as the reported iron reduction129 were
carried out concurrently to determine the most suitable synthesis. The platinum oxide
method resulted in a mixture that required further purification, while the use of tin chloride
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gave numerous products that were difficult to separate (Method 2 and 3, Scheme 2.4).
However, the iron reduction from the established synthetic route129 proved to be the most
reliable and consistent method, generating the desired aminobenzamide [60] at moderate
yields of 65% (Method 4, Scheme 2.4).

2.2.3 Synthesis of 4-Amino-7-benzyloxy-N-(3'-bromophenyl)-6methoxyquinazoline [52] and 4-Amino-7-benzyloxy-N-(3'-chlorophenyl)6-methoxyquinazoline [53]
Upon completion of the key intermediate [51] synthesis (Section 2.2.1) focus moved
towards the preparation of the novel anilinoquinazoline targets (see Scheme 2.2). Both 3bromoaniline and 3-chloroaniline# were used in the nucleophilic displacement reaction with
the chloroquinazoline [51] (Scheme 2.5).

O

Cl
N

O

N

H2 N

R

DMF, 80 oC, N 2

HN
O
O

R
N

N

1 hr
[51]

[52] R=Br, 71%
[53] R=Cl, 79%

Scheme 2.5: Nucleophilic displacement reaction used to form anilinoquinazoline derivatives [52] and [53].

Heating the chloroquinazoline and the 3-bromo or 3-chloro substituted aniline in DMF
under nitrogen atmosphere for 1 hour resulted in a precipitate, which was separated by
vacuum filtration to give the desired 4-amino-7-benzyloxy-N-(3'-bromophenyl)-6#

As previously stated, 3-ethynylaniline was also used, refer to discussion in Section 2.2.8.1
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methoxyquinazoline

[52]

or

4-amino-7-benzyloxy-N-(3'-chlorophenyl)-6-methoxy

quinazoline [53] in 40%-60% yields. These yields were optimised to 71% and 79%
respectively by reducing the solvent volume and therefore increasing concentration of the
reactants.

Analysis of the 1H NMR spectra of [52] and [53] showed the appearance of doublet and
doublet of doublet peaks between 8.03-7.45 ppm in a typical meta substitution pattern,
corresponding to the anilino protons. There was also a slight upfield shift from 9.02 to 8.86
ppm of the peak assigned to the H2 proton, arising from the substitution of NH in place of
the chloro substituent. The high resolution mass spectrum showed a peak at m/z at
436.0665 assigned to the molecular ion of [52]. In the MS-CI mass spectrum, peaks were
seen at m/z 436 and m/z 91 assigned as [M+1] and the tropylium ion [C7H7] respectively.

2.2.4 Synthesis of 4-Amino-N-(3'-bromophenyl)-7-hydroxy-6-methoxy
quinazoline [44] and 4-Amino-N-(3'-chlorophenyl)-7-hydroxy-6-methoxy
quinazoline [45]
The anilinoquinazoline derivatives [52] and [53] were deprotected as outlined in Scheme
2.6.

HN
O
O

R
N

TFA

N

reflux, 45 min

N
[52] R=Br
[53] R=Cl

R

HN
O
HO

N
[44] R=Br, 99%
[45] R=Cl, 69%

Scheme 2.6: Deprotection of anilinoquinazolinone derivatives [52] and [53].
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In a typical reaction, the benzyloxy derivative, eg [52], in TFA was heated at reflux for 45
minutes to debenzylate the quinazoline. After cooling and treatment with base (NH3), the
free hydroxyl derivative [44]♣ was isolated in 99% yield. The corresponding chloro
derivative [45] was isolated in 69% yield.

1

H NMR spectral analysis of [45] revealed a loss of benzyl proton peaks between 7.45 and

5.34 ppm and the appearance of a peak at 10.38 ppm, indicating replacement with an OH
moiety. The 13C NMR spectrum provided further confirmation of the deprotected derivative
[45] through the corresponding peaks for quinazoline (157–143, 109-102 ppm) and aniline
carbons (141-120 ppm) while peaks in the benzyl region (136-128 ppm) were absent.
Analysis of the HRMS showed that the measured m/z peak of 302.0704 was comparable to
the calculated mass 302.0696 of [45]. Confirmation of [44] was achieved through
equivalent peaks in the 1H NMR spectrum to those previously reported131 and a [M+1] ion
of 346 in the mass spectrum.

2.2.5 Synthesis of 4-Amino-N-(3'-bromophenyl)-7-(2'-hydroxyethoxy)6-methoxyquinazoline [54] and 4-Amino-N-(3'-chlorophenyl)-7-(2'hydroxyethoxy)-6-methoxyquinazoline [55]
The deprotected anilinoquinazolines were initially alkylated by the addition of 2bromoethanol to a mixture of the deprotected derivative (eg [44]) and potassium carbonate
in anhydrous acetone and heating at reflux for 48 hours (Scheme 2.7 – Method A).

♣

The synthesis of [44] has been reported,131,136 however only minimal spectral data was provided.
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Separation by column chromatography using gradient elution afforded the O-alkylated
products [54] and [55] in 36% and 25% yields respectively.

R
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O
HO

N
N
[44] R=Br
[45] R=Cl

OH
Method A: K2CO3 , Br
CH3 COCH 3 , reflux, 48 hr
Method B: i) Br

OAc

K2CO3 / KI/ TBAI/ DMF, rt, 40-64 hr
ii) K2CO3 , MeOH/H 2 O, 65 oC, 20 min

R

HN
O
HO

O

N
N

[54] R=Br, 36% (a); 80% (b)
[55] R=Cl, 25% (a); 75% (b)

Scheme 2.7: Alkylation of deprotected anilinoquinazoline derivatives [44] and [45]. Product synthesised
using 2-bromoethanol in Method A or via an acetate intermediate and deprotection in Method B.

The alkylation step was optimisedℵ with the synthesis of an acetate ethoxy intermediate
and subsequent deprotection as outlined in Scheme 2.7 – Method B. Dramatic increases in
yield were achieved using this method, producing 80% of [54] and 75% of [55].

Both 1H NMR spectra of [54] and [55] showed the appearance of triplet and doublet of
triplet peaks at 4.17 and 3.80 ppm, respectively, associated with the ethyl hydroxy
substitution. It is noted that these are shifted slightly downfield from 2-bromoethanol,
where the bromo substituent is less deshielding. Peaks seen at 70.4 and 59.2 ppm in the 13C
NMR spectrum could also be assigned to the CH2 carbons. HRMS also confirmed the
formation of [54] and [55], revealing peaks at m/z 388.0297 (calculated 388.0297) and m/z
346.0943 (calculated 346.0958) respectively.

ℵ

Optimisation of this synthetic step was performed by C. Fookes
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2.2.6 Synthesis of 4-Amino-N-(3'-bromophenyl)-7-(2'-toluenesulfonyl
ethoxy)-6-methoxyquinazoline [39] and 4-Amino-N-(3'-chlorophenyl)-7(2'-toluenesulfonylethoxy)-6-methoxyquinazoline [40]
The tosylate precursors, [39] and [40], were prepared via base treatment of the hydroxy
starting material ([54] and [55]) using N,N,N',N'-tetramethylhexane-1,6-diamine, followed
by the addition of toluenesulfonyl chloride (Scheme 2.8). Extraction followed by
purification using column chromatography provided 4-amino-N-(3'-bromophenyl)-7-(2'toluenesulfonyl)ethoxy-6-methoxyquinazoline [39] and 4-amino-N-(3'-chlorophenyl)-7-(2'toluenesulfonyl)ethoxy-6-methoxy quinazoline [40] in 30% and 58% yields respectively.

i) Me2 N(CH 2) 6NMe2

HN
O
HO

O

R
N

HN

ACN, 80 o C, 15 min

O

ii) TsCl, rt, 5-20 hr

N

TsO

[54] R=Br
[55] R=Cl

O

R
N

N

[39] R=Br, 30%
[40] R=Cl, 58%

Scheme 2.8: Formation of tosylate precursors [39] and [40].

The 1H NMR spectra of [39] and [40] both showed a downfield shift of the CH2 proton
peaks, now appearing between 4.42 and 4.37 ppm, and additional peaks in the aryl (7.827.44 ppm) and methyl (2.39 ppm) regions which confirmed the tosyl formation. Greater
resolution of these 1H NMR spectra also revealed more detailed coupling patterns for the
peaks assigned to the H4' and H6' aniline protons. As well as the ortho coupling (doublet, J
= 8.0 Hz), weak meta coupling with H2' and H6'/H4' (dd, J = 2.0, 2.0 Hz) could be seen.
The analysis of HRMS for [39] and [40] revealed peaks at m/z 544.0546 and m/z 500.1033
respectively, which were comparable to their calculated masses.
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2.2.7 Synthesis of 4-Amino-N-(3'-bromophenyl)-7-(2'-fluoroethoxy)-6methoxyquinazoline [36] and 4-Amino-N-(3'-chlorophenyl)-7-(2'-fluoro
ethoxy)-6-methoxyquinazoline [37]
With the preparation of the tosylate precursors complete, the final stage was the formation
of the fluorine standards [36] and [37] (Scheme 2.9). The deprotected derivatives [44] and
[45] in anhydrous acetone were treated with potassium carbonate and 1-bromo-2fluoroethane and the mixture was heated at reflux for 24-48 hours (Scheme 2.9 – Method
A). The crude products were separated by column chromatography using gradient elution to
afford 4-amino-7-(2-fluoroethoxy)-N-(3'-bromophenyl)-6-methoxy quinazoline [36] and 4amino-7-(2-fluoroethoxy)-N-(3'-chlorophenyl)-6-methoxy quinazoline [37] in 14% and
41% yields respectively.
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[44] R=Br
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Method A: K2CO3 , Br
CH3 COCH 3 , reflux, 24-48 hr
F
Method B: Br
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HN
O
F

O

R
N

N

[36] R=Br, 14% (a); 72% (b)
[37] R=Cl, 41% (a); 65% (b)

Scheme 2.9: Synthesis of fluorine standards [36] and [37]. Using Method A: 1-bromo-2-fluoroethane, K2CO3,
CH3COCH3 at reflux, or method B: 1-bromo-2-fluoroethane, K2CO3, KI, TBAI, DMF at room temp.

Alternatively, the optimised procedure∝ using potassium iodide and tetrabutylammonium
iodide in anhydrous DMF at room temperature (Scheme 2.9 – Method B), gave greatly
improved yields ([36]: 72%, [37]: 65%) without the need of chromatographic separation.

∝

Optimisation of this synthetic step was performed by C. Fookes
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In both 1H NMR and

13

C NMR spectra for [36] and [37] the appearance of peaks in the

alkyl region, 4.87-4.39 ppm (1H) and 82-67 ppm (13C), corresponded to the -OCH2CH2F
substituent. Characteristic 1H-19F and 13C-19F heteronuclear coupling was also observed in
the alkyl regions of the 1H and 13C NMR spectra of [36] and [37]. Further confirmation of
the fluorine standards was achieved through elemental analysis, eg [37] (C17H15N3O2ClF)
was found to have C, 58.98; H, 4.31; N, 11.91 compared to calculated values of C, 58.71;
H, 4.35; N, 12.08.

2.2.8 Synthesis of Additional Fluorine-18 and Carbon-11 Derivatives
As described in Section 2.1, Series I also provides access to the fluorine-18 standard and
precursor, [38] and [41], as well as the carbon-11 precursors, [44], [46] and [45] (see Figure
2.2). The synthesis of these derivatives is outlined in the following sections.

2.2.8.1 Attempted Synthesis of 4-Amino-N-(3'-ethynylphenyl)-7-(2'-fluoro
ethoxy)-6-methoxyquinazoline [38] and 4-Amino-N-(3'-ethynylphenyl)-7-(2'-toluene
sulfonylethoxy)-6-methoxyquinazoline [41]
Utilising the same synthetic strategy as the bromo and chloro derivatives ([36] and [37],
Scheme 2.2), Scheme 2.10 outlines the attempted synthesis of a fluorine-18
radiopharmaceutical standard with an ethynyl substituent [38], from the key intermediate
[51].
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[38] R=F / [28] R=18 F

Scheme 2.10: Synthetic route for ethynyl fluorine derivative [38]; (a) 3-ethynylaniline, DMF, 80 °C, N2, 1 hr;
(b) TFA, reflux, 45 min. If the deprotected product [46] was successfully obtained, alkylation reactions could
yield the hydroxy intermediate [63] towards the tosylate precursor [41], or the fluorine standard [38].

The first step involved the nucleophilic displacement reaction between chloroquinazoline
and 3-ethynylaniline, resulting in the ethynyl quinazoline product [62] in 83% yield. The
mass spectrum showed an m/z peak of 382 (assigned M+1), while peaks in the 1H NMR
spectrum assigned to the benzyl (5.3, 7.4-7.6 ppm), anilinoquinazoline (7.4-8.8 ppm),
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methoxy (4.0 ppm), and ethynyl protons (4.3 ppm), provided further evidence for the
synthesis of [62].

Removal of the C-7 benzyl group using TFA did not result in the desired 4-amino-7hydroxy-N-(3'-ethynylphenyl)-6-methoxyquinazoline [46] (Scheme 2.10). However the
product that was obtained in 75% yield, was tentatively identified as 1-[3-(7-hydroxy-6methoxy-quinazolin-4-ylamino)-phenyl]-ethanone [64] (Scheme 2.11) through NMR and
mass spectral analysis.

HN
O

N

O

N

TFA, reflux
45 min
75%

HN
O
HO

[62]

N

O

N
[64]

Scheme 2.11: Alternative deprotection synthetic route for ethynyl anilinoquinazolinone derivative [62].

In the proton NMR of [64], there was a loss of peaks between 7.4 and 7.6 ppm indicating
successful debenzylation. Other aromatic peaks were assigned to quinazoline and aniline
protons, and the peak at 3.98 ppm corresponding to the 6-methoxy. On comparison to [62]
the characteristic ethynyl proton (4.3 ppm) was no longer present, however there was a
peak at 2.6 ppm with relative integration of 3. The 13C NMR showed a corresponding peak
at 26.8 ppm, indicating the presence of a CH3 group. This peak and another at 197.8 ppm
(assigned C=O), replaced the 2 peaks that were previously seen for the ethynyl substituent
(81.5-83.0 ppm). Low resolution mass spectral analysis also pointed towards the formation
of [64] with a m/z peak of 310, which corresponded to [M+1].
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While this outcome was not originally anticipated, it is likely to occur via Markovnikov
addition of water across the triple bond of the acetylene.137,138 There are also some
examples of the formation of phenyl ketones from acetylene in solvents such as TFA or
triflic acid in more recent years.139 To achieve debenzylation of this ethynyl substituted
quinazoline [62] without ketone formation, milder, anhydrous conditions would need to be
considered.

Further investigation or optimisations were not attempted during this project, as the 3bromo and 3-chloro derivatives (Section 2.2.7) had became the focal point of the fluorine18 derivatives. Therefore, this synthetic route (Scheme 2.10) was no longer pursued.

2.2.8.2 Carbon-11 Precursors [44]-[45]
Synthesis of carbon-11 precursors for radiopharmaceutical development (Figure 2.2) was
initiated during the Series I fluorine derivatives synthesis (Schemes 2.2). The bromo and
chloro deprotected derivatives previously isolated ([44] and [45]) – summarised in Scheme
2.12) can also act as precursors in carbon-11 radiolabelling.

HN
O
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R
N

N
[52] R=Br
[53] R=Cl

ref lux
45-50 min

R

HN

TFA

O
HO

N
N
[44] R=Br
[45] R=Cl

Scheme 2.12: Summary of deprotected derivatives, [44] and [45], synthesised for use as carbon-11
radiopharmaceutical precursors. These were isolated during the Series I fluorine derivative synthesis (Scheme
2.2).
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The deprotected ethynyl derivative [46] may have also shown potential as a carbon-11
precursor if the synthesis had been developed further (Section 2.2.8.1). All of the
corresponding standards ([13], [42] and [43] – Figure 2.2) could be accessed via the
following Series II synthesis and will be discussed further in Section 2.3.5.

2.3 Series II Synthesis
The 6,7-dimethoxyanilinoquinazoline synthetic targets can be obtained through the
preliminary synthesis of the key intermediates [43] and [68] (Scheme 2.13), followed by
separate synthetic routes (Schemes 2.14 and 2.15) for the iodine and fluorine standards,
[47] & [49] and their precursors, [48] & [50].
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[65]
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[43] R=C≡ CH

Cl
H2N
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N

O

N
[67]

[68] R=OH

Scheme 2.13: Proposed synthesis for preliminary 6,7-dimethoxyanilinoquinazoline intermediates.

The key intermediates can be accessed by cyclisation of 2-amino-4,5-dimethoxybenzoic
acid [65] using formamide to give the hydroxyquinazoline [66]. Subsequent chlorination
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should yield 4-chloro-6,7-dimethoxyquinazoline [67], which can undergo nucleophilic
displacement reactions with aniline derivatives eg 3-ethynyl or 3-hydroxy.

The ethynyl anilinoquinazoline derivative ([43] – Scheme 2.13) can be converted to a
stannane precursor [48] and iodine standard [47] according to Scheme 2.14. Using
tributyltin hydride with the initiator, AIBN, the ethynyl derivative can be transformed into
the

key

precursor

compound,

4-amino-N-(3'-tributylstannylethenylphenyl)-6,7-

dimethoxyquinazoline [48]. This stannane can either undergo iodination to give the
standard [47] or be used in the radiochemical reaction to give the iodine-123 product [30];
the latter will be discussed in Chapter 3 (Section 3.3).
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O
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Scheme 2.14: Proposed synthesis for 6,7-dimethoxyanilinoquinazoline incorporating iodine. Both the
standard [47] and radiolabelled equivalent [30] are produced via the stannane intermediate [48].
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Alternatively, using the hydroxyl anilinoquinazoline ([68] – Scheme 2.13), formation of a
fluorine standard [49] and its tosylate precursor [50] can be facilitated through the synthesis
outlined in Scheme 2.15. The hydroxyl derivative can undergo alkylation with either
bromoethanol or bromofluoroethane to give the intermediate [69] and the fluoro standard
[49]. The tosylate precursor required for subsequent radiochemical reaction could then be
prepared using [69] and tosyl chloride.
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base

HN
O
O

N
N
[50]

Scheme 2.15: Proposed synthesis for 6,7-dimethoxy anilinoquinazoline incorporating fluorine. The standard
[49] is achieved through direct alkylation of the 3-hydroxy substituent, while the radiolabelled equivalent [29]
requires a tosylate intermediate [50].
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2.3.1 Synthesis of 4-Amino-N-(3'-ethynylphenyl)-6,7-dimethoxy
quinazoline [43] and 4-Amino-N-(3'-hydroxyphenyl)-6,7-dimethoxy
quinazoline [68]
The synthesis of the key dimethoxyquinazoline intermediates [43] and [68] was adapted
from Johnstrom131 and Hennequin74 (Scheme 2.16). Therefore a solution of commercially
available aminobenzoic acid [65] in formamide was heated at 150 °C for 24 hours giving
the hydroxyquinazoline [66] in 46% yield. This was a significant improvement in yield to
that reported (22%),131 due to the extended reaction time used.
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[43] R=C≡ CH, 94%
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Cl
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N
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[68] R=OH, 78%

Scheme 2.16: Synthesis of [43] and [68]: (a) H2NCHO, 150 °C, 24 hr; (b) SOCl2, DMF (2 drops), reflux, 4
hr; (c) DMF, 80 °C, N2, 1 hr.

Treatment of [66] with thionyl chloride at reflux resulted in [67] in 83% yield, which was
reacted with either 3-ethynylaniline or 3-hydroxyaniline in DMF at 80 °C under nitrogen
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giving rise to the aniline derivatives, [43] and [68] in 94% and 78% yields respectively
(Scheme 2.16).

The 1H NMR spectrum of [43] showed a singlet peak at 4.27 ppm, corresponding to the
terminal proton of the 3-C≡CH substituent, which was also seen through peaks at 82.9 and
81.3 ppm in the

13

C NMR spectrum. Confirmation of [68] was achieved through the

assignment of peaks in the aryl (8.80-6.74 ppm) and alkyl (4.01-3.99 ppm) regions of the
1

H NMR spectrum, as well as a peak at 11.23 ppm associated with the 3-OH aniline

substituent. The high resolution mass spectrum revealed a peak at m/z 298.1205 which was
comparable to the calculated mass of 298.1192.

2.3.2 Synthesis of 4-Amino-N-(3'-tributylstannylethenylphenyl)-6,7dimethoxyquinazoline [48]
Hydrostannylation of the ethynyl derivative [43] was achieved using tributyl tin hydride
and the radical initiator AIBN (Scheme 2.17).

HN
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N
N

dioxane, 80 o C, N 2
23 hr, 78%

O
O

N
N

[43]

Scheme 2.17: Free radical hydrostannylation reaction of ethynyl derivative [43].
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Sn(Bu)3

HN

n-(Bu)3 SnH, AIBN

[48]

To a mixture of the ethynyl derivative [43] and tributyltin hydride in anhydrous dioxane,
was added a catalytic amount of AIBN and the mixture was heated under nitrogen
atmosphere for 28 hours. Separation of the crude product was achieved by column
chromatography using gradient elution, yielding 78% of the stannane derivative [48]. This
derivative was formed as an isomeric mixture, however full analysis of the cis and trans
isomers was carried out after conversion to the iodo standard (next section 2.3.3).

In the 1H NMR spectrum of [48], three multiplets between 1.53 and 0.97 ppm with relative
integration of six each accounted for the tributyltin CH2 protons and a triplet peak at 0.88
ppm (integration 9H) corresponded to the tributyltin CH3 protons. Additional evidence was
provided by a peak at m/z 598 in the mass spectrum, which was assigned [M+Sn118].

2.3.3 Synthesis of 4-Amino-N-(3'-iodoethenylphenyl)-6,7-dimethoxy
quinazoline [47]
For the electrophilic substitution reaction shown in Scheme 2.18, iodine was added
dropwise to a solution of the stannane derivative [48] in chloroform.
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N
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Scheme 2.18: Formation of iodine standard [47].
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After stirring at room temperature under nitrogen atmosphere for 4 hours, the reaction
mixture was quenched via extraction with sodium metabisulphite solution. The resulting
crude product from the organic extract was separated by column chromatography with
gradient elution, giving the iodine standard [47] in 74% yield as a cis/trans mixture (6:1 =
E:Z). Detailed NMR analysis revealed peaks between 7.0 and 8.5 ppm, assigned to
anilinoquinazoline protons, and 2 singlet peaks at 4.0 ppm corresponding to the methoxy
groups. Doublet peaks at 7.1 and 7.5 ppm showed typical trans coupling constant of 15.0
Hz, while the minor isomer could be seen through doublets at 6.7 and 7.4 ppm (coupling
constant 9.0 Hz).

Subsequent separation and purification by HPLC yielded very small quantities of the cis
and trans isomers of [47]. These were both confirmed by high resolution mass spectral
analysis, showing peaks at m/z 434.0341 (cis) and m/z 434.0374 (trans), which were
consistent with the calculated mass (434.0366).

2.3.4 Attempted Synthesis of 4-Amino-N-(3'-(2''-tosylethoxy)phenyl)6,7-dimethoxyquinazoline [50] and 4-Amino-N-(3'-(2''-fluoroethoxy)
phenyl)-6,7-dimethoxyquinazoline [49]
The strategy towards the dimethoxy tosylate precursor [50] and fluorine standard [49] for
subsequent radiolabelling involved the formation of the ethoxyhydroxy derivative [69]
(Scheme 2.19).
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Scheme 2.19: Alkylation of hydroxy derivative [68]. Following alkylation, the proposed syntheses of the
fluorine [49] and tosylate [50] derivatives were not pursued.

This was achieved through the addition of 2-bromoethanol to a mixture of the hydroxy
derivative [68] and potassium carbonate in anhydrous acetone and heating at reflux for 48
hours. Separation by column chromatography using gradient elution gave 4-amino-N-(3'(2''-hydroxyethoxy)phenyl)-6,7-dimethoxyquinazoline [69] in 43% yield.

Addition of the hydroxyethoxy substituent was confirmed by 1H and

13

C NMR spectral

analysis of [69], showing peaks at 4.19, 3.80 ppm (1H) and 83.5, 80.5 ppm (13C), associated
with the alkyl chain. A peak at m/z 342.1459 in the high resolution mass spectrum also
corresponded to the calculated [M+1]+ for [69].
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During this synthesis, new dataφ revealed that long chain substitution on the aniline ring
may not be beneficial to binding. This information combined with time constraints, lead to
the decision of not pursuing the synthesis of [50] and [49] (Scheme 2.19).

2.3.5 Synthesis of 4-Amino-N-(3'-bromophenyl)-6,7-dimethoxy
quinazoline [13] and 4-Amino-N-(3'-chlorophenyl)-6,7-dimethoxy
quinazoline [42]: Carbon-11 Standards
Carbon-11 radiopharmaceutical development during this project required the synthesis of
both the bromo and chloro derivatives [13] and [42] (Scheme 2.20), along with the ethynyl
derivative [43] synthesised earlier (Scheme 2.16), to act as standards.
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[42] R=Cl, 81%
[13] R=Br, 21%

Scheme 2.20: Synthesis of derivatives [42] and [13]; standards for carbon-11 radiochemistry.

The chloro and bromo dimethoxy derivatives could be formed through the key aniline and
chloroquinazoline displacement reaction (Scheme 2.20) which was discussed in Sections
2.1, 2.2.3 and 2.3.1. This was successfully achieved (using the same method as outlined in

φ

Data was obtained from concurrent docking studies carried out, see Chapter 5, Section 5.3.1
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Scheme 2.16c), isolating the chloro [42] and bromo [13]♦ derivatives in 81% and 21%
yields respectively.

1

H NMR spectral analysis of [42] showed peaks between 7.91 and 7.36 ppm, with

characteristic meta splitting patterns for the aniline protons. The high resolution mass
spectrum revealed a peak at m/z 316.0864 [M+1]+, which was comparable to the calculated
mass m/z 316.0853 of [42].

The corresponding deprotected precursors ([44]-[46]) also required for carbon-11 labelling,
have already been described in the Series I synthesis (Sections 2.2.4 and 2.2.8.2).
Conversion of these precursors may occur via the radiochemical reaction with [11C] methyl
iodide (Scheme 2.21), while the standards ([13], [42] and [43]) assist with product
characterisation and purification.
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[44] R=Br
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[32] R=Cl
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Scheme 2.21: Carbon-11 radiolabelling of anilinoquinazoline derivatives [44] - [46].

♦

The bromo derivative [13] was spectroscopically identical to that reported in literature.131,140
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2.4 Summary
Series I synthesis resulted in the fluorine standards ([36] and [37] – Scheme 2.9) and their
tosylate precursors ([39] and [40] – Scheme 2.8), while Series II yielded the iodine standard
([47] – Scheme 2.18) and stannane precursor ([48] – Scheme 2.17). Additionally the carbon
standards ([42], [43] and [13] – Schemes 2.16 and 2.21) and deprotected precursors ([44]
and [45] – Scheme 2.12) were successfully synthesised during the Series I and II syntheses.
However due to limited resources, only fluorine-18 and iodine-123 labelling could be
pursued further in this project (Chapter 3).
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Chapter 3: Radiochemical Synthesis

3.1 General Strategy
After the preparation of the chemical standards and precursors (Chapter 2), synthesis of the
radiolabelled target compounds (see Figure 2.1) could be undertaken. Both fluorine
standards [36]-[37] and their tosylate precursors [39]-[40] could be used to develop
fluorine-18 compounds [26] and [27], while the iodine standard [47] and it's stannane
precursor [48] can be utilised in the synthesis of the iodine-123 derivative [30]. However,
carbon-11 was not accessible, so this set of standards and precursors could not be pursued
further during the time frame of the project.

The Fluorine-18 radiochemical synthesis involves nucleophilic substitution and can be
influenced by many variables including solvent, cations and temperature.141 Potassium
[18F]fluoride has been widely used, particularly with the aid of the aminopolyether
Kryptofix 222 (K2.2.2) as a complexing agent for solubilising potassium salts and forming
nucleophilic or “naked” [18F]fluoride ion. Dipolar aprotic solvents are most commonly used
in fluorination reactions eg acetonitrile (ACN), dimethylformamide (DMF). Conversion
from a tosylate precursor also requires the addition of a suitable base (eg potassium
carbonate) to neutralise any sulfonic acid components.141 The fluorine-18 radiolabelled
derivatives can be used in subsequent biological evaluation and potentially act as PET
imaging agents.
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Electrophilic substitution is the method used for iodine-123 radiolabelling from a stannane
precursor.142 Oxidising agents such as iodine monohalide, N-chloramides and peracids
release hypochlorous acid (HOCl) which oxidises iodide to the electrophilic I+.
Chloramine-T (N-chloro-p-toluenesulfonic acid) acts as a very strong oxidant for
electrophilic iodination.143 The iodine-123 radiochemical products may prove useful for
SPECT imaging and in vivo studies.

3.2 Synthesis of Fluorine-18 Radiolabelled Derivatives [26] and [27]
The Series I fluorine standards, [36] and [37] (Section 2.2.7), were to be developed as
radiopharmaceuticals via their tosylate precursors, [39] and [40] (Section 2.2.6). The
radiochemical synthesis began with the complex formation of K2.2.2, base and K[18F] to
which the precursor, [39] or [40], was added (Scheme 3.1).
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H[18F], K2.2.2
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[27] R=Cl

Scheme 3.1: Radiochemical synthesis of [26] and [27]. Conditions include H[18F], K2.2.2 with variable
solvent, base and temperature. (More details in Table 3.1)

A number of different methods were carried out for this reaction to optimise the
radiochemical yield (RCY)φ of the products [26] and [27] (Table 3.1). These included

φ

Radiochemical yield (RCY) is a percentage calculation of 'Measured activity in the collected product' out of
'Total activity used in the reaction'.
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variation of the solvent (ACN, DMF or DMA), base (potassium carbonate (K2CO3) or
potassium oxalate (K2C2O4)) and temperature (100-160 °C) for both derivatives.
Table 3.1: Reaction conditions & radiochemical yields for the synthesis of [26] and [27]. Variations in the
base (potassium carbonate (K2CO3)/ potassium oxalate (K2C2O4)), solvent (ACN/ DMF/ DMA) and
temperature (100-160 °C) were employed for each derivative ([27] Methods 1-5, [26] Methods 6-9).
Method
1a
1b
2
3a
3b
3c
4a
4b
4c
5a
5b
5c
5d
6
7
8a
8b
9a
9b
9c
9d

Precursor
> Product

Rxn
Solvent

Base

Temp
(°C)

[40] > [27]

DMF

K2CO3

150

[40] > [27]

DMF

K2C2O4

150

[40] > [27]

DMA

K2CO3

160

[40] > [27]

DMA

K2C2O4

150

[40] > [27]

DMA

K2C2O4

160

[39] > [26]
[39] > [26]

ACN
DMF

K2CO3
K2CO3

100
150

[39] > [26]

DMA

K2C2O4

150

[39] > [26]

DMA

K2C2O4

160

Collected Yield (% RCY)
5 min
10 min 15 min
4.6
4.4
5.8
0
25.2
35
35
41
13.5
14
15.5
11.7
7.8
5
36.9
28.7
27.6
25.2
36.9
28.7
27.7
38.2
34.6
32.6
29
29
18.7
24.8
12.5
0
1.5
2.9
3.3
3.7
30
28
22
33.66
31.22
15.78
25.1
24.2
23.1
24.2
15.6
8
9
3
9
8
10

While fluorine-18 labelling of alkyl tosylates usually proceeds at temperatures around 100
°C in acetonitrile (ACN), higher yields and cleaner reactions were obtained when these
tosylate precursors were heated to higher temperatures (150-160 °C) in solvents such as
dimethylformamide (DMF) and dimethylacetamide (DMA). Only small yields (3-6%) of
both [26] and [27] were initially obtained using potassium carbonate in DMF at 150 °C
(Methods 1, 7 – Table 3.1), however dramatic increases in yield were achieved by changing
the solvent (DMA) or base (potassium oxalate). Substitution of the milder oxalate base
resulted in fewer degradation products and therefore higher yields.
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The highest radiochemical yield from the 3-chloro substituted tosyl precursor [40] was at
the slightly higher reaction temperature of 160 °C (Method 5a, Table 3.1), however the best
and most consistent results were obtained using potassium oxalate in DMA at 150 °C
(Methods 4a-c, Table 3.1). These reaction conditions also suited the formation of the 3bromo substituted F-18 derivative [26] (Methods 8a-b, Table 3.1). It is also noted that
under these conditions higher yields were achieved within 5 minutes, with longer reaction
times resulting in slightly lower yields. Therefore the optimised conditions for this
radiochemical synthesis, using potassium oxalate in DMA at 150 °C for 5 minutes, isolated
4-amino-7-(2-[18F]fluoro)ethoxy-N-(3'-bromophenyl)-6-methoxyquinazoline [26] and 4amino-7-(2-[18F]fluoro)ethoxy-N-(3'-chlorophenyl)-6-methoxyquinazoline

[27]

in

radiochemical yields of 30-37%.

The radiochemical yields were determined after purification and analysis of product by
HPLC. After injection of the reaction mixture onto HPLC, the eluent was monitored for
both activity and UV-visible fractions. The radiolabelled product is associated with a large
activity peak but no traceable UV and should ideally be separate from other UV-visible
reaction products. This is shown in the HPLC purification analysis of [27] (Figure 3.1). In
the UV-visible trace there are 4 major reaction by-products at 1, 8, 9.5 and 10 minutes
retention time (RT). Unreacted fluorine-18 can be seen after 5 mins in the activity trace,
with the second peak at 10.8 minutes RT corresponding to the desired labelled product [27].
Specific activity ranged from 1500 to 3100 Ci/mmol depending on the source of fluoride.
HPLC analysis of the standard [37] with identical conditions (75% ACN: 25% NH4HCO3
at 10 mL/min) provided confirmation of the product at 10.8 minutes RT (Figure 3.2).
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Figure 3.1: HPLC purification of [27] radiochemical synthesis (mobile phase: 75% ACN: 25% NH4HCO3 at
10 mL/min). Top: UV-visible reaction by-products; Bottom: Activity trace showing F-18 labelled product at
retention time of 10.9 minutes in 32% RCY.
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Figure 3.2: HPLC analysis of the standard [37] (mobile phase: 75% ACN 25% NH4HCO3 at 10 mL/min).
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Similar results were obtained during the HPLC purification analysis of [26] (Figure 3.3).
The major UV-visible by-products eluted at retention times of 8.5, 10.5 and 11 minutes,
while the desired labelled product [26] was collected at 11.6 minutes RT. This was also
confirmed by HPLC analysis of the standard [36] in identical conditions (75% ACN: 25%
NH4HCO3 at 10 mL/min).
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Figure 3.3: HPLC purification of [26] radiochemical synthesis (mobile phase: 75% ACN 25% NH4HCO3 at
10 mL/min). Top: UV-visible reaction by-products; Bottom: Activity trace showing F-18 labelled product at
retention time of 11.6 minutes in 22% RCY.
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3.3 Synthesis of Iodine-123 Radiolabelled Derivative [30]
The Series II iodine standard, [47], (Section 2.3.3) was converted to the radiolabelled
equivalent [30] using the stannane precursor [48] (Section 2.3.2). Previous work involving
iodine-123 labelling of similar dimethoxy quinazoline derivatives144 showed that
chloramine-T was superior to other oxidising agents tested (eg peracetic acid). Therefore,
chloramine-T was used for the electrophilic radioiodination of [48] (Scheme 3.2).

Sn(Bu) 3

HN
O
O

N
N

Na[123I]
chloramine-T

I 123

HN
O
O

[48]

N
N
[30]

Scheme 3.2: Radiochemical synthesis of [30]

After stirring at room temperature for 5 minutes, the reaction was quenched and
neutralised, followed by purification on reverse phase HPLC. Figure 3.4 illustrates the
HPLC analysis during purification, showing peaks for both UV-visible (blue) and
radioactive compounds (red). The first radioactive peak at 3 minutes represented unreacted
123

I, while the next 2 peaks collected at 18 and 24 minutes represented the cis and trans

isomers of 4-amino-N-(3'-[123I]iodoethenylphenyl)-6,7-dimethoxyquinazoline [30]. This
was confirmed by HPLC analysis of the iodine standard [47] performed in identical
conditions (60% ACN: 40% 0.1 M ammonium acetate at 4 mL/min) showing cis and trans
at retention times of 18 and 24 minutes (Figure 3.5). Therefore the cis and trans isomers of
[30] were obtained in 7% and 64% RCY respectively (E:Z = 8:1). A specific activity of
>2500 Ci/mmol was achieved for the radioiodinated compounds.
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Figure 3.4: HPLC purification of [30] (mobile phase: 60% ACN: 40% 0.1 M ammonium acetate at 4
mL/min). Top: UV-visible (blue) reaction by-products; Bottom: Radioactivity trace (red) with cis (18 min)
and trans (24 min) isomers in 7% and 64% RCY respectively.
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Figure 3.5: HPLC analysis of iodine standard [47] (mobile phase: 60% ACN: 40% 0.1 M ammonium acetate
at 4 mL/min). UV active trace (grey). Peaks at 18 and 24 minutes correspond to cis and trans isomers
respectively.
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3.4 Summary
The synthesis of both fluorine-18 derivatives has been optimised, affording [26] and [27] in
30-37% RCY with specific activity of 1500-3100 Ci/mmol (55-115 GBq/mmol). Time was
spent developing the method and purification process in preparation for in vivo studies. The
iodine-123 derivative [30] was also successfully synthesised, yielding both cis and trans
isomers from the electrophilic radioiodination reaction in 71% RCY (E:Z = 8:1) and
specific activity greater than 2500 Ci/mmol (92 GBq/mmol). These radiofluorinated and
radioiodinated derivatives, along with the corresponding standards ([36], [37], [47] Chapter 2), are now available for biological evaluation.

65

66

Chapter 4: Biological Evaluation

4.1 General Strategy
The biological properties of the radiolabelled derivatives ([26], [27] and [30]) and their
chemical standards ([36], [37] and [47]) can be evaluated using both in vitro and in vivo
studies. The in vitro studies could determine the affinity and specificity of each of the
synthesised compounds for the EGF and VEGF RTKs, whilst the in vivo studies could
provide information on biodistribution, specific uptake and clearance.

4.2 Biological Evaluation of Fluorine Derivatives
The fluorine standards [36] and [37] were subjected to in vitro evaluation to assess their
affinity and selectivity for the EGFR and VEGFR tyrosine kinases. The corresponding
labelled derivatives [26] and [27] were to follow with in vivo imaging studies, however due
to animal tumour model unavailability these studies could not be undertaken during the
time frame of this project.

4.2.1 In Vitro Testing of Fluorine Standards [36] and [37]
Both of the fluorine derivatives [36] and [37] were evaluated in vitroφ across a panel of
seven kinases, including the targets EGFR and VEGFR (KDR & Flt1 subtypes). Other
kinases were chosen to test the selectivity of compounds, these were PDGFR & FGFR
φ

In vitro testing performed by Caliper Life Sciences145,146
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(closely related kinase families), IGFR (weakly related kinase family) and Akt
(serine/threonine kinase).24,56 Strong inhibition was revealed in both the EGF and VEGF
RTKs. For the 3-bromo substituted derivative [36], EGFR showed 100% inhibition at both
concentrations, while both VEGFR tyrosine kinases (KDR and Flt1) had between 85-100%
inhibition at higher concentration (10-5 M) then dropped below 40% inhibition when at 10-7
M concentration (Figure 4.1). Some inhibition was also seen for both FGFR1 and PDGFRa,
while IGF1R and Akt1 showed almost no inhibition. Therefore, [36] not only showed
significant activity for both EGFR and VEGFR but also exhibits selectivity over several
other kinases tested.
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Figure 4.1: Kinase assay for the 3-bromo substituted derivative [36]. The average percent (%) inhibition is
shown for all seven kinases measured at concentrations of 10-5 M (back row) and 10-7 M (front row).

The kinase family tree (Figure 1.2) illustrates how the FGF and PDGF families stem from
similar roots as the VEGF family, whereas the IGF family is more segregated24 and Akt is a
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member of the Ser/Thr kinase family.56 Therefore the assay results also correlated with the
common or different kinase family origins.

Very similar in vitro assay results were obtained for the 3-chloro substituted derivative [37]
across the seven kinases (Figure 4.2). It was most effective in EGFR (100% inhibition at
both concentrations), closely followed by the VEGFR tyrosine kinases (>95% at 10-5 M and
between 19-42% at 10-7 M). FGFR1 and PDGFRa again showed moderate inhibition but
very little activity seen from IGF1R or Akt1. Therefore, this derivative [37] also showed
promise, having good activity and selectivity for the EGF and VEGF RTKs.
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Figure 4.2: Kinase assay for the chloro-substituted derivative [37]. The average percent (%) inhibition is
shown for all seven kinases measured at concentrations of 10-5 M (back row) and 10-7 M (front row).

Since there was a very strong inhibition profile for EGFR in both kinase assays, an IC50
was obtained for this RTK. The percent inhibition/activity was measured over a range of 10
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to 12 concentrations∗ and the results graphed to measure the point at which 50% inhibition
was achieved (Figure 4.3). High activity was confirmed for both derivatives recording IC50
values of 1.2 nM and 3.4 nM for [36] and [37] respectively.

Figure 4.3: IC50 graphs for the fluorine standards [36] and [37]. The graphs show the percent inhibition/
activity of the tested compound in EGFR over concentrations between 10-5 M and 10-11 M. From this the IC50
values were determined as 1.2 nM and 3.4 nM respectively.

Both of the synthesised fluorine compounds [36] and [37] have proven to have potent
EGFR inhibitory activity in vitro. Results also indicated retention of in vitro activity
between the 3-bromo substituted compound [36] and the 3-chloro derivative [37]. They
also exhibited good in vitro activity against VEGFR, while displaying selectivity over other
kinases tested. After the in vivo evaluation (imaging and biodistribution studies) is
completed, the efficacy of these derivatives as radiopharmaceuticals may be determined.
∗

IC50 testing performed by Caliper Life Sciences145,147
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4.3 Biological Evaluation of Iodine Derivative
The labelled iodine derivative [47] was subjected to in vitro and in vivo biological
evaluation to test affinity for the EGFR tyrosine kinase. Preliminary in vitro screening was
carried out using an EGF binding assay, followed by more detailed investigation in vivo.
Imaging studies were initially performed to visualise any uptake in the tumour and to
determine the general pharmacokinetic profile of the radiolabelled molecule. Further
analysis was then carried out using biodistribution studies. As [47] was formed in both the
trans and cis configurations, (E:Z ratio = 8:1) biodistribution studies were undertaken for
each.

4.3.1 In Vitro Testing of Iodine Standard [47]
The trans isomer of the iodine standard [47] (and other target compounds [36], [37] [42]
and [43]) were subjected to in vitro EGF binding studies and found to be inactive at 10-5 M
for this assay♣ (See appendix). At the time of evaluation, this was the only in vitro EGF
assay commercially available.ϒ However, since this only represented extracellular binding
and not intracellular kinase activity, the results were inconclusive. Consequently, further in
vivo evaluation was undertaken to study the uptake and binding of the iodine-123 labelled
derivative [30].

♣

EGF binding assay performed by Novascreen (now Caliper Life Sciences)145,148
The iodinated derivatives were completed earlier in the project. Focus had moved onto the fluorinated
derivatives once extensive kinase assays had become commercially available (See Section 4.2.1)
ϒ
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4.3.2 In Vivo Imaging of [123I] Derivative [30]
Rats bearing mammary adenocarcinoma derived tumoursℵ implanted on their left shoulder,
were injected with the

123

I radiolabelled compound [30] (trans isomer). Planar SPECT

images were acquired at a range of time points from 10 minutes post injection up to 6 hours
post injection. Figure 4.4 shows the uptake of radiotracer [30] after 1, 4 and 6 hours.

(a)

(b)

(c)

Figure 4.4: Rat imaging studies of the 123I labelled compound [30] trans isomer; Images acquired (a) 1 hour
post injection, (b) 4 hours post injection (c) 6 hours post injection.

During the first hour extensive distribution throughout the body was observed including
some evidence of uptake in the tumour. Interestingly the highest uptake was observed in the
gastrointestinal tract (GIT) with early thyroid uptake suggesting rapid metabolism and
deiodination. The lungs and liver showed moderate uptake. At 4 and 6 h intense uptake
was still observed in the GIT with low uptake in the liver, lungs kidneys all while
maintaining some uptake in the tumour. Thyroid uptake, particularly at later time points,

ℵ

The 13762MAT cell line/mammary adenocarcinoma, developed as a tumour model for angiogenesis,149 had
also demonstrated tumour uptake with the EGFR compound [123I]PD-153035.150 While no quantitative data
on the levels of growth factor expression could be obtained at the time, it was the most appropriate cell line/
tumour model available when our studies commenced.
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indicated extensive in vivo metabolism and deiodination. The bladder and kidneys showed
comparatively lower uptake/clearance indicating predominant and progressive clearance via
the GIT. The low uptake of [30] in the tumour was consistent with that described for other
compounds in the literature. For example, [18F]Dasatinib, a multi-targeted kinase inhibitor
also indicated tumour uptake to be approximately 1.1% of the injected dose (estimated from
PET imaging regions of interest analysis)151 with excretion through the liver, GIT, kidney
and bladder.

Although the rat imaging studies performed have revealed some uptake in the tumour, more
detailed studies are needed to determine the precise interaction, specificity and selectivity
of [30] with the tumour.

4.3.3 Biodistribution Studies of [123I] Derivative [30]
A number of rats bearing mammary adenocarcinoma derived tumours were injected with
the radiolabelled compound [30] and sacrificed at 15 minutes, 1, 3, 6 and 24 hours to excise
the tissue for analysis. The radioactivity measured in each organ and tissue, represented as
percent injected dose per gram (%ID/g), was used to study the relative biodistribution of
the radiotracer in the whole body over time. An extensive study at multiple time points was
performed for the more predominant trans isomer of [30], while the cis isomer also
underwent biodistribution analysis at 1 and 3 hours post injection for comparison. A
summary of the biodistribution data for trans [30] in key tissues and organs is illustrated in
Figure 4.5.
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Figure 4.5: Key tissues and organs for the biodistribution study of the 123I labelled compound trans [30] in
rats.

Uptake in the tumour (0.5-0.7 %ID/g) although relatively low, remained relatively constant
throughout the first 6 hours of the study. These figures are consistent with values described
for other radiolabelled RTK inhibitors in the literature103,113,151 but lower than that reported
by Abourbeh,152 however, the latter involved the use of radiolabelled irreversible RTK
inhibitors.

Full biodistribution data and uptake of the trans radiotracer [30] in all tissues and organs
over 24 hours is shown in Figure 4.6. The relatively high thyroid uptake indicated strong
evidence of in vivo metabolism/deiodination which only progressively increased over the
course of the study (as previously seen in imaging studies). Interestingly, the liver, kidney
and bladder, indicated moderate uptake of activity, all of which decreased over time. The
activity in the blood was relatively low and also rapidly decreased over the time course of
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the study. However, the activity in blood was higher than that of the tumour at all times
giving tumour to blood ratios less than unity.
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Figure 4.6: Biodistribution data for the 123I labelled compound trans [30] in rats.

♦

It was difficult to measure the small mass of the thyroid accurately, producing error in %ID/g. However we
were still able to ascertain that thyroid uptake increased throughout 24 hr, suggesting in vivo metabolism/
deiodination.
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These results were comparable to previous studies on other radiolabelled EGF RTK
quinazoline derivatives.108,109,113,152 By far the highest uptake (other than thyroid) was
observed in the stomach and GIT and is entirely consistent with data reported for other
RTKs in the literature. Activity in all of these organs increased significantly over time and
although it may be considered as the predominant route of excretion, any relevant
association with RTKs in these tissues and organs is unknown.

Similar results were obtained from the biodistribution study of the minor cis isomer of [30].
While only 1 and 3 hour time points were measured, the same overall uptake and clearance
trends could be observed (Figure 4.7). The notable exceptions were the even higher uptake
of activity in the thyroid, stomach and GIT, confirming signs of rapid in vivo metabolism
and deiodination. Tumour uptake of cis [30] was slightly lower (~0.35 %ID/g) when
compared to trans [30] (~0.5-0.6 %ID/g) at 1 and 3 hours (Figure 4.8). This may have been
due to the comparatively higher radiotracer measurement in the gastrointestinal tract (GIT)
at these time points.

As expected, these comparative results confirm, that the cis/trans substitution pattern on the
3' position of the aniline ring did not significantly alter the overall behaviour of the
quinazoline RTK inhibitors.
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Biodistribution of cis [30] in F344 rats with adenocarcinoma
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Figure 4.7: Biodistribution data for the 123I labelled compound cis [30] in rats.
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Figure 4.8: Comparison of tumour uptake (%ID/g) of cis and trans isomers of the 123I labelled compound
[30] in rats biodistribution studies.

Although both the cis and trans isomers indicated relatively low tumour uptake, it is most
likely consistent with the relative “quantities” of RTK over-expression in the tumour.∝ Of
greater significance is the specific binding and the tumour to blood and tumour to muscle
ratios. The respective tumour to blood and tumour to muscle ratios from the biodistribution
studies of the cis and trans isomers of [30] are provided in Table 4.1. The trans isomer of
[30] showed tumour to blood (T/B) ratios between 0.6 and 0.7 over the first 6 hours, which
were directly in line with those obtained for the cis isomer of [30]. While tumour to muscle
(T/M) ratios for trans [30] started just below 2 and by 3 hours post injection had peaked at
4, corresponding again to the cis [30] T/M ratios (3.4-4.1) between 1 and 3 hours post
injection (Table 4.1).

∝

These parameters were not studied in this project and require further investigation and experimentation.
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Table 4.1: Tumour/Blood and Tumour/ Muscle Ratios - from biodistribution studies of 123I labelled
compound cis and trans [30] in rats.
trans [30]
Tumour/ Blood (T/B)
Tumour/ Muscle (T/M)
cis [30]
Tumour/ Blood (T/B)
Tumour/ Muscle (T/M)

15 min
0.6
1.9

1 hr
0.7
3.5
1 hr
0.7
3.4

3 hr
0.7
4.0
3 hr
0.6
4.1

6 hr
0.6
3.8

24 hr
0.8
5.0

Therefore, the in vivo evaluation of both cis and trans isomers of the iodine-123 labelled
derivative [30] demonstrated some uptake in the rat mammary adenocarcinoma models
expressing EGFR, with similar biodistribution profiles for both isomers. However further
development of derivatives may create a radiotracer with higher uptake in the tumour while
minimising in vivo metabolism and rapid clearance.

4.4 Summary
The synthesised radiolabelled compounds and their standards (Chapters 2 and 3) were
subjected to biological studies. In vitro evaluation of the fluorine standards [36] and [37] in
seven kinase enzyme assays, showed strong affinity and selectivity for both the EGF and
VEGF RTKs. For both compounds the best activity was seen for EGFR, with subsequent
IC50 measurement revealing [36] (1.2 nM) and [37] (3.4 nM) as potent inhibitors of EGFR.
These initial results were promising and provide great potential for these fluorine
substituted RTK inhibitors. Future in vivo studies of the corresponding radiofluorinated
derivatives ([26] and [27]) will help to assess their capability as radiopharmaceuticals.

For the iodine derivatives, the focus was on in vivo evaluation. Imaging studies in tumour
bearing rats confirmed uptake of trans [30] in the tumour, however the nature of this uptake
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still needed to be determined. A more detailed analysis was carried out with biodistribution
studies of both the cis and trans isomers in tumour bearing rats. While there was uptake in
the tumour, the evidence of in vivo metabolism and clearance via the stomach and GIT
showed that further optimisation of these GF RTK derivatives is needed.
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Chapter 5: Structure-Based Drug Design

5.1 Structure-Based Drug Design
Structure-based drug design was derived from the ‘lock and key’ concept, where the ‘lock’
is the biochemical target (e.g. receptor) that the specific ligand (e.g. drug/inhibitor) ‘key’
must fit into.126,153 In the past, studies were limited to the structure-activity analysis of
multiple ligands (keys) in an attempt to deduce information about the structure of the target
(lock).126 However, the 3-dimensional structural information obtained through X-ray
crystallography, NMR and homology modelling has enabled great advances in structurebased drug design.115,126,153 Detailed analysis of target crystal structures provides invaluable
data about the size, shape and chemical properties of the binding site. Furthermore,
computer-aided methods can be employed to investigate the binding interactions between
ligands and the target receptor. This information can be very useful in determining the
affinity and selectivity of a ligand to its target site.

In this project, ligands targeting the EGFR and VEGFR were studied. Investigation of the
3-dimensional receptor structure could identify ligand binding sites and reveal the
distinguishing features required for potent and selective inhibitors. This investigation began
with the study and comparison of the EGFR and VEGFR crystal structures currently
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available∝, subsequently incorporating computer-aided drug design techniques to gain
insight into the binding interactions.

5.2 EGFR and VEGFR Crystal Structures
A number of crystal structures of the EGFR and VEGFR tyrosine kinase domains♣ have
been elucidated in recent years, including native structures with or without an inhibitor
bound.118 Both the EGFR and VEGFR tyrosine kinase domains consist of 2 lobes (Cterminal and N-terminal) which are separated by a pocket where ATP or competitive
inhibitor binding occurs (Figure 5.1).120,121

C-terminal
lobe

Binding
pocket

(a)

N-terminal
lobe

C-terminal
lobe

Binding
pocket

N-terminal
lobe

(b)

Figure 5.1: Native Crystal Structures of the Tyrosine Kinase Domains for (a) EGFR: 1M14 and (b) VEGFR:
1Y6B.φ Both receptor kinases consist of 2 lobes, C-terminal lobe (left side of each structure) and N-terminal
lobe (right side of each structure), with the ATP binding pocket between the lobes.

∝

Crystal structures published up to 2006 were used for these studies,120,121,125 comparisons with more recently
published structures are covered later in the chapter (Section 5.4)
♣
The intracellular portion of growth factor receptors contains the tyrosine kinase domain, a region
particularly important for ATP binding which results in cell signaling (refer to Figure 1, Section 1.3).
φ
Only inhibitor bound VEGFR crystal structures were available at the time of this investigation, so it is
represented here with the inhibitor removed
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The N-terminal lobe is mostly comprised of  sheets/strands, while the C-terminal lobe is
dominated more by  helices.120 Functionally important regions common to both the EGFR
and VEGFR kinase domains are the glycine rich nucleotide binding loop (residues Gly695Gly700; Gly841-Gly846), activation loop (residues Asp831-Val852; Phe1046-Thr1075)
and the catalytic loop (residues His811-Asn818; His1026-Asn1033), shown for EGFR in
Figure 5.2.120,121 This catalytic loop contains the highly conserved HRDLAARN sequence
among receptor tyrosine kinases, with the aspartic acid residue (D813; D1028) essential for
catalysis of the phosphorylation reaction.120,121

Figure 5.2: Important Regions of the Growth Factor Tyrosine Kinase Domain, illustrated using the EGFR
crystal structure, 1M14. The C-terminal lobe (red ribbon) and N-terminal lobe (blue ribbon) contain the
glycine-rich nucleotide binding loop (magenta ribbon), activation loop (yellow ribbon) and the highly
conserved HRDLAARN catalytic loop (green ribbon).
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While sequence conservation occurs among the tyrosine kinases, selective inhibitors can
arise due to small variations in the amino acid structure of the binding pocket.154 Sequence
alignments have been published comparing EGFR and FGFR (Fibroblast Growth Factor
Receptor),24,154 as well as VEGFR and FGFR,121,155 however there is no direct comparison
of the amino acid sequence of EGFR and VEGFR. This comparative analysis would prove
useful in identifying the areas of difference between these two receptors and their binding
sites. Furthermore, this data can be applied to the development of targeted/selective EGFR
and VEGFR inhibitors.

5.2.1 Comparative Analysis of EGFR and VEGFR Crystal Structures
Crystal structures can be compared through their primary amino acid sequences, secondary
features (e.g.  helices,  sheets) and their overall 3-dimensional structure by
superimposition. The first step in analysing the EGFR and VEGFR crystal structure
sequences required the generation of difference distance matrices (DDMs) using the
software, Proflex.156

DDMs are a calculated comparison of two (or more) protein conformations, A and B, based
on the distance matrix (DM) rij between the ith and jth amino acids of each conformation.156
One DM is subtracted from the other through calculation of the difference Δrij between
elements rijA and rijB with corresponding values of i and j. This calculation yields the DDM
comparing conformations A and B and is more directly defined by:
Δrij = | rijA - rijB |
for all combinations of i and j, storing in a square matrix with i and j along the axes.156
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When conformations A and B are identical, even if they are not superimposed, the
corresponding distances rijA and rijB are the same and therefore, the difference Δrij is equal
to zero. However, a residue (x) in a different position in one structure will have different
distances to every other residue (j) in the protein and the DDM differences will be non-zero
for every Δrij value where i = x. Furthermore, the value of Δrij indicates the magnitude of
conformational change between the two structures and this is represented in the DDM by
clusters/regions of dissimilarity.156 The DDM output consists of a colour contour graph
bound by x and y axes, where both axes represent the residue number and the third
dimension illustrates the distance moved by a residue/region through a user-specified
colour code. In each DDM, the regions of movement are mirrored on either side of the
diagonal between the x and y axes.

The Proflex method was initially applied to the EGFR and VEGFR crystal structures
separately to assess their similarity and suitability for future studies. For EGFR, the native
1M14 and inhibitor bound 1M17 crystal structures were compared (Figure 5.3a). In
addition, two inhibitor bound VEGFR crystal structures, 1Y6A and 1Y6B, have been
evaluated (Figure 5.3b). The DDM graphs generated show a majority of blue (0-3 Å) which
illustrates that both of the crystal structure comparisons were almost identical (Figure 5.3).
Due to this similarity of the available EGFR and VEGFR crystal structures, 1M17 and
1Y6B were chosen for these and subsequent studies, as they contained a greater number of
residues than 1M14 and 1Y6A, respectively.
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(a)

(b)

Figure 5.3: DDM graphs comparing growth factor receptors: a) EGFR: 1M17 vs 1M14 crystal structures; b)
VEGFR: 1Y6A vs 1Y6B crystal structures. Both graphs represented distance moved between residues as:
blue = 0-3 Å, green = 3-5 Å, yellow = 5-9 Å, red = 9-15 Å, white > 15 Å. Therefore each pair of growth
factor receptor crystal structures were almost identical being within 0-3 Å.

Subsequent Proflex analysis of the EGFR and VEGFR crystal structure sequences (1M17
vs 1Y6B) generated the DDM shown in Figure 5.4, where the coloured regions indicated
movement of up to 3.0 Å (blue), 5.0 Å (green), 9.0 Å (yellow), 15.0 Å (red) and >15.0 Å
(white). While there is a section of the EGFR vs VEGFR DDM (Figure 5.4) indicating
relatively small movements between residues (blue/green areas), the majority shows a
greater magnitude of conformational change (yellow/red/white areas) between EGFR and
VEGFR.
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Figure 5.4: DDM graph comparison of EGFR (1M17) vs VEGFR (1Y6B) crystal structures.
Represents distance moved between residues: blue = 0-3 Å, green = 3-5 Å, yellow = 5-9 Å, red = 9-15 Å,
white > 15 Å.

The large regions of dissimilarity seen in the EGFR vs VEGFR DDM most likely arise
from Proflex’s method of aligning the amino acid sequences prior to performing distance
calculations. During alignment, only exact amino acid matches are made with necessary
spaces added in the sequences to maximise the number of matches. This does not translate
well for the EGFR/VEGFR alignment,♠ which has many similar but not identical regions.
Therefore, there are insufficient identical regions between EGFR and VEGFR for proflex to
provide an accurate alignment.

♠

See appendix for Proflex sequence alignment
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Consequently focus moved to Clustal W#, a general purpose sequence alignment program
for proteins, which calculates the best match for the selected sequences, and aligns them
such that the identities, similarities and differences can be analysed.157-159 The program
applies weight matrices and gap penalties during the alignment to achieve more realistic
and accurate results.158 Phylogeny guide trees are utilised to determine the evolutionary
distances between the proteins so that different amino acid weight matrices can be applied
during sequence analysis. Also, gaps in amino acid sequences should not be random, most
often they fall between secondary structural elements (e.g.  helices,  sheets) and this is
one of the ways that the method of gap penalties improves the outcome.158

Submission of the EGFR and VEGFR crystal structure sequences into Clustal W resulted in
an alignment more accurate and consistent with previous sequence alignments among other
growth factors.24,121,154 Of particular note is the HRDLAARN sequence conservation
(Figure 5.5; Row 4, Residues 154-161) in the catalytic loop.

#

Clustal W 1.83 was used in this project, however Clustal W 2.0 was released in more recent years.
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Figure 5.5: Sequence alignment of EGFR (1M17) vs VEGFR (1Y6B) crystal structures generated from
Clustal W. Darkest shading = exact residue match, Lighter shades = similar amino acid residues in alignment.
Note: Common HRDLAARN section in catalytic loop - Row 4, Residues 154-161.

A visual 3D comparison of the EGFR and VEGFR crystal structures was then obtained via
superimposition of the alignment generated by Clustal W. The inverse superimposition (ie
EGFR superimposed onto VEGFR followed by VEGFR superimposed onto EGFR) yielded
an identical RMSDϒ of 3.00 which verified the result. The overlayed crystal structures
showed that both receptors consist of similar  helices in the C-terminal and  sheets in the
N-terminal with the binding pocket in between (Figure 5.6).

ϒ

RMSD = Root Mean Square Difference. Lower values signify close alignment, whereas higher values
indicate poor alignment.
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N-terminal

Binding Pocket

C-terminal

Figure 5.6: Alignment of EGFR (1M17 - yellow) and VEGFR (1Y6B - purple) crystal structures. Both
receptors consist of an alpha helical C-terminal (right hand side), binding pocket (middle) and an N-terminal
containing beta sheets (left hand side).

The binding pockets of both the EGFR and VEGFR tyrosine kinase domains are normally
involved in ATP binding (refer to Figure 1.1). Individual residues important in the binding
of ATP have been reported154 for EGFR and other growth factor receptors, but not VEGFR.
Therefore, using the known EGFR ATP binding residues and EGFR/VEGFR alignment
from Clustal W, the VEGFR ATP binding residues could also be derived and these are
summarised as shown in Table 5.1. Some of the HRDLAARN amino acids (shown in blue
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in Table 5.1) appear in this group, further highlighting their catalytic function and high
conservation among growth factor receptors (refer to Section 5.2).

EGFR Crystal
Structure Residue
Leu694
Gly695
Gly697
Ala698
Phe699
Gly700
Val702
Ala719
Lys721
Cys751
Thr766
Leu768
Met769
Cys773
Asp813
Ala815
Arg817
Asn818
Leu820
Thr830
Asp831

***
***
***
***
***
***
***
***
***
*
*
**
*
*
***
***
***
***
***
**
***

VEGFR Crystal
Structure Residue
Leu838
Gly839
Gly841
Ala842
Phe843
Gly844
Val846
Ala864
Lys866
Val897
Val914
Phe916
Cys917
Asn921
Asp1026
Ala1028
Arg1030
Asn1031
Leu1033
Cys1043
Asp1044

Table 5.1: ATP binding residues found in EGFR (1M17) and VEGFR (1Y6B) crystal structures. Most of
these key residues are exactly the same (***), closely related (**) or not too dissimilar (*) between the two
receptors. Residues highlighted in green make up part of the highly conserved HRDLAARN region
throughout growth factor receptors. VEGFR residues in grey italics are included for comparison, however
they not defined in the crystal structure.

The key ATP residues of the binding pocket are similar between EGFR and VEGFR and
this is visualised in Figure 5.7.
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(a)

(b)
Figure 5.7: EGFR and VEGFR crystal structures aligned showing ATP binding residues in the binding cleft:
(a) EGFR (1M17) – yellow ribbon with orange ATP binding residues and VEGFR (1Y6B) – purple ribbon
with red ATP binding residues; (b) Magnified view of (a), showing detail of the amino acid residues
important for ATP binding (EGFR – yellow ribbons + orange residues, VEGFR – purple ribbons + red
residues).
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Throughout the comparative analysis of EGFR and VEGFR they have shown similar
features, particularly in the binding regions e.g. catalytic loop and other ATP binding
residues. However, further investigation of inhibitor interaction with each of these receptors
could highlight the subtle differences and provide the keys to selectivity and affinity.

5.3 Computer Aided Drug Design
One of the most useful applications of crystallography is computer-aided drug design
(CADD).160 Computational methodologies have become a vital component of drug
discovery by providing valuable tools to speed up the lead identification and optimisation
process.116,161 In particular, the method of docking small molecules into a protein binding
site has become widely used for high-throughput hit identification. Furthermore, similar
calculations can assist lead optimisation through efficient testing/docking of modified
active structures in computer models.116 These results can be combined with known
structure-activity relationship (SAR) data to further optimise and refine target compounds.
Of the reported techniques for automated docking simulations, AutoDock is a robust
method.127

AutoDock is a software packageℵ designed to provide an automated procedure for
predicting bound conformations of small flexible ligands (e.g. substrates or inhibitors) to
target macromolecules/proteins (e.g. receptors).127,162 Initially, the ligand is randomly
placed outside the target receptor, then translations, orientations and conformations are
explored until an ideal fit is found.127,160 For rapid performance of this operation, AutoDock
ℵ

The AutoDock 3.0 program suite was used for this project, including AutoGrid 3.0 and the AutoDock Tools
(ADT) user interface. Version 4 only became available part way through these studies.163,164
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requires grid maps, one for each atom type of the ligand e.g. C, O, N, H and a separate
electrostatic potential grid, pre-calculated by AutoGrid (part of the AutoDock suite).160,162
Each grid map consists of a three dimensional lattice encompassing the protein target area
(e.g. binding site) and a probe atom is sequentially placed at each of the regular grid points
(See Figure 5.8).160,162 The interaction energy of the each probe atom is calculated and
stored for each atom type with the protein, along with an electrostatic potential grid,
calculated using a positively charged (+1) probe.160,165 Once completed, these grids are used
as look-up tables for the rapid evaluation of ligand conformations during the docking
calculation.160,165

Figure 5.8: Schematic Representation of an Autogrid Map.162 The entire protein (or the target binding site) is
surrounded by a three dimensional grid and a probe atom is placed at each regularly spaced grid point. The
probe atom is used to calculate interaction energies for each ligand atom type and the electrostatic potential.
These energies are stored in look-up tables for use during ligand conformation evaluation, significantly
reducing the time needed for docking calculations.
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The exploration of possible ligand conformations can be carried out using one of four
methods provided by AutoDock: simulated annealing (SA), Local Search (LS), genetic
algorithm (GA) and Lamarckian genetic algorithm (LGA).127 Simulated annealing is an
earlier functionality that is now rarely used, due to the global search and energy
minimization techniques provided in the more recent, optimised methods. The GA method
employs Darwinian principles to generate a random population of conformations, which
undergoes selection, mutation and crossover to give a new population, known as the next
generation. This process is repeated over a number of generations defined by the user, with
AutoDock reporting the ligand/s with the lowest binding energy. In the hybrid LGA
method, each GA generation is followed by a local search (LS), improving the overall
‘smoothness’ and ‘fitness’ of lowest energy ligand.127 LGA provides the most efficient,
reliable and successful performance and therefore is the preferred methodology. The ligand
conformations and corresponding energies generated during AutoDock’s algorithm are then
analysed and placed within clusters based on a user defined RMSD (usually set between 0.5
and 1.5).162

Utilising AutoDock, docking studies on EGFR and VEGFR can be performed with various
inhibitors. Crystal structures of the EGFR and VEGFR kinase domains supply the target
protein information for these docking studies and can also help to map out the general
binding site region via bound inhibitor examples, such as 1M17 and 1Y6B (Figure 5.9).
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(a)

(b)
Figure 5.9: Examples of Crystal Structures of inhibitor bound EGFR and VEGFR kinase domains to be used
in AutoDock studies (a) 1M17: EGFR with Erlotinib bound; (b) 1Y6B: VEGFR with oxazole bound. Both
crystal structures clearly show the inhibitors binding in the cleft/pocket area between the N and C terminals,
outlining the binding region to be applied in docking studies.

Docking of a number of known and theoretical inhibitors can prove valuable, with
examination of the resulting bound conformations providing further information about
ligand placement and mode of binding in the receptor binding site. Ultimately, the aim of
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these docking studies was to reveal the similarities and/or differences between the EGFR
and VEGFR receptors binding sites, as well as how they influence and help towards the
development of selective, high affinity ligands (incorporating 18F, 123I for labelling).

Furthermore, as the inhibitor bound crystal structures continue to be elucidated,122,166-170
more clues are provided about EGFR and VEGFR binding. In addition, these other crystal
structures can be used to validate the results obtained from Autodock predictions. All of the
data obtained through the utilisation of computer-aided technology could lead to the
optimisation of EGF/VEGF RTK inhibitors.

5.3.1 EGFR Docking Studies and Analysis
The calibration of AutoDock for EGFR docking studies was carried out using the inhibitor
bound crystal structure, 1M17. This process involved drawing and optimising the ligand,
Erlotinib, for docking into the EGFR crystal structure (with inhibitor removed), to predict
the binding results. It is also important to note that during the preparation of the receptor
crystal structure for docking, all insignificant water molecules are removed ie those not
involved in ligand binding.171 Therefore, only one water molecule directly within the
binding area was retained.

These results were compared to the binding position and properties of the crystal structure
bound inhibitor. The predicted Erlotinib conformation (as generated in the major cluster of
the docking results) was very similar to the actual binding conformation, showing almost
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all the same interactions as the crystal structure (Figure 5.10). These results validate the use
of Autodock methodology for further docking studies in the EGFR.

(a)

(b)

Figure 5.10: Calibration of the AutoDock Method using Inhibitor bound EGFR Crystal Structure 1M17 (a)
Full view of 1M17, EGFR (ribbons) with Erlotinib bound (grey carbon structure), overlayed with Autodock’s
predicted conformation (orange structure); (b) Magnified view clearly shows how the predicted conformation
(orange structure) is very similar to the actual bound conformation from the crystal structure, 1M17. Many of
the same interactions are shared by both conformations as the quinazoline core and aniline group adopt the
same conformation, with only the alkoxy side chains differing slightly.

A number of known compounds and potential target compounds were chosen for docking.
Table 5.2 outlines all of the compounds tested in the docking studies, with those tested in
EGFR marked in blue (stars represent strong inhibition for this receptor, while dashes were
tests performed for weak or unknown inhibition values). The EGFR testing encompassed
compounds which were non-selective, EGFR selective, VEGFR selective and potential
target compounds.

98

A
A
B
B
B
B
B
B
B
B
B
B
B
B
B
B
C
C
C
D
E
F

Series

A

R2

Name
(if known)
Oxazole 39
Oxazole 46
Erlotinib (OSI774)
Iressa (ZD1839)
CI1033 (irreversible)
ZD6474
PD153035
GW2016
[36]
[37]
[42]
[47]
[49]
[73]
[74]
ZD4190
SU5416
SU11248
SU6668
PTK787
AEE788
AZD2171

N
H OMe

R1
N

R3

R1

R2
N
H

R2

D

N
N
N

-O(CH2)2OCH3
-OCH3
-O(CH2)3morpholine
-OCH2piperidineCH3
-OCH3
-H
-O(CH2)2F
-O(CH2)2F
-OCH3
-OCH3
-OCH3
-OCH3
-OCH3
-O(CH2)2-1,2,3triazole
-H
-F
-H
-

N
H
O
C

-Et
-NHCH2-cyclopropane
-O(CH2)2OCH3
-O(CH2)3morpholine
-NHCOCHCH2
-OCH3
-OCH3
-furanCH2NH(CH2)2SO2CH3
-OCH3
-OCH3
-OCH3
-OCH3
-OCH3
-OCH3
-OCH3
-OCH3
-H
-CONH(CH2)2N(Et)2
-(CH2)2COOH
-

B

N

HN

HN

Cl

R3

N
E

N
H

3-ethynyl
3-Cl, 4-F
3-Cl, 4-F
2-F, 4-Br
3-Br
3-Cl, 4-OCH2(3-FPh)
3-Br
3-Cl
3-Cl
3-CHCHI
3-O(CH2)2F
3-(CH2)2F
3-F
2-F, 4-Br
-

N

N

C
N
-

σ

X

N

HN

Ph

N
C
-

σ

Y

‘
*
‘

*
*
*
*
*
*
‘
‘
‘
‘
‘
‘
‘

EGFR

N
F

*
*
*
*
*
*
*

‘
‘

‘

*

*
*
‘
‘

VEGFR

O

O
N

O
F

22 nM 125
38 nM 125
2 nM 75
5 nM 75
0.8 nM 77
500 nM; 40 nM 70
0.029 nM 75
10 nM 52
30 nM 74
220 nM 63
38 nM 63
2100 nM 62
37 nM 62,75
2 nM; 77 nM 87
1 nM 62,63

Lit. IC50 Values

N

H
N
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Table 5.2: Summary of Docked Compounds in EGFR and VEGFR (Literature IC50 values are quoted for known inhibitors of EGFR and VEGFR where
available). All known inhibitors were tested/docked into its respective receptor (*) to study binding interactions, while the theoretical/synthetic series ([36]-[74])
and some of the known inhibitors were docked into different receptors (‘) to investigate other interactions. σNote: X and Y functionalities only appear in Series A
structures.

Comp
#
70
71
18
17
19
20
13
72
36
37
42
47
49
73
74
21
7
9
8
10
11
22

Y
X

O

N

SO2R1

R1

All of the EGFR docking studies revealed similar results (Figure 5.11), where the binding
consistently occurred throughout one region of the binding cleft having interactions with
Met769, Gln767, Thr766 and Gly772/Cys773 while some portions of the ligands/inhibitors
often also extended into the hydrophobic binding pocket.

(a)

(b)

(c)

(d)

Figure 5.11: EGFR with cluster of docked conformations generated using Autodock. (a) Full view of
receptor (represented in space filling view; N terminal on the left, C terminal on the right and binding pocket
in the middle) with docked inhibitors in binding pocket; (b) Full view rotated 90° to reveal greater view of the
inhibitors in binding pocket; (c) & (d) magnified views of (b) revealing similar/ consistent interactions in one
main region and many inhibitors extending up into the hydrophobic binding pocket (aniline substituent).
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Most of the EGFR AutoDock studies produced very good results having a small to medium
number of clusters, with the majority of conformers falling within the top clusters. Some
examples of the docked compounds are outlined to highlight the favourable and negative
binding interactions that have been discovered in these studies.

Docking of ZD1839 [17] into EGFR resulted in two major conformations which were very
similar (Figure 5.12). Therefore the same general interactions were seen with H-bonds
between the quinazoline N atoms and Met769/Gln767/Thr766, the aniline reaching back
into the hydrophobic binding pocket and the morpholine side chains extending out of the
binding pocket.
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(a)

(b)
F
O

HN
N

O
O

(c)

Cl
N

N

(d)

Figure 5.12: ZD1839 [17] docked conformations in EGFR generated using Autodock. (a) Full view of
receptor (N terminal at top, C terminal at bottom and binding cleft in the middle) with docked conformations
(green and blue structures) in binding cleft; (b) Full view rotated 90° to reveal greater view of the
conformations in binding pocket; (c) Magnified view of the top two docked conformations revealing
interactions with the EGF receptor; (d) A more detailed view of the top docked conformation (representing 50
out 250 possible conformations), clearly showing the interactions between the quinazoline N atoms with
Met769/Gln767 and Thr766 and the aniline in the hydrophobic binding pocket.
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The major conformations of PD153035 [13] generated by docking into EGFR are
represented in Figure 5.13. Despite slightly different orientations, both conformations show
the same general interactions exhibiting H-bonds between the quinazoline N atoms and
Gln767/Thr766, 6-OMe and Gly772, while the aniline appears in the hydrophobic binding
pocket with the 3-Br substituent either directed towards Asp831/Phe832 or Lys721.

(a)

(b)
HN
O
O

Br
N

N

Figure 5.13: PD153035 [13] docked conformations in EGFR generated using Autodock. (a) Magnified view
of the top two docked conformations (green and yellow structures) revealing interactions with the EGF
receptor; (b) A transparent view shows the interactions in greater detail, revealing binding between the
quinazoline N atoms and Gln767/Thr766, 6-OMe and Gly772 and the aniline in the hydrophobic binding
pocket with the 3-Br substituent either directed towards Asp831/Phe832 or Lys721.

The synthetic inhibitor [36] was also docked into EGFR with positive results. Out of the
250 possible conformers, over 200 were represented in two clusters that showed very
similar conformations (Figure 5.14). General H-bond interactions seen for these predicted
bound conformations were between the quinazoline N atoms and Gln767/Thr766, 6-OMe/F
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and Gly772 with the 3-Br substituted aniline in the hydrophobic binding pocket directed
towards either Asp831 or Lys721/Ile765.

(a)

(b)
HN
O
F

(c)

O

Br
N

N

(d)

Figure 5.14: [36] docked conformations in EGFR generated using Autodock. (a) Full view of receptor with
docked conformations (green and blue structures) in binding cleft; (b) Rotated (90° to the left and moved
from horizontal to vertical) view of (a); (c) Magnified view of (b) to highlight binding interactions within the
pocket; (d) Transparent view of (c) to show residues involved in binding and reveal more detail within the
hydrophobic binding pocket, where the aniline substituents can interact with Lys721 or Asp831/Phe832.

Similar results were obtained for the synthetic inhibitor [37], where two major clusters
included almost all of the 250 possible conformers. These clusters contained similar
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conformations with H-bond interactions noted between the quinazoline N atoms and
Met769/Gln767/Thr766, NH and H2O, 6-OMe/F and Gly772 (Figure 5.15). The 3-Cl
aniline in the hydrophobic binding pocket also showed varying interactions with Asp831
and Lys721/Ile765.

(a)

(b)
HN
O
F

O

Cl
N

N

Figure 5.15: [37] docked conformations in EGFR generated using Autodock. (a) Magnified view of the top
two docked conformations (green and blue structures) revealing interactions with the EGF receptor; (b) A
transparent view shows the interactions in greater detail, revealing binding between the quinazoline N atoms
and Thr766/Gln767/Met769, 6-OMe and Gly772 and the aniline directed up into in the hydrophobic binding
pocket.

Docking of [49] (a theoretical inhibitor) into EGFR formed part of an investigation into the
effect of bulky aniline substituents. The results showed many similar conformers in the
major cluster/s with the following general interactions seen: quinazoline N atoms and
Met769/Gln767/Thr766, NH and H2O, 7-OMe and Gly772 (Figure 5.16). The aniline in the
hydrophobic binding pocket showed variable positions between Asp831/Phe832 and
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Lys721/Ile765 and was sitting further out of the binding pocket due to the 3-OCH2CH2F
substituent.

(a)

(b)
HN
O
O

(c)
O

F

N
N

Figure 5.16: [49] docked conformations in EGFR generated using Autodock. (a) Magnified view of major
docked conformation of [49] (green structures) in EGFR receptor binding cleft; (b) Transparent view of (a),
highlighting key H-bond interactions; (c) Rotated view of (a) illustrates how the bulky substituted aniline
places the inhibitor further out of the hydrophobic binding pocket.

Finally, a comparison of the predicted bound conformations with the crystal structure
Erlotinib was performed to highlight the binding trends discovered throughout these
docking studies in EGFR (Figure 5.17). Most of the ligands tested were anilinoquinazolines
and therefore, receptor binding occurred through the same key interactions (Figure 5.17a).
The quinazoline core binds in the centre of the binding cleft through H-bond interactions
between the quinazoline N1/N3 atoms and Met769/Gln767/Thr766. The aniline group fits
into the hydrophobic pocket (towards the back of the binding cleft) where smaller
substituents e.g. halogens can interact with Asp831/Phe832 or Lys721/Ile765. The alkoxy
side chains lie at the edge of the binding pocket, however some positive interactions were
seen with Gly772/Cys773 for inhibitors with longer chains (particularly at the 6 position).
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(a)

(b)

(c)

(e)

(d)

(f)

Figure 5.17: Binding trends of EGFR docking studies and comparison with Erlotinib [18] from 1M17 crystal
structure. (a) Docked conformations (coloured structures) compared with Erlotinib [18] (grey carbon
structure) illustrating general binding trends (Green residues and interactions) formed throughout EGFR
docking studies; (b) Surface view of EGFR with structures from (a) in binding pocket; (c) Transparent view
of (b) with docked conformations (coloured structures) and Erlotinib [18] (grey carbon structure) in EGFR
binding cleft, key residues are noted in green; (d) Docked conformations of the known ligands, ZD1839 [17]
(yellow) and PD153035 [13] (green) with Erlotinib [18] (grey carbon structure) in EGFR binding cleft
(transparent view); (e) Docked conformations of the synthetic ligands, [36] (blue) and …cont. over page…
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… [37] (purple) show very close resemblance to Erlotinib [18] (grey carbon structure) in EGFR binding cleft
(transparent view); (f) Docked conformations of the ligands with bulky aniline substituents, [47] (magenta)
and [49] (orange), show different orientation around the quinazoline core compared with Erlotinib [18] (grey
carbon structure) as they are forced out of the hydrophobic binding pocket (transparent view).

Docked conformations of known inhibitors e.g. Iressa (ZD1839) [17] and PD153035 [13]
are very similar to the actual binding position of Erlotinib [18] (Figure 5.17d). In addition,
the synthetic compounds, [36] and [37] showed a close resemblance to the Erlotinib crystal
structure, picking up on the same key interactions (Figure 5.17e). These studies also
highlighted the effect of bulky aniline substituents, forcing it out of the hydrophobic pocket
and altering the remaining position of the quinazoline in the binding cleft, as seen in the
case of [47] and [49] (Figure 5.17f).

5.3.2 VEGFR Docking Studies and Analysis
Both of the oxazole inhibitors ([70] and [71], Table 5.2) in the VEGFR crystal structures,
1Y6A and 1Y6B, were used to calibrate the AutoDock methodology. This was performed
as previously described for EGFR in Section 5.3.1. The predicted bound conformations of
these oxazole molecules were very similar to actual bound conformations (See appendix),
showing the same important H-bond interactions.

The Proflex DDM performed previously on 1Y6A and 1Y6B (see Figure 5.3b) determined
there was no significant difference between the VEGFR crystal structures. Therefore, 1Y6B
was also used for the docking experiments as it was a more complete structure.
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Docking studies in VEGFR were performed for a number of compounds (See Table 5.2;
green data), including known inhibitors (stars) and weak or theoretical inhibitors (dashes).
Throughout these studies Glu915 and Cys917 were usually found to be involved in binding,
but the predicted binding position and therefore other interactions varied greatly (Figure
5.18). This may be due to the more open channel-like area for binding in the VEGFR
crystal structure.

(a)

(b)

(c)

(d)

Figure 5.18: VEGFR with cluster of docked conformations generated using Autodock. (a) Full view of
receptor (represented in space filling view; N terminal on the left, C terminal on the right and binding cleft in
the middle) with docked inhibitors in binding cleft; (b) Fullview rotated 90° to reveal greater view of the
inhibitors in binding pocket; (c) & (d) magnified views of (b) reveal a more varied spread of conformations
throughout the binding cleft, with only some utilising the small pocket (seen more clearly in d).
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The VEGFR AutoDock studies resulted in a medium to large number of clusters, with each
cluster often only containing a small number of conformers, which greatly decreases the
predictability of the expected binding position. The following examples are some of the
best docked compounds, highlighting the favourable and negative interactions that have
been discovered in these studies of a diverse compound set.

Docking of PTK787 [10] into VEGFR resulted in two major clusters which represented
very different conformations (Figure 5.19). The largest cluster showed H-bond interactions
between NH and Cys917, NH and Gly920, pyridyl N atoms with Leu838/Arg840 and the
phenyl group was directed out of the binding pocket. The other major conformation placed
the phthalazine core in same region as above, but laying sideways such that the pyridyl N
atoms was in the Ala864/Val865/Val912 region and the phenyl group interacted with
Asn921 on the edge of binding pocket.

110

(a)

(b)
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N

(c)

(d)

Figure 5.19: PTK787 [10] docked conformations in VEGFR generated using Autodock. (a) Full view of
receptor (represented in space filling view; C terminal on the left, N terminal on the right and binding cleft in
the middle) with docked inhibitors in binding cleft; (b) Fullview rotated 90° to reveal better view of the
inhibitors in binding pocket; (c) Magnified view of the top two docked conformations (yellow - largest
cluster, green - 2nd largest cluster) within the VEGF receptor; (d) Transparent view of (c) revealing the
different binding interactions within the VEGF receptor for the two top docked conformations.

The indolinone inhibitor, SU5416 [7], also performed well in VEGFR docking studies,
producing interesting results. Upon comparing the conformations seen in the top clusters,
very different binding positions and interactions were observed (Figure 5.20). The major
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cluster (green) shows the pyrrole group pointing back into the binding pocket, with the
indolinone core occupying the groove leading out of the binding pocket. H-bond interaction
is mainly between Glu915 and indolinone NH and C=O. In contrast, the 2nd largest cluster
(orange) placed the indolinone core in same region as the pyrrole group of the cluster above
(ie back of binding pocket) with its pyrrole side chain extending into space at the side of the
binding pocket. The indolinone NH and C=O are involved in H-bond interactions with
Glu883 and Lys866.

(a)

(b)

N
H

N
H
O

Figure 5.20: SU5416 [7] docked conformations in VEGFR generated using Autodock. (a) Magnified view of
the top two docked conformations (green – largest cluster, orange – 2nd largest cluster) revealing predicted
binding within the VEGF receptor; (b) A transparent view shows the binding interactions in greater detail,
revealing H-bonds between the core indolinone NH and C=O and Glu915 (green) or Glu883/Lys866 (orange).

The synthetic inhibitor [47] was also docked into VEGFR with good results. One large
cluster dominated, but showed similar conformations to the other top clusters. General Hbond interactions were seen between the quinazoline N3 and Glu883/Lys866, NH and
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Gly841, 6-OMe and Cys917, and the 3-iodoethenyl aniline substituent in the hydrophobic
binding pocket directed towards Asn1031 (Figure 5.21).

(a)

(b)
HN
O
O

(c)

O
O
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N

N

(d)

Figure 5.21: [47] docked conformations in VEGFR generated using Autodock. (a) Full view of receptor
(represented in space filling view; C terminal on the bottom, N terminal at the top and binding pocket in the
middle) with docked inhibitors in binding pocket; (b) Full view rotated 90° to reveal better view of the
inhibitors in binding pocket; (c) Magnified view of the top two docked conformations (green represents
largest cluster, while yellow is second largest cluster) within the VEGF receptor; (d) Transparent view of (c)
revealing the predicted binding interactions within the VEGF receptor for the two top docked conformations.
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The known bound conformations of oxazole [70] and [71] (1Y6A & 1Y6B crystal
structures) were compared to the docking results obtained for VEGFR. Selected docked
conformations are shown alongside both oxazole molecules to illustrate how binding varied
within the VEGFR binding cleft (Figure 5.22). Even within individual compound families,
such as the indolinones, predicted binding is spread throughout the binding cleft (Figure
5.22c). Of particular note is SU5416 [7], where the two major docked conformations for
this one compound (light and dark purple, Figure 5.22c) exhibit different binding patterns.
For the few quinazoline compounds tested in VEGFR, there was also mixed results (Figure
5.22d). While [47] (orange) showed binding towards the back of the binding cleft with the
iodoethenylaniline group interacting at the upper back opening, the predicted binding of
[37] (yellow) placed the quinazoline core and chloroaniline group at the binding cleft's
edge. The docked conformations generated for other types of inhibitors continued the trend
of different binding regions throughout the binding cleft e.g. PTK787 [10] (blue) and
AEE788 [11] (green) in Figure 5.22e. However, most of the docked compounds overlapped
with, at least partially, the known binding area of the oxazoles and many were involved in
the same key H-bond interactions e.g. Glu883/Lys866, Cys917/Gly915.
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(a)

(c)

(b)

(d)

(e)

Figure 5.22: Binding trends of VEGFR docking studies and comparison with oxazole from 1Y6A/1Y6B
crystal structures. (a) Docked conformations (coloured structures) compared with oxazole molecules [70] and
[71] (grey carbon structures), illustrating general binding trends formed throughout VEGFR docking studies;
(b) Surface view of VEGFR binding cleft containing structures from (a); (c) Docked conformations of
indolinone ligands, SU5416 [7] (light and dark purple) and SU6668 (red) are quite varied within the same
family with each conformation utilising different regions of the VEGFR binding cleft, all of which bind at
similar points to the oxazoles [70] and [71] (grey carbon structures); (d) Docked conformations of the
quinazoline ligands, with oxazoles [70] and [71] (grey carbon structures) in VEGFR binding cleft - [47]
(orange) binds further back in cleft with the iodoethenylaniline substituent interacting at upper opening (top
right corner) and [37] (yellow) is closer to the binding cleft's edge with the chloroaniline protruding out
(bottom left corner); (e) Examples of docked conformations for other compound families: PTK787 [10] (blue)
and AEE788 [11] (green), show more unique binding orientations for the VEGFR binding cleft while still
incorporating some of the key binding regions for oxazoles [70] and [71] (grey carbon structures).
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5.3.3 Comparing EGFR and VEGFR Docking Results
The summary of all of the docking studies in Table 5.2 shows how the inhibitor/ligand
structures are more varied for VEGFR, compared to quinazoline dominated EGFR
inhibitors. The calibration molecules used for VEGFR (oxazoles; [70] and [71]) are also
quite different to other compounds tested, where as EGFR had the quinazoline structure,
Erlotinib [18] as the calibration molecule. This may have contributed to the fact that better
and more consistent results were obtained for the EGFR docking runs (vs VEGFR).

All of the VEGFR crystal structures available did not map ~50 residues between Tyr936
and Phe997 (most likely due to flexibility of region). If these residues are part of the key
binding region this would prove crucial to the outcome of the docking results. However, it
has been shown that these residues form part of the Kinase Insert Domain (KID) and their
deletion has no effect on intrinsic kinase activity.121 The ~50 unmapped residues should
appear between Tyr936 and Phe997, which are highlighted in Figure 5.23 to identify the
KID area within the C terminal.
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Figure 5.23: VEGFR crystal structure (1Y6B) highlighting residues not mapped within the Kinase Insert
Domain (KID): There are no amino acids mapped between Tyr936 and Phe997 (Blue residues) in the VEGFR
crystal structure. However since these are part of the Kinase Insert Domain within the C terminal, it is
expected to not greatly affect the docking studies.

It was hoped to be able to draw conclusions about the subtle similarities and differences
which lead to small changes in binding interactions between these growth factor receptors
and their inhibitors. Despite the clear and consistent trends witnessed in the EGFR docking
studies, the results gained from the VEGFR model were much more varied and not as
reliable. Therefore we could not fully establish the unique features of VEGFR and its
inhibitors compared to EGFR.

However, the AutoDock studies did provide some valuable docking results, particularly for
the theoretical/synthetic inhibitors, e.g. [36] and [37]. Both compounds generated consistent
results within their docking studies and the predicted conformations and interactions were
very similar to the known, potent inhibitor Erlotinib [18]. Therefore, [36] and [37] showed
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greater potential as EGFR inhibitors. This was ultimately supported by very promising in
vitro data obtained once synthesis was complete (see Section 4.2.1).

In contrast, [47] didn’t seem to fit as well in EGFR, having a bulky aniline substituent, but
showed reasonable results for VEGFR. This could suggest a weaker inhibitor that would be
VEGFR selective. Since only in vivo data for an EGFR model has been completed for this
compound (showing some inhibition, see Section 4.3), further testing would be required to
investigate the VEGFR affinity and selectivity of [47].

5.3.4 Limitations of Docking/Autodock
Some other limitations or problems that were encountered while carrying out the AutoDock
studies may have contributed to the results obtained. These are important considerations
when analysing results for future studies.

Ligands containing longer flexible chains gave poorer results (when consistent RMS
tolerances were used throughout runs). This is due to an increase in the variability of the
conformations generated and should be considered during analysis or when setting RMS
tolerances.

Docking studies can be performed with the ligand starting from any position outside of the
receptor. However in brief testing, marginally better results were obtained when the ligand
started the docking run within the binding region/grid. This would need to be investigated
further and if necessary, taken into account for future AutoDock studies.
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The AutoDock program also limited the type of ligand to be docked, as ligands with more
than 5 different atom types could not be used. This proved problematic since the ligands in
this project often contained multiple halogens and occasionally sulphur as well. Alternative
ligands with different atom composition were evaluated initially, however once details on
how to change the AutoDock software to allow more atom types were sourced,♦ all ligands
could be successfully docked.

5.4 Comparing Docking Studies with Crystal Structures
Since starting work on docking studies, additional crystal structures of the EGFR and
VEGFR kinase domains have been published.122,123,166-170 These crystal structures contain
complexed inhibitors and serve as a useful tool in furthering the CADD process. This is
particularly the case for the EGFR, as some of the inhibitors previously tested in the
docking studies are now present in the crystal structures.ƒ Therefore a direct comparison of
the theoretical docking and the actual binding modes can be carried out.

The EGFR crystal structures 2ITY and 2J6M contain the bound inhibitors, Iressa (ZD1839)
[17] and AEE788 [11], respectively.122,166 The predicted docked conformations of Iressa
and AEE788 [11] generated using Autodock (see Section 5.3.1) were superimposed onto
these crystal structures for comparison.

♦

See experimental for details (Section 7.6.4)
Crystal structures containing mutant EGFR were also published by this group.122,166 Additional Autodock
studies with the native mutant EGFR would be required before comparing docked conformations of bound
inhibitors in these crystal structures.

ƒ
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The most striking resemblance occurred between the predicted and bound conformations of
Iressa in EGFR (Figure 5.24), with the anilinoquinazoline core overlapping and only the
morpholine side chain altering position slighty.

(a)

(b)
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O
O
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N

Figure 5.24: Superimposition of the crystal structures 1M17 (yellow) and 2ITY (green) containing the
inhibitor ZD1839 (Iressa): (a) The bound inhibitor ZD1839 [17] (grey/element format) from the 2ITY crystal
structure is aligned with the docked conformation (orange) generated using 1M17 in Autodock, within the
superimposed crystal structures; (b) the magnified view clearly shows how closely the docked conformation
resembles the actual mode of binding seen in the inhibitor bound crystal structure, with only the morpholine
side deviating slightly.

Consequently, the major binding interactions (e.g. H-bonds with Gln767, Met769, Gly772
and Lys721) are also shared by both conformations (Figure 5.25).
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(a)

(b)

Figure 5.25: Binding Interaction Comparison of the crystal structure and docked conformation for the
inhibitor ZD1839 (Iressa): The bound inhibitor ZD1839 [17] (grey/element format) from the 2ITY crystal
structure is aligned with the docked conformation (orange) generated using 1M17 in Autodock and shown in
a surface model of the EGFR receptor to highlight binding interactions. (a) Quinazoline core and aniline are
aligned so that H-bond interaction is shared by both conformations is between the quinazoline N1 and
Met769; (b) H-bond interactions are highlighted and revealed in greater detail by the transparent view.
Interactions include: Omorph with Ser696, 6-OMe with Gly772, quinazoline N1 and N3 with Met769 and
Gln767, and the 3-Cl or 4-F aniline substituents interacting with either Lys721 or Asp831 (crystal structure
and docked conformation respectively).

There was also a close resemblance between the predicted and bound conformations of
AEE788 [11] in EGFR (Figure 5.26), with similar positions of the pyrrolopyrimidine core
while the pyridine group reaches back into the pocket and the phenyl/pyrazine chains
extend out of the binding pocket.
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Figure 5.26: Superimposition of the crystal structures 1M17 (yellow) and 2J6M (blue) containing the
inhibitor AEE788 [11]: (a) The bound inhibitor AEE788 [11] (grey/element format) from the 2J6M crystal
structure is aligned with the docked conformation (green) generated using 1M17 in Autodock, within the
superimposed crystal structures; (b) the magnified view shows how the docked conformation resembles the
actual mode of binding seen in the inhibitor bound crystal structure, through similar positions of the
pyrrolopyrimidine core with the phenyl/pyrazine chains extending out of the binding pocket (front of page)
while the pyridine group reaches back into the pocket.

The major binding interaction shared by both conformations is the H-bond between the
pyrrolopyrimidine N atoms and Met 769 (Figure 5.27).
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(a)

(b)

Figure 5.27: Binding Interaction Comparison of the crystal structure and docked conformation for the
inhibitor AEE788 [11]: The bound inhibitor AEE788 [11] (grey/element format) from the 2J6M crystal
structure is aligned with the docked conformation (green) generated using 1M17 in Autodock and shown in a
surface model of the EGFR receptor to highlight binding interactions. (a) Top view of aligned inhibitors in
binding pocket, showing the crossover between the pyrrolopyrimidine core and both having the pyridine side
chain occupying the space at the rear of the binding pocket while the phenyl/pyrazine chains extend out of the
binding pocket (bottom of page). (b) Main H-bond interaction (dashed lines: dark grey - bound inhibitor,
green – docked conformation) shared by both conformations is between the pyrrolopyrimidine N atoms and
Met769.

While there was also a number of new VEGFR crystal structures complexed with
inhibitors,167-170 none of them contained the same inhibitors as those used in docking
studies. Therefore, further evaluation is required when the appropriate crystal structures
become available.

For the comparisons with complexed EGFR crystal structures very similar binding
interactions were seen to those predicted by our docking studies. This not only validates the
AutoDock methodology, but provides further justification to expand on these initial studies
in the search for potent and selective EGF and VEGF RTK inhibitors.
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5.5 Summary
Detailed analysis of the target RTK crystal structures was performed, including the first
direct alignment EGFR and VEGFR (Section 5.2). This highlighted the similarities between
their binding sites e.g. key residues involved in ATP/inhibitor binding and the common
HRDLAARN catalytic loop.

Further studies using computer-aided tools such as AutoDock, enabled visualisation of
inhibitor binding within each receptor. The results for EGFR proved most useful, with
predicted binding forming consistent patterns for the test compounds. Inhibitor docking in
VEGFR was more varied since the binding area appeared to be more open, having a
channel-like shape. However for most of the docked compounds, a few common binding
interactions were maintained e.g. Glu915 and Cys917. More definitive results for VEGFR
docking studies may be possible as crystal structure data progresses or by refining the
compound test set.

The EGFR docking studies have been able to provide both confirmation and further insight
into the anilinoquinazoline SAR. The quinazoline core sits in the main binding area with
the aniline group reaching back into a hydrophobic pocket. So the larger flexible chains are
well tolerated at the 6 and 7 positions, as they reach along the edge of the binding pocket.
Electron rich groups also work well in these chains, having favourable interactions with
residues such as Gly772 and Cys773. Key interactions between the quinazoline N1 and N3
with Thr766/Gln767/Met769 also appear to be important for binding.
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The EGFR docking results also showed that small substituents (e.g. halogens) interact
positively with residues in the hydrophobic pocket e.g. Lys721/Asp831/Phe832. However,
bulky substituents could prove detrimental as the aniline group is forced out of the
hydrophobic pocket, which may also alter key quinazoline interactions in the main binding
area.

These outcomes were applied during the later stages of synthetic development in this
project, allowing focus on the 3-chloro and 3-bromo substituted fluorine derivatives ([36]
& [37]), rather than pursuing more derivatives with alkyl substituents on the aniline moiety
(e.g. [49]). As the drug design process continues, the insights gained through these
computer-aided techniques will help refine future target compounds.
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Chapter 6: Conclusions & Future Directions

6.1 Conclusions
The development of novel

18

F,

123

I and 11C radiopharmaceuticals [26]-[32] began with the

synthesis of corresponding standards and precursors. Using the Series I and II synthetic
pathways most of the target compounds [13], [36]-[37], [39]-[40], [42]-[48] (Figure 2.2)
were successfully synthesised. New or alternative synthetic schemes were developed where
necessary and some improvements to pre-existing methods were also made.

For the fluorine standards [36]-[37] and corresponding tosyl precursors [39]-[40] produced,
subsequent radiolabelling with

18

F (in optimised conditions using potassium oxalate in

DMA at 150 °C for 5 minutes) gave the radiofluorinated derivatives [26]-[27] in 30-37%
RCY. Biological evaluation started with in vitro testing of the fluorine standards [36]-[37].
Of the seven kinases assayed (EGFR, KDR, Flt1, FGFR1, PDGFRa, IGF1R, Akt1), the
highest percent inhibition was seen for EGFR (100%) and VEGFR (100%: KDR, 85-95%:
Flt1) at 10-5 M. These compounds also displayed selectivity for the target receptors with
average or poor inhibition profiles for the other kinases tested. Further IC50 analysis was
obtained for EGFR, revealing activity of 1.2 nM and 3.4 nM for [36] and [37] respectively.

After the iodine standard [47] and stannane precursor [48] were synthesised, the

123

I

radiotracer [30] was produced via electrophilic radioiodination using chloramine-T in 71%
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RCY (E:Z = 8:1). In vivo evaluation revealed some tumour uptake, with up to 0.7 %ID/g
measured for the biodistribution of trans [30] and tumour to blood ratios consistent for both
isomers (T/B 0.6-0.7). Evidence of in vivo metabolism and deiodination (GIT, thyroid) was
seen, as well as rapid blood clearance.

During the Series I and II syntheses, the carbon standards [13], [42]-[43] and their
deprotected precursors [44]-[45] were successfully produced with a view to producing
radiocarbon derivatives. However, once the chemical synthesis was complete, resources for
11

C labelling couldn't be obtained for this project.

Complimentary structure-based and computer-aided drug design methods revealed more
information about the target RTKs (EGF and VEGF) and predicted binding of ligands/
inhibitors. Alignment, superimposition and analysis of the target RTK crystal structures
highlighted the similarities between their binding sites and key residues involved in
ATP/inhibitor binding (e.g. HRDLAARN catalytic loop).

Using the computer-aided tool, Auto-Dock, simulation and visualisation of predicted
inhibitor binding in both EGFR and VEGFR was carried out. For VEGFR, inhibitor
docking occurred at various positions along the open channel-like binding cleft, although
many shared key binding interactions with residues Glu915 and Cys917. More definitive
conclusions or SAR could not be ascertained from these initial studies in VEGFR (either
due to compound test set or crystal structure resolution).
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The results for EGFR proved very useful, with predicted binding forming consistent
patterns for the test compounds. The main outcomes reflect and build on the established
anilinoquinazoline SAR. The quinazoline core sits in the main binding area (key
interactions occur between the quinazoline N1 and N3 with Thr766/Gln767/Met769), with
the aniline group reaching back into a hydrophobic pocket. Larger flexible chains with
electron rich groups work well at the 6 and 7 positions, as they reach along the edge of the
binding pocket and interact with residues such as Gly772 and Cys773.

The effect of aniline substituents on predicted binding position was of particular interest.
Positive interaction was seen between small substituents (e.g. halogens) and residues in the
hydrophobic pocket e.g. Lys721/Asp831/Phe832. However, when bulky substituents were
introduced the aniline group was forced out of the hydrophobic pocket, changing key
quinazoline interactions in the main binding area and possibly reduced activity.

Due to these discoveries, the docking studies performed on the target iodine [47] and
fluorine derivatives [36]-[37], [49] also helped provide focus during synthetic development,
choosing to pursue 3-chloro and 3-bromo derivatives over those with alkyl substituents on
the aniline moiety. In the EGFR docking studies, the iodine compound [47] with a bulky
aniline substituent did not seem to bind as well. Initial in vivo evaluation of this compound
showed some tumour uptake, however it would not be suitable as a radiotracer. The
strongest results in the EGFR docking studies were obtained for the target fluorine
compounds, which correlated with the in vitro testing results obtained for these compounds
(EGFR IC50 1.2 nM [36]; 3.4 nM [37]).
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6.2 Future Directions
Further biological evaluation of the

18

F and

123

I radiopharmaceuticals synthesised in this

project is required. In vivo PET imaging, biodistribution and metabolite analysis of the
radiofluorinated derivatives [26]-[27] will help to determine their efficacy as
radiopharmaceuticals. More superior in vitro analysis of the iodine compound [47] could
provide further information about binding to EGF and VEGF RTKs and be compared
against predicted binding from docking studies. If better in vitro results are obtained for
VEGFR, [47] could also be evaluated in vivo using a VEGFR tumour model.

Once the resources for

11

C radiolabelling become available, the synthesised standards and

precursors can be utilised to develop these radiopharmaceuticals. This would be followed
by full biological evaluation and analysis including imaging, biodistribution and metabolite
studies. In addition, investigation into the relative amounts of RTK expression in the
tumour model/s used will impact upon the results obtained for all biological studies of the
radiolabelled compounds.

Extension of the CADD studies could provide more information towards the optimisation
GF RTK inhibitors as radiopharmaceuticals. New crystal structures are constantly being
published and these may provide new data for inclusion in docking studies or analysis. For
example, improvements in the resolution of VEGFR crystal structures may lead to more
accurate docking results (this may also be achieved by refining the compound test set). The
availability of EGFR mutant strain crystal structures in more recent years, also opens
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another opportunity for future docking studies and may provide useful data to help develop
inhibitors to combat resistance. As more inhibitor bound crystal structures arise, they can
also be used to validate the predicted binding found in AutoDock studies or to expand
future studies.

Therefore, the EGF and VEGF RTK inhibitors continue to present an opportunity for novel
development of PET and SPECT radiotracers. The availability of new animal models,
improved in vitro binding assays and widespread access to modern small animal imaging
systems will enable the development of improved radiotracers. Refinement and
derivatisation of the inhibitor structure, aided by structure-based drug design techniques,
may result in further 18F and

123

I molecules with improved pharmacokinetic and metabolic

profiles in vivo.
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Chapter 7: Experimental
7.1 Synthesis - General Comments
Starting materials were purchased from Aldrich Chemical Co. Inc, Lancaster and Fluka
and were used as received. For all of the procedures involving petroleum ether, the 60-80
°C BP range was used. Carrier free [123I]NaI in 0.1 M NaOH was obtained from Australian
Radioisotopes, Australia. [18F]HF was produced on a GE PET trace Cyclotron via the
18

O(p, n)18F nuclear reaction (RPAH, Camperdown, Australia).

Proton and carbon nuclear magnetic resonance (NMR) spectra were determined using a
Bruker 400 MHz spectrometer. Spectra were recorded in deuterated dimethylsulfoxide (d6DMSO), unless otherwise specified. Chemical shifts (δ) in parts per million (ppm) were
measured relative to the internal standard (eg d6-DMSO 1H: δ 2.5 ppm,

13

C: δ 39.5 ppm).

Signals are reported as a singlet (s), doublet (d), doublet of doublets (dd), triplet (t), doublet
of triplets (dt) and multiplet (m). Coupling constants were measured in Hertz (Hz).

Chemical ionization (CI), electron impact (EI) and electrospray (ESI) mass spectra were
obtained using either a Shimadzu QP5000, VG Quattro triple quadrupole system or
Autospec high resolution mass spectrometer. Elemental analyses were performed at the
Campbell Microanalytical Laboratory, University of Otago (New Zealand) using a Carlo
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Erba 1106 Elemental Analyser. Melting points were determined in open capillary tubes
using a SRS Optimet automated melting point system, MPA 100 and are uncorrected.

Analytical thin layer chromatography (TLC) was performed on Merck Kieselgel 60 F254
precoated polyester plates with a thickness of 250 μm, with Rf established using an UVlamp at 254 nm. Column chromatography was performed on Merck Kieselgel 60 (220-440
mesh). Chromatography solvents were measured by volume.

High performance liquid chromatography (HPLC) analysis of the iodine-123 product was
performed on an Alltech Econosil semipreparative RP C-18 column using a Waters 510
pump, a Spectrophysics-Linear UV detector set at 254nm and an in-line NaI-Berthold
radioactivity detector. The fluorine-18 product was analyzed by HPLC, consisting of a
Waters 510 pump, a Linear UV-Vis detector (λ = 210 nm) in series with a Berthhold β+flow detector, on a Alltima C18 prep column (250 x 22mm) eluted with 75% ACN 25%
NH4HCO3 (10 mM, pH8) at 10 mL/min. Radioactivity was measured with a Capintec
R15C dose calibrator.

The synthesis of the anilinoquinazoline derivatives for both Series I and Series II are
outlined in the following sections, 7.2 and 7.3. Within each series compounds are presented
in order of synthesis, with references provided for known compounds. Subsequent
radiochemical synthesis and biological evaluation of these compounds is outlined in
Sections 7.4 and 7.5 respectively. Further investigation of these and other known
compounds using computer-aided methods are detailed in Section 7.6.
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7.2 Series I Synthesis
7.2.1 4-Benzyloxy-5-methoxy-2-nitrobenzaldehyde [57] 129
4-Benzyloxy-3-methoxybenzaldehyde [56] (25.0 g, 0.103 mol) was

O
O

H

O

NO2

slowly added to concentrated nitric acid (150 mL, 70%) at 0 °C
over a period of 30 min. The temperature was then brought to 15 °C

over 30 min before being added to ice water. The resulting yellow precipitate was collected
by vacuum filtration to yield 4-benzyloxy-5-methoxy-2-nitrobenzaldehyde [57] (29.4 g,
99%) as a pale yellow powder. Mp 123-130 °C (Lit 123-133 °C)129. 1H NMR (CDCl3), δ
10.44, s, 1H, CHO; 7.67, s, 1H, H3; 7.47-7.36, m, 6H, H6 and Ph; 5.27, s, 2H, CH2O; 4.02,
s, 3H, OMe. 13C NMR, δ 187.6, C=O; 153.6, C4; 151.3, C5; 143.5, C1; 134.8, C2; 128.8,
C3' and C5'; 128.6, C1'; 127.5, C2' and C6'; 125.6, C4'; 109.9, C6; 108.8, C3; 71.5, OCH2;
56.6, OMe. MS ESI- m/z 286 (M-, 10%), 226 (100%). HRMS ESI+ (C15H14NO5) calculated
mass 288.0872, found 288.0867.

7.2.2 4-Benzyloxy-5-methoxy-2-nitrobenzoic acid [58] 129
O
O
O

A hot solution (~60 °C) of 10% KMnO4 (300 mL) was added

OH gradually
NO2

to a solution of 4-benzyloxy-5-methoxy-2-nitro-

benzaldehyde [57] (29.3 g, 0.102 mol) in acetone (300 mL). After

40 min, the insoluble materials were filtered and the filter cake was washed with hot water
(200 mL). The filtrate was reduced in vacuo and the resulting aqueous solution was
acidified with concentrated HCl. Vacuum filtration of the precipitate yielded 4-benzyloxy5-methoxy-2-nitrobenzoic acid [58] (20.8 g, 67%) as a yellow powder. Mp 170-175 °C (Lit
135

163-165 °C)129. 1H NMR (CDCl3), δ 7.45-7.33, m, 6H, H3 and Ph; 7.23, s, 1H, H6; 5.22, s,
2H, CH2O; 3.99, s, 3H, OMe. 13C NMR, δ 172.0, C=O; 152.8, C4; 149.1, C5; 136.2, C2;
128.6, C3' and C5'; 128.1, C1'; 127.2, C2' and C6'; 124.4, C4'; 121.9, C1; 112.7, C3; 112.4,
C6; 70.8, OCH2; 56.0, OMe. MS ESI- m/z 302 (M-, 68%), 258 (95%), 152 (100%). HRMS
ESI+ (C15H14NO6) calculated mass 304.0821, found 304.0821.

7.2.3 4-Benzyloxy-5-methoxy-2-nitrobenzamide [59] 129
A solution of 4-benzyloxy-5-methoxy-2-nitrobenzoic acid [58]
O
O
O

NH2 (12.0 g, 0.039 mol) in SOCl2 (90 mL) was heated at reflux for 22
NO2

hr. After evaporation of SOCl2 under reduced pressure, the

residue was dissolved in dioxane (150 mL). Ammonia gas was slowly bubbled into the
solution for 2 hr. The resulting precipitate was filtered and washed sequentially with water
and isopropanol, then dried under vacuum to yield 4-benzyloxy-5-methoxy-2nitrobenzamide [59] (9.56 g, 80%) as a pale yellow solid. Mp 185-190 °C (Lit 188-190
°C)129. 1H NMR, δ 7.97, s, 1H, NH; 7.68, s, 1H, H3/H6; 7.58, s, 1H, NH; 7.47-7.35, m, 5H,
Ph; 7.12, s, 1H, H6/H3; 5.23, s, 2H, CH2O; 3.91, s, 3H, OMe.

C NMR, δ 167.2, C=O;

13

152.6, C5; 147.6, C4; 139.3, C2; 136.1, C1; 128.6, C1'; 128.2, C3' and C5'; 128.0, C4';
127.3, C2' and C6'; 111.0, C3; 108.8, C6; 70.4, OCH2; 56.5, OMe. MS ESI+ m/z 303 (M-,
20%), 286 (100%). HRMS ESI+ (C15H15N2O6) calculated mass 303.0981, found 303.0994.

136

7.2.4 2-Amino-4-benzyloxy-5-methoxybenzamide [60]
Method 1 129

O
O
O

NH2

A mixture of 4-benzyloxy-5-methoxy-2-nitrobenzamide [59] (2.33

NH2

g, 7.62 mmol) and glacial acetic acid (60 mL) was heated to 90 °C
and Fe powder (2.15 g, 38.5 mmol) was added slowly. After 45 min at 90 °C, the reaction
mixture was filtered and the insolubles were washed with hot acetic acid. The filtrate was
poured into a 10% HCl solution and the resulting precipitate was filtered, slurried in hot
water and made basic with 10% NaOH. The precipitate was collected by vacuum filtration,
washed with isopropanol and dried under vacuum to give 2-amino-4-benzyloxy-5methoxybenzamide [60] (1.36 g, 65%) as a pale yellow solid. Mp 157-158 °C (Lit 157-158
°C)129. 1H NMR, δ 7.45-7.32, m, 6H, H3/H6 and Ph; 7.14, s, 1H, NH; 6.40, s, 1H, NH;
6.38, s, 1H, H6/H3; 5.03, s, 2H, CH2O; 3.68, s, 3H, OMe. 13C NMR, δ 167.3, C=O; 150.1,
C4; 148.4, C5; 136.7, C1; 128.3, C3' and C5'; 127.8, C1'; 127.7, C2' and C6'; 126.8, C4';
120.5, C2; 112.3, C3; 111.1, C6; 69.7, OCH2; 55.5, OMe. MS ESI- m/z 271 (M-, 12%), 93
(100%). HRMS ESI+ (C15H17N2O3) calculated mass 273.1239, found 273.1237.

Method 2
A solution of 4-benzyloxy-5-methoxy-2-nitrobenzamide [59] (10 g, 0.03 mmol) in acetic
acid (100 mL) with a catalytic amount of Pd/C (10%, 1 g) was hydrogenated using 40 psi
H2 for 4 hr. The catalyst was removed by filtration through celite and the acetic acid was
evaporated under vacuum to yield 2-amino-4-benzyloxy-5-methoxybenzamide [60] (7.1 g,
79%) as an orange-yellow solid, which was spectroscopically identical to that reported in
7.2.4 Method 1.
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7.2.5 7-Benzyloxy-4-hydroxy-6-methoxyquinazoline [61] 74,132
OH
O

N

O

N

A mixture of 2-amino-4-benzyloxy-3-methoxybenzamide [60]
(2.16 g, 7.93 mmol) and Gold’s reagent (1.59 g, 9.72 mmol) in
dioxane (25 mL) was heated at reflux for 24 hr with stirring.

Sodium acetate (0.65 g, 7.92 mmol) and acetic acid (0.35 mL, 6.15 mmol) were added and
the reaction was heated for a further 3 hr. The volatile components were removed by
evaporation and water was added to the residue. The resulting solid was collected by
filtration, washed with water and dried under vacuum, yielding 7-benzyloxy-4-hydroxy-6methoxyquinazoline [61] (2.01 g, 90%) as a brown-orange solid. Mp 252-254 °C (Lit 266
°C dec)74. 1H NMR, δ 7.97, s, 1H, H2; 7.49-7.33, m, 6H, H5 and Ph; 7.23, s, 1H, H8; 5.25,
s, 2H, CH2O; 3.88, s, 3H, OMe.
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C NMR, δ 160.1, C4; 153.4, C2; 148.7, C7; 144.7, C6;

143.9, C8a; 136.3, C1'; 128.5, C3' and C5'; 128.1, C4'; 127.9, C2' and C6'; 115.8, C8;
109.3, C5; 105.2, C4a; 70.1, OCH2; 55.8, OMe. MS ESI- m/z 281 (M-, 100%), 113 (23%).

7.2.6 7-Benzyloxy-4-chloro-6-methoxyquinazoline [51]
Cl
O
O

N
N

Method 1 140
7-Benzyloxy-4-hydroxy-6-methoxyquinazoline [61] (1.52 g, 5.39
mmol) in excess POCl3 (20 mL) was heated at reflux for 4 hr. After

cooling to room temperature, excess POCl3 was removed by evaporation and the residue
was dissolved in ethyl acetate and washed with 0.5 M NaOH. The organic fraction was
dried (MgSO4), evaporated and dried under vacuum to yield 7-benzyloxy-4-chloro-6methoxyquinazoline [51] (1.12 g, 69%) as an off white solid. Mp 160-164 °C. 1H NMR
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(CDCl3), δ 8.85, s, 1H, H2; 8.36, s, 1H, H5; 7.50-7.35, m, 6H, H8 and Ph; 5.33, s, 2H,
CH2O; 4.07, s, 3H, OMe. 13C NMR, δ 157.9, C4; 155.6, C7/C2; 152.2, C2/C7; 151.5, C6;
135.7, C1'; 128.6, C3' and C5'; 128.3, C4'; 128.1, C2' and C6'; 118.6, C4a; 108.0, C8;
102.4, C5; 70.6, OCH2; 56.2, OMe. MS ESI+ m/z 301 (M+, 5%), 323 (M++Na, 100%).
HRMS ESI+ (C16H14N2O2Cl) calculated mass 301.0744, found 301.0738.

Method 2 74
A solution of 7-benzyloxy-4-hydroxy-6-methoxyquinazoline [61] (1.26 g, 4.46 mmol) in
SOCl2 (20 mL) and DMF (4 drops) was stirred and heated at reflux for 18 hr. After cooling
to room temperature, excess SOCl2 was removed by evaporation. The residue was triturated
with ether, filtered and dried under vacuum to give 7-benzyloxy-4-chloro-6methoxyquinazoline [51] (1.18 g, 88%) as an orange solid, which was spectroscopically
identical to that reported in 7.2.6 Method 1.

7.2.7 4-Amino-7-benzyloxy-N-(3'-bromophenyl)-6-methoxyquinazoline
[52] 136
6'

O
3"

O

5

4'

Br [51] (15.6 g, 0.052 mol) and 3-bromoaniline (8.41 mL, 0.076

HN
N
N

A mixture of 7-benzyloxy-4-chloro-6-methoxyquinazoline

2

mol) in anhydrous DMF (80 mL) was heated at 80 °C under
N2 for 3 hr. After cooling to room temperature the precipitate

was collected by vacuum filtration, washed with ethyl acetate and dried under vacuum to
give 4-amino-7-benzyloxy-N-(3'-bromophenyl)-6-methoxyquinazoline [52] (16.1 g, 71%)
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as a white solid. Mp 229.7-230 °C. 1H NMR, δ 8.86, s, 1H, H2; 8.39, s, 1H, H5; 8.03, dd, J
= 2.0, 2.0 Hz, 1H, H2'; 7.80-7.77, m, 1H, H4'; 7.55-7.38, m, 8H, H5', H6', H8 and Ph; 5.34,
s, 2H, CH2O; 4.03, s, 3H, OMe.
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C NMR, δ 158.1, C4; 155.2, C2; 150.4, C7; 148.9, C6;

138.7, C1'; 136.0, C8a; 135.3, C1''; 130.6, C5'; 128.7, C3'; 128.6, C3'' and C5''; 128.4, C4'';
128.3, C2'' and C6''; 127.0, C4'; 123.4, C2'; 121.1, C6'; 107.6, C8; 104.2, C5; 101.2, C4a;
70.7, OCH2; 57.1, OMe. MS CI m/z 436 (M+Br79, 10%), 438 (M+Br81, 10%), 268 (71%), 91
(C7H7+, 100%). HR MS CI (C22H19N3O2Br) calculated mass 436.0661, found 436.0665.

7.2.8 4-Amino-7-hydroxy-N-(3'-bromophenyl)-6-methoxyquinazoline
[44] 131,136 ♠
4-Amino-7-benzyloxy-N-(3'-bromophenyl)-6-methoxyquinazoline
HN
O

Br [52] (812 mg, 1.87 mmol) in TFA (15 mL) was heated at reflux for
N

HO

N

45 min. After cooling, the solution was poured onto ice and the

resulting precipitate was collected by vacuum filtration, then dissolved in MeOH and made
basic with NH3. After removal of MeOH, the residue was triturated with water. The
precipitate was collected by vacuum filtration, washed with ether and dried under vacuum
to give 4-amino-7-hydroxy-N-(3'-bromophenyl)-6-methoxyquinazoline [44] (640 mg, 99%)
as a pale yellow solid. Mp 268-268.7 °C. 1H NMR, δ 10.38, s, 1H, OH; 9.46, s, 1H, NH;
8.45, s, 1H, H2; 8.15, dd, J = 2.0, 2.0 Hz, 1H, H2'; 7.90-7.87, m, 1H, H4'; 7.82, s, 1H, H5;
7.35, dd, J = 8.0, 8.0 Hz, 1H, H5'; 7.28-7.25, m, 1H, H6'; 7.08, s, 1H, H8; 3.98, s, 3H,
OMe.
♠

13

C NMR, δ 156.9, C4; 154.3, C2; 150.8, C7; 149.4, C6; 142.0, C8a; 140.2, C1';

Synthesis of [44] is reported131,136 with only minimal spectral provided. The method used here differs
slightly from that reported in the literature.
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130.5, C5'; 127.0, C3'; 125.3, C4'; 121.8, C2'; 121.2, C6'; 107.4, C4a; 106.8, C8; 102.8, C5;
56.4, OMe. MS ESI+ m/z 346 (M+Br79, 100%), 348 (M+Br81, 99%), 268 (11%). HRMS ESI+
(C15H13N3O2Br) calculated mass 346.0191, found 346.0207.

7.2.9 4-Amino-7-(2-hydroxyethoxy)-N-(3'-bromophenyl)-6-methoxy
quinazoline [54]
Method 1
HN
O
HO

O

Br To a mixture of 4-amino-7-hydroxy-N-(3'-bromophenyl)-6N

N

methoxyquinazoline [44] (300 mg, 0.87 mmol) and K2CO3

(359 mg, 2.6 mmol) in anhydrous acetone (15 mL) was added 2-bromoethanol (0.068 mL,
0.95 mmol). After heating at reflux for 28 hr, 2-bromoethanol (0.017 mL, 0.24 mmol) was
added and the mixture was heated at reflux for a further 20 hr. After cooling to room
temperature, acetone was removed by evaporation and the residue was suspended in water
and made neutral using HCl. The precipitate was collected by vacuum filtration and washed
with water and ether. The resulting crude product was chromatographed on a normal phase
silica column (50% ethyl acetate in petroleum ether with gradient elution up to 10%
methanol in ethyl acetate) to yield 4-amino-7-(2-hydroxyethoxy)-N-(3'-bromophenyl)-6methoxyquinazoline [54] (120 mg, 36%) as a white solid. Mp 251.5-252.6 °C. 1H NMR, δ
9.53, s, 1H, NH; 8.52, s, 1H, H2; 8.15, dd, J = 2.0, 2.0 Hz, 1H, H2'; 7.90-7.88, m, 1H,
H4'/H6'; 7.83, s, 1H, H5; 7.36, dd, J = 8.0, 8.0 Hz, H5'; 7.29-7.27, m, 1H, H6'/H4'; 7.22, s,
1H, H8; 4.93, t, J = 5.2 Hz, 1H, OH; 4.17, t, J = 4.8 Hz, 2H, HOCH2CH2O; 3.98, s, 3H,
OMe; 3.80, dt, J = 4.8, 5.2 Hz, 2H, HOCH2CH2O.

C NMR, δ 155.9, C4; 153.8, C7;

13
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152.6, C2; 149.1, C6; 147.0, C1'; 141.3, C8a; 130.3, C5'; 125.5, C4'; 124.0, C2'; 121.2, C3';
120.5, C6'; 108.8, C4a; 107.8, C8; 101.8, C5; 70.4, HOCH2CH2O; 59.2, HOCH2CH2O;
56.1, OMe. MS ESI- m/z 388 (M-Br79, 98%), 390 (M+Br81, 96%). HRMS ESI(C17H15N3O3Br) calculated mass 388.0297, found 388.0297. Elemental Analysis
(C17H16N3O3Br) calculated C, 52.32; H, 4.13; N, 10.77; found C, 52.65; H, 4.09; N, 10.58.

Method 2
A mixture of 4-amino-7-hydroxy-N-(3'-bromophenyl)-6-methoxyquinazoline [44] (1.384 g,
4.0 mmol), 2-bromoethylacetate (0.660 mL, 6.0 mmol), K2CO3 (1.656 g, 12 mmol),
potassium iodide (50 mg, 0.30 mmol) and tetrabutylammonium iodide (55 mg, 0.15 mmol)
in anhydrous DMF (8 mL) was stirred vigorously at room temperature for 40 hr with the
exclusion of light. The mixture was diluted with ethyl acetate (75 mL) and washed (water 6
x 30 mL; brine 20 mL), each wash back extracted with ethyl acetate (30 mL). Evaporation
of the combined organic extracts gave a pale yellow crystalline solid (1.718 g) which was
dissolved in boiling MeOH (40 mL). A solution of K2CO3 (1.10 g, 8.0 mmol) in H2O (20
mL) was added slowly and heating at 70 °C continued for 20 min. After cooling to room
temperature, the precipitate was collected, washed with cold MeOH:H2O (2:1) and dried
under

vacuum

to

yield

4-amino-7-(2-hydroxyethoxy)-N-(3'-bromophenyl)-6-

methoxyquinazoline [54] (1.251 g, 80%) as pale lemon flakes, which was spectroscopically
identical to that reported in 7.2.14 Method 1.
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7.2.10 4-Amino-7-(2-tosylethoxy)-N-(3'-bromophenyl)-6-methoxy
quinazoline [39]
A
HN
O
TsO

O

mixture

of

4-amino-7-(2-hydroxyethoxy)-N-(3'-bromo

Br phenyl)-6-methoxyquinazoline [54] (110 mg, 0.28 mmol) and
N

N

Me2N(CH2)6NMe2 (0.090 mL, 0.42 mmol) in ACN (15 mL)

was heated to approx 80 °C to create a solution. After cooling to room temp, the solution
was placed in an ice water bath and TsCl (81 mg, 0.42 mmol) in ACN (10 mL) was added
dropwise. After stirring for 5 hr, the cooled solution was brought to room temp and stirred
o/n. Water (20 mL) was added to the solution and extracted with ethyl acetate (3 x 20 mL).
The combined organic extracts were dried (MgSO4), evaporated and vacuum dried to give
the crude product. Purification using silica gel chromatography gave 4-amino-7-(2tosylethoxy)-N-(3'-bromophenyl)-6-methoxyquinazoline [39] (46 mg, 30%) as a white
solid. Mp 240-242 °C. 1H NMR, δ 9.55, s, 1H, NH; 8.52, s, 1H, H2; 8.15, dd, J = 2.0, 2.0
Hz, 1H, H2'; 7.91-7.88, m, 1H, H4'; 7.84, s, 1H, H5; 7.82, d, J = 8.0 Hz, 2H, H2'' and H6'';
7.44, d, J = 8.0 Hz, 2H, H3'' and H5''; 7.36, dd, J = 8.0, 8.0 Hz, H5'; 7.30-7.28, m, 1H, H6';
7.17, s, 1H, H8; 4.42-4.37, m, 4H, OCH2CH2Ts; 3.99, s, 3H, OMe; 2.39, s, 3H, TsCH3. 13C
NMR, δ 156.0, C4; 152.7, C7; 152.6, C2; 148.9, C6; 146.8, C1'; 145.0, C4”; 141.2, C8a;
132.1, C1”; 130.4, C5'; 130.1, C3” and C5”; 127.6, C2” and C6”; 125.6, C4'; 124.0, C2';
121.2, C3'; 120.6, C6'; 109.2, C4a; 108.2, C8; 102.1, C5; 68.7, TsOCH2CH2O; 66.1,
TsOCH2CH2O; 56.3, OCH3; 21.0, PhCH3. MS ESI- m/z 542 (M+Br79, 99%), 544 (M+Br81,
100%), 113 (85%). HRMS ESI+ (C24H23N3O5SBr) calculated mass 544.0542, found
544.0546. Elemental Analysis (C24H22N3O5SBr) calculated C, 52.95; H, 4.07; N, 7.72;
found C, 53.24; H, 4.05; N, 8.10.
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7.2.11 4-Amino-7-(2-fluoroethoxy)-N-(3'-bromophenyl)-6-methoxy
quinazoline [36] ∝
Method 1
Br To a mixture of 4-amino-7-hydroxy-N-(3'-bromophenyl)-6-

HN
O
F

O

N
N

methoxyquinazoline [44] (201 mg, 0.58 mmol) and K2CO3 (241

mg, 1.74 mmol) in anhydrous acetone (10 mL) was added 1-bromo-2-fluoroethane (0.048
mL, 0.64 mmol) and the reaction was heated at reflux for 24 hr. After cooling to room
temperature, acetone was removed by evaporation and the residue was suspended in water
and made neutral using HCl. The precipitate was collected by vacuum filtration and washed
with water and ether. The resulting crude product was subject to gravity silica gel column
chromatography (50% ethyl acetate in petroleum ether with gradient elution up to 10%
methanol in ethyl acetate) to yield 4-amino-7-(2-fluoroethoxy)-N-(3'-bromophenyl)-6methoxyquinazoline [36] (32 mg, 14%) as an off white solid. Mp 201 °C. 1H NMR, δ 9.56,
s, 1H, NH; 8.53, s, 1H, H2; 8.15, dd, J = 2.0, 2.0 Hz, 1H, H2'; 7.90-7.88, m, 1H, H4'/H6';
7.86, s, 1H, H5; 7.36, dd, J = 8.0, 8.0 Hz, H5'; 7.29-7.27, m, 1H, H4'; 7.25, s, 1H, H8; 4.83,
dt, JHF = 48 Hz, J = 3.6 Hz, 2H, OCH2CH2F; 4.43, dt, JHF = 30 Hz, J = 3.6 Hz, 2H,
OCH2CH2F; 3.99, s, 3H, OMe.
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C NMR, δ 156.0, C4; 153.1, C2; 152.7, C7; 149.0, C6;

147.0, C1'; 141.2, C8a; 130.4, C5'; 125.8, C3'; 124.0, C4'; 121.1, C2'; 120.7, C6'; 109.1,
C4a; 108.0, C5/C8; 101.95, C8/C5; 81.8, d, JCF = 170 Hz, FCH2CH2O; 67.9, d, JCF = 20
Hz, FCH2CH2O; 56.3, OMe. MS ESI- m/z 390 (M+Br79, 36%), 392 (M+Br81, 35%), 113
(100%). HRMS ESI+ (C17H16N3O2BrF) calculated mass 392.0410, found 392.0421.

∝

Synthesis of [29] is reported104,130,131 with no details of the synthetic route utilised or any spectral data
provided.
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Elemental Analysis (C17H15N3O2BrF) calculated C, 52.06; H, 3.85; N, 10.71; found C,
52.48; H, 3.85; N, 10.54.

Method 2
A mixture of 4-amino-7-hydroxy-N-(3'-bromophenyl)-6-methoxyquinazoline [44] (346 mg,
1.0 mmol), 1-bromo-2-fluoroethane (0.112 mL, 1.5 mmol), K2CO3 (0.414 g, 3 mmol),
potassium iodide (15 mg, 0.09 mmol) and tetrabutylammonium iodide (15 mg, 0.04 mmol)
in anhydrous DMF (2 mL) was stirred vigorously at room temperature for 90 hr with the
exclusion of light. The mixture was diluted with ethyl acetate (12 mL) and washed with
water (5 x 5 mL) and brine (5 mL), Both aqueous layers were backwashed with ethyl
acetate (10 mL) and the combined organic extracts were passed through a 1 cm silica plug
using a Pasteur pipette and the resulting solution evaporated until crystallization started (~5
mL). Further crystallization o/n gave pale yellow fluffy needles of 4-amino-7-(2fluoroethoxy)-N-(3'-bromophenyl)-6-methoxyquinazoline [36] (284 mg, 72%), which was
spectroscopically identical to that reported in 7.2.15 Method 1.

7.2.12 4-Amino-7-benzyloxy-N-(3'-chlorophenyl)-6-methoxy
quinazoline [53] 74
A mixture of 7-benzyloxy-4-chloro-6-methoxyquinazoline [51]
HN
O
O

Cl (10.0 g, 0.033 mol) and 3-chloroaniline (5.25 mL, 0.050 mol)
N

N

in anhydrous DMF (60 mL) was heated at 80 °C under N2 for 1
hr. After cooling to room temperature the precipitate was

collected by vacuum filtration, washed with ethyl acetate and dried under vacuum to give
145

4-amino-7-benzyloxy-N-(3'-chlorophenyl)-6-methoxyquinazoline [53] (10.3 g, 79%) as a
white crystalline solid. Mp 216.7-216.9 °C. 1H NMR, δ 8.87, s, 1H, H2; 8.35, s, 1H, H5;
7.90, dd, J = 2.0, 2.0 Hz, 1H, H2'; 7.73-7.71, m, 1H, H4'; 7.54-7.36, m, 8H, H5', H6', H8
and Ph; 5.34, s, 2H, CH2O; 4.03, s, 3H, OMe. 13C NMR, δ 158.2, C4; 155.3, C2; 150.5, C7;
149.0, C6; 138.6, C1'; 135.9, C8a; 135.3, C1''; 132.9, C3'; 130.4, C5'; 128.7, C3'' and C5'';
128.6, C4''; 128.4, C2'' and C6''; 126.0, C4'; 124.4, C2'; 123.2, C6'; 107.6, C4a; 104.2, C8;
101.2, C5; 70.7, OCH2; 57.1, OMe. MS ESI+ m/z 392 (M+Cl35, 100%), 394 (M+Cl37, 38%).
HRMS ESI+ (C22H19N3O2Cl) calculated mass 392.1166, found 392.1155.

7.2.13 4-Amino-7-hydroxy-N-(3'-chlorophenyl)-6-methoxyquinazoline
[45] 74
4-Amino-7-benzyloxy-N-(3'-chlorophenyl)-6-methoxyquinazoline
HN
O
HO

Cl
N

N

[53] (1.34 g, 3.42 mmol) in TFA (30 mL) was heated at reflux for 2
hr. After cooling, the solution was poured onto ice and the resulting

precipitate was collected by vacuum filtration, then dissolved in MeOH and made basic
with NH3. After removal of MeOH, the residue was triturated with water. The precipitate
was collected by vacuum filtration, washed with ether and dried to give 4-amino-7hydroxy-N-(3'-chlorophenyl)-6-methoxyquinazoline [45] (0.72 g, 69%) as a pale yellow
solid. Mp 130-135 °C. 1H NMR, δ 9.92, s, 1H, NH; 8.57, s, 1H, H2; 7.98, dd, J = 2.0, 2.0
Hz, 1H, H2'; 7.88, s, 1H, H5; 7.77-7.75, m, 1H, H4'; 7.44, dd, J = 8.0, 8.0 Hz, 1H, H5';
7.22-7.19, m, 1H, H6'; 7.12, s, 1H, H8; 3.98, s, 3H, OMe.
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C NMR, δ 156.6, C4; 153.9,

C2; 151.3, C7; 149.2, C6; 143.8, C8a; 140.5, C1'; 132.8, C3'; 130.2, C5'; 123.5, C4'; 122.0,
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C2'; 120.9, C6'; 108.1, C4a; 107.8, C8; 102.6, C5; 56.3, OMe. MS ESI- m/z 300 (M-Cl35,
19%), 302 (M-Cl37, 7%), 113 (100%). HRMS ESI+ (C15H13N3O2Cl) calculated mass
302.0696, found 302.0704.

7.2.14 4-Amino-7-(2-hydroxyethoxy)-N-(3'-chlorophenyl)-6-methoxy
quinazoline [55]
Method 1
HN
O
HO

O

Cl

To a mixture of 4-amino-7-hydroxy-N-(3'-chlorophenyl)-6-

N
N

methoxyquinazoline [45] (350 mg, 1.16 mmol) and K2CO3

(482 mg, 3.49 mmol, 3 eq) in anhydrous acetone (25 mL) was added 2-bromoethanol
(0.092 mL, 1.27 mmol). After heating at reflux for 29 hr, 2-bromoethanol (0.0036 mL, 0.05
mmol) was added and the mixture was heated at reflux for a further 19 hr. After cooling to
room temperature, acetone was removed by evaporation and the residue was suspended in
water and made neutral using HCl. The precipitate was collected by vacuum filtration and
washed with water and ether. The resulting crude product was chromatographed on normal
phase silica column (50% ethyl acetate in petroleum ether with gradient elution up to 10%
methanol in ethyl acetate) to yield 4-amino-7-(2-hydroxyethoxy)-N-(3'-chlorophenyl)-6methoxyquinazoline [55] (82 mg, 25%) as a white solid. Mp 255-257 °C. 1H NMR, δ 9.54,
s, 1H, NH; 8.52, s, 1H, H2; 8.04, dd, J = 2.0, 2.0 Hz, 1H, H2'; 7.84, s, 1H, H5; 7.83-7.80,
m, 1H, H6'; 7.41, dd, J = 8.0, 8.0 Hz, H5'; 7.22, s, 1H, H8; 7.16-7.13, m or ddd, J = 8.0,
2.0, 2.0 Hz, 1H, H4'; 4.94, t, J = 5.2 Hz, 1H, OH; 4.17, t, J = 4.8 Hz, 2H, HOCH2CH2O;
3.98, s, 3H, OMe; 3.81, dt, J = 4.8, 5.2 Hz, 2H, HOCH2CH2O.

C NMR, δ 156.0, C4;
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153.8, C2; 152.6, C7; 149.1, C6; 147.1, C1'; 141.2, C8a; 132.7, C5'; 130.0, C4'; 122.7, C3';
121.2, C2'; 120.1, C6'; 108.9, C8; 107.8, C5; 101.8, C4a; 70.4, HOCH2CH2O; 59.3,
HOCH2CH2O; 56.2, OMe. MS ESI- m/z 344 (M-Cl35, 34%), 346 (M-Cl37, 13%), 113
(100%). HRMS ESI+ (C17H17N3O3Cl) calculated mass 346.0958, found 346.0943.
Elemental Analysis (C17H16N3O3Cl) calculated C, 59.05; H, 4.66; N, 12.15; found C, 59.26;
H, 4.69; N, 11.88.

Method 2
A mixture of 4-amino-7-hydroxy-N-(3'-chlorophenyl)-6-methoxyquinazoline [45] (1.206 g,
4.0 mmol), 2-bromoethylacetate (0.660 mL, 6.0 mmol), K2CO3 (1.656 g, 12 mmol),
potassium iodide (50 mg, 0.30 mmol) and tetrabutylammonium iodide (55 mg, 0.15 mmol)
in anhydrous DMF (8 mL) was stirred vigorously at room temperature for 64 hr with the
exclusion of light. The mixture was diluted with ethyl acetate (75 mL) and washed with
water (6 x 30 mL) and brine (20 mL). Each aqueous layer was back extracted with ethyl
acetate (30 mL). Evaporation of the organic extracts gave a pale yellow crystalline solid
(1.502 g) which was dissolved in boiling MeOH (30 mL) and stirred while a solution of
K2CO3 (1.10 g, 8 mmol) in H2O (15 mL) was added slowly. Boiling was continued for 20
min. After cooling to room temperature, the precipitate was collected, washed with cold
MeOH: H2O (2:1) and dried to yield 4-amino-7-(2-hydroxyethoxy)-N-(3'-chlorophenyl)-6methoxyquinazoline [55] (1.251 g, 80%) as a pale avocado coloured powder, which was
spectroscopically identical to that reported in 7.2.19 Method 1.
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7.2.15 4-Amino-7-(2-tosylethoxy)-N-(3'-chlorophenyl)-6-methoxy
quinazoline [40]
A

TsO

O

of

4-amino-7-(2-hydroxyethoxy)-N-(3'-

Cl chlorophenyl)-6-methoxyquinazoline [55] (70 mg, 0.20

HN
O

mixture

N

mmol) and Me2N(CH2)6NMe2 (0.065 mL, 0.30 mmol) in

N

ACN (15 mL) was heated to 80 °C to create a solution. After cooling and placing the
solution in an ice bath, TsCl (58 mg, 0.3 mmol) in ACN (10 mL) was added dropwise. The
solution was then stirred at room temp o/n. Water (20 mL) was added to the solution and
extracted with ethyl acetate (3 x 20 mL) and washed with brine. The combined organic
extracts were dried (MgSO4), evaporated and vacuum dried to give the crude product.
Purification

using

silica

chromatography

gave

4-amino-7-(2-tosylethoxy)-N-(3'-

chlorophenyl)-6-methoxyquinazoline [40] (58 mg, 58%) as a white solid. Mp 240-242 °C.
1

H NMR, δ 9.57, s, 1H, NH; 8.52, s, 1H, H2; 8.04, dd, J = 2.0, 2.0 Hz, H2'; 7.84, s, 1H,

H5; 7.84-7.81, m, 1H, H4'; 7.82, d, J = 8.0 Hz, 2H, H2'' and H6''; 7.45, d, J = 8.0 Hz, 2H,
H3'' and H5''; 7.42, dd, J = 8.0, 8.0 Hz, 1H, H5'; 7.17, s, 1H, H8; 7.17-7.14, m, 1H, H6';
4.42-4.37, m, 4H, OCH2CH2Ts; 3.98, s, 3H, OCH3; 2.38, s, 3H, TsCH3. 13C NMR, δ 156.0,
C4; 152.7, C7; 152.6, C2; 148.9, C6; 146.8, C1'; 145.0, C4''; 141.1, C8a; 132.7, C3'; 132.1,
C1''; 130.1, C3'' and C5''; 130.0, C5'; 127.6, C2'' and C6''; 122.7, C4'; 121.2, C2'; 120.2,
C6'; 109.2, C4a; 108.2, C8; 102.1, C5; 68.7, OCH2CH2Ts; 66.1, OCH2CH2Ts; 56.3, OMe;
21.0, TsCH3. MS ESI- m/z 498 (M-Cl35, 18%), 500 (M-Cl37, 8%), 113 (100%). HRMS ESI+
(C24H23N3O5SCl) calculated mass 500.1047, found 500.1033. Elemental Analysis
(C24H22N3O5SCl) calculated C, 57.66; H, 4.44; N, 8.40; found C, 57.80; H, 4.39; N, 8.54.
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7.2.16 4-Amino-7-(2-fluoroethoxy)-N-(3'-chlorophenyl)-6-methoxy
quinazoline [37]
Method 1
HN
O
F

O

Cl To a mixture of 4-amino-7-hydroxy-N-(3'-chlorophenyl)-6N

N

methoxyquinazoline [45] (100 mg, 0.33 mmol) and K2CO3 (138

mg, 1.0 mmol) in anhydrous acetone (10 mL) was added 1-bromo-2-fluoroethane (0.027
mL, 0.365 mmol). After heating at reflux for 29 hr, 1-bromo-2-fluoroethane (0.001 mL,
0.013 mmol) was added and the mixture was heated at reflux for a further 19 hr. After
cooling to room temperature, acetone was removed by evaporation and the residue was
suspended in water and made neutral using HCl. The precipitate was collected by vacuum
filtration and washed with water and ether. The resulting crude product was
chromatographed using gravity silica gel column (50% ethyl acetate in petroleum ether
with gradient elution up to 10% methanol in ethyl acetate) to yield 4-amino-7-(2fluoroethoxy)-N-(3'-chlorophenyl)-6-methoxyquinazoline [37] (47 mg, 41%) as a white
solid. Mp 201 °C. 1H NMR (CDCl3), δ 8.69, s, 1H, H2; 7.85, dd, J = 2.0, 2.0 Hz, 1H, H2';
7.58-7.56, m, 1H, H4'/H6'; 7.31, dd, J = 8.0, 8.0 Hz, 1H, H5'; 7.24, s, 1H, H5; 7.14-7.11,
m, 1H, H6'/H4'; 7.06, s, 1H, H8; 4.87, dt, JHF = 48 Hz, J = 4.0 Hz, 2H, OCH2CH2F; 4.39,
dt, JHF = 28 Hz, J = 4.0 Hz, 2H, OCH2CH2F; 3.99, s, 3H, OMe. 13C NMR, δ 155.9, C4;
153.1, C2; 152.6, C7; 148.9, C6; 146.8, C1'; 141.0, C8a; 132.6, C5'; 129.9, C3'; 122.6, C4';
121.1, C2'; 120.1, C6'; 109.1, C4a; 108.0, C5/C8; 101.9, C8/C5; 81.8, d, JCF = 170 Hz,
FCH2CH2O; 67.8, d, JCF = 20 Hz, FCH2CH2O; 56.2, OMe. MS ESI- m/z 346 (M-Cl35, 45%),
348 (M-Cl37, 16%), 113 (100%). HRMS ESI+ (C17H16N3O2ClF) calculated mass 348.0915,
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found 348.0921. Elemental Analysis (C17H15N3O2ClF) calculated C, 58.71; H, 4.35; N,
12.08; found C, 58.98; H, 4.31; N, 11.91.

Method 2
A mixture of 4-amino-7-hydroxy-N-(3'-chlorophenyl)-6-methoxyquinazoline [45] (301.5
mg, 1.0 mmol), 1-bromo-2-fluoroethane (0.112 mL, 1.5 mmol), K2CO3 (0.414 g, 3.0
mmol), potassium iodide (15 mg, 0.09 mmol) and tetrabutylammonium iodide (15 mg, 0.04
mmol) in anhydrous DMF (2 mL) was stirred vigorously at room temperature for 42 hr
with the exclusion of light. The mixture was diluted with ethyl acetate (12 mL) and washed
with water (5 x 5 mL) and brine (5 mL). Both aqueous layers were backwashed with ethyl
acetate (10 mL) and the combined organic extracts were passed through a 1 cm silica plug
(Pasteur pipette). The resulting solution was then evaporated to give a pale green solid,
which was recrystallised from ethyl acetate to yield 4-amino-7-(2-fluoroethoxy)-N-(3'chlorophenyl)-6-methoxy quinazoline [37] (226 mg, 65%) as pale yellow fluffy needles,
which was spectroscopically identical to that reported in 7.2.21 Method 1.

7.2.17 4-Amino-7-benzyloxy-N-(3'-ethynylphenyl)-6-methoxy
quinazoline [62]
A mixture of 7-benzyloxy-4-chloro-6-methoxyquinazoline
HN
O
O

[51] (0.39 g, 1.30 mmol) and 3-ethynylaniline (0.21 mL,
N

N

0.235 g, 2.01 mmol) in anhydrous DMF (15 mL) was heated
at 80 °C under N2 for 1 hr. After cooling to room

temperature the precipitate was collected by vacuum filtration and washed with ethyl
151

acetate to give 4-amino-7-benzyloxy-N-(3'-ethynylphenyl)-6-methoxyquinazoline [62]
(0.41 g, 83%) as a white solid. Mp 253 °C. 1H NMR, δ 8.83, s, 1H, H2; 8.33, s, 1H, H5;
7.88, s, 1H, H2'; 7.80-7.77, m, 1H, H4'; 7.54-7.39, m, 8H, H5', H6', H8 and Ph; 5.34, s, 2H,
CH2O; 4.29, s, 1H, C≡CH; 4.02, s, 3H, OMe. 13C NMR, δ 158.1, C4; 155.1, C2; 150.4, C7;
149.2, C6; 137.5, C1'; 135.4, C8a; 129.5, C1''; 129.3, C5'; 128.7, C3'' and C5''; 128.5, C4'';
128.4, C2'' and C6''; 127.5, C3'; 125.2, C4'; 122.1, C2'; 115.7, C6'; 107.6, C4a; 104.0, C8;
101.6, C5; 83.0, C≡CH; 81.4, C≡CH; 70.7, OCH2; 57.0, OMe. MS ESI+ m/z 382 (M+,
100%), 123 (10%). HRMS ESI+ (C24H20N3O2) calculated mass 382.1556, found 382.1551.

7.2.18 1-[3-(7-Hydroxy-6-methoxy-quinazolin-4-ylamino)-phenyl]ethanone [64]
A

solution

of

4-amino-7-benzyloxy-N-(3'-ethynylphenyl)-6-

methoxyquinazoline [62] (420 mg, 1.1 mmol) in TFA (10 mL)
was heated at reflux for 45 min. After cooling, the solution was
poured onto ice and the resulting precipitate was collected by vacuum filtration, then
dissolved in MeOH and made basic with NH3. After the removal of MeOH, the residue was
triturated with water. The precipitate was collected by vacuum filtration, washed with ether
and dried under vacuum to give 1-[3-(7-hydroxy-6-methoxy-quinazolin-4-ylamino)phenyl]-ethanone [64] (240 mg, 75%) as a pale yellow solid. 1H NMR, δ 10.49, bs, 1H,
OH; 9.72, s, 1H, NH, 8.46, s, 1H, H2; 8.29, t, J = 2.0 Hz, 1H, H2'; 8.20, d, J = 8.0 Hz, 1H,
H6'; 7.88, s, 1H, H5; 7.74, d, J = 8.0 Hz, 1H, H6'; 7.55, t, J = 8.0 Hz, 1H, H5', 7.09, s, 1H,
H8; 3.99, s, 3H, OMe; 2.62, s, 3H, COMe. 13C NMR, δ 198.4, C=O; 156.9, C4; 153.7, C2;
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152.8, C7; 149.4, C6; 146.8, C1'; 140.5, C8a; 137.7, C5'; 129.4, C3'; 127.4, C4'; 124.0, C2';
121.7, C6'; 110.2, C4a; 108.7, C8; 102.9, C5; 56.8, OMe; 27.4, COMe. MS ESI+ m/z 310
(M+, 100%).

7.3 Series II Synthesis
7.3.1 6,7-Dimethoxy-4-hydroxyquinazoline [66] 131
OH
O
O

N
N

2-Amino-4,5-dimethoxybenzoic acid [65] (12.27 g, 0.062 mol) in
formamide (100 mL) was heated at 150 °C for 24 hr with stirring. After

cooling to room temperature, the precipitate was collected by filtration, washed with water
and dried under vacuum to give 6,7-dimethoxy-4-hydroxyquinazoline [66] (5.88 g, 46%) as
a dark brown solid. Mp 280-294 °C (Lit 270-298 °C). 1H NMR, δ 7.97, s, 1H, H2; 7.43, s,
1H, H8/H5; 7.12, s, 1H, H5/H8; 3.90, s, 3H, OMe; 3.87, s, 3H, OMe.

13

C NMR, δ 160.0,

C4; 154.4, C2; 148.5, C7; 144.8, C6; 143.8, C8a; 115.6, C4a; 108.0, C8; 104.9, C5; 55.9,
OMe; 55.7, OMe. MS ESI- m/z 205 (M-, 7%), 113 (100%). HRMS ESI+ (C10H11N2O3)
calculated mass 207.0770, found 207.0698.

7.3.2 4-Chloro-6,7-dimethoxyquinazoline [67] 74
Cl
O
O

N
N

A solution of 6,7-dimethoxy-4-hydroxyquinazoline [66] (1.02 g, 4.95 mol)
in SOCl2 (15 mL) and DMF (2 drops) was heated at reflux for 4 hr with

stirring. After cooling to room temperature, excess SOCl2 was removed by evaporation and
the residue was triturated with ether. The solid was collected by vacuum filtration and dried
to yield 4-chloro-6,7-dimethoxyquinazoline [67] (0.92 g, 83%) as a brown solid. Mp 181-
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184 °C (Lit 184-186 °C)9. 1H NMR, δ 9.04, s, 1H, H2; 7.48, s, 1H, H8/H5; 7.41, s, 1H,
H5/H8; 3.93, s, 3H, OMe; 3.91, s, 3H, OMe. 13C NMR, δ 157.8, C4; 156.7, C2; 152.2, C7;
151.4, C6; 148.6, C8a; 118.6, C4a; 106.9, C8; 102.2, C5; 56.5, OMe; 56.2, OMe. MS ESI+
m/z 225 (M-Cl35, 100%), 227 (M-Cl37, 36%). HRMS ESI+ (C10H10N2O2Cl) calculated mass
225.0431, found 225.0421.

7.3.3 4-Amino-N-(3'-ethynylphenyl)-6,7-dimethoxyquinazoline [43]
A mixture of 4-chloro-6,7-dimethoxyquinazoline [67] (0.598 g,
HN
O
O

N
N

2.66 mmol) and 3-ethynylaniline (0.419 mL, 0.469 g, 4.02 mmol)
in anhydrous DMF (25 mL) was heated at 80 °C under N2 for 1 hr.

After cooling to room temperature the precipitate was collected by vacuum filtration and
washed with ethyl acetate to give 4-amino-N-(3'-ethynylphenyl)-6,7-dimethoxy quinazoline
[43] (0.766 g, 94%) as a white solid. Mp 207 °C. 1H NMR, δ 8.86, s, 1H, H2; 8.36, s, 1H,
H5; 7.88, s, 1H, H2'; 7.78, d, J = 8.0 Hz, 1H, H6'; 7.50, t, J = 8.0 Hz, 1H, H5'; 7.41, d, J =
8.0 Hz, 1H, H4'; 7.37, s, 1H, H8; 4.27, s, 1H, C≡CH; 4.02, s, 3H, OMe; 4.00, s, 3H, OMe.
C NMR, δ 158.2, C4; 156.4, C2; 150.2, C7; 148.7, C6; 137.3, C8a; 129.3, C1'; 129.2, C5';
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127.6, C4'; 125.3, C6'; 122.0, C2'; 107.4, C4a; 104.0, C8; 99.8, C5; 99.1, C3'; 82.9, C≡CH;
81.3, C≡CH; 57.0, OMe; 56.5, OMe. MS ESI- m/z 304 (M-, 14%), 113 (100%). HRMS ESI+
(C18H16N3O2)

calculated

mass

306.1243,

found

306.1238.

Elemental

Analysis

(C18H15N3O2) calculated C, 70.81; H, 4.95; N, 13.76; found C, 70.57; H, 5.07; N, 13.48.
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7.3.4 4-Amino-N-(3'-tributylstannylethenylphenyl)-6,7-dimethoxy
quinazoline [48]
To
HN
O
O

Sn(Bu)3

a

mixture

of

4-amino-N-(3'-ethynylphenyl)-6,7-

dimethoxyquinazoline [43] (0.398 g, 1.30 mmol) and n-

N
N

Bu3SnH (0.52 mL, 1.93 mmol) in anhydrous dioxane (5

mL) was added a catalytic amount of AIBN (20 mg). The reaction mixture was heated at 80
°C under N2 for 4.5 hr. An additional amount of n-Bu3SnH (0.05 mL, 0.19 mmol) and
AIBN (~10 mg) was then added to the solution and heating at 80 °C under N2 continued for
18.5 hr. One additional aliquot of n-Bu3SnH (0.05 mL, 0.19 mmol) was then added to the
solution with heating at 80 °C under N2 continuing for a further 5 hr. After cooling to room
temperature, dioxane was removed under reduced pressure. The resulting crude product
was subjected to silica gel column chromatography (30% ethyl acetate in petroleum ether
with gradient elution up to 100% ethyl acetate) to yield the cis/trans product, 4-amino-N(3'-tributylstannylethenylphenyl)-6,7-dimethoxyquinazoline [48] (0.604 g, 78%) as a
yellow solid. 1H NMR, δ 9.50, s, 1H, NH; 8.47, s, 1H, H2; 7.88, s, 1H, H2'; 7.85, s, 1H,
H5; 7.78, d, J = 8.0 Hz, 1H, H6'; 7.50, dd, J = 8.0, 8.0 Hz, 1H, H5'; 7.41, d, J = 8.0 Hz, 1H,
H4'; 7.19, s, 1H, H8; 6.88, d, 1H, HC=CH; 6.78, d, 1H, HC=CH; 3.93, s, 3H, OMe; 3.92, s,
3H, OMe; 1.53, m, 6H, Sn(CH2CH2CH2CH3)3; 1.31, m, 6H, Sn(CH2CH2CH2CH3)3; 0.97,
m, 6H, Sn(CH2CH2CH2CH3)3; 0.88, t, J = 8.0 Hz, 9H, Sn(CH2CH2CH2CH3)3. MS ESI+ m/z
596 (M+Sn116, 82%), 598 (M+Sn118, 100%).
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7.3.5 4-Amino-N-(3'-iodoethenylphenyl)-6,7-dimethoxyquinazoline [47]
To a solution of 4-amino-N-(3'-tributylstannylethenylanilino)-6,7HN
O
O

I
N

N

dimethoxyquinazoline [48] (60 mg, 0.1 mmol) in CHCl3 (5 mL),
a solution of I2 (32 mg, 0.13 mmol) in CHCl3 (7 mL) was added

dropwise. The solution was stirred at room temperature under N2 for 4 hr. The reaction
mixture was extracted with a solution of Na2S2O5 (480 mg) in water (12 mL) and the
chloroform extract was evaporated under vacuum. The resulting crude product was
chromatographed using a gravity silica gel column (30% ethyl acetate in petroleum ether
with gradient elution up to 100% ethyl acetate) to yield 4-amino-N-(3'-iodoethenylphenyl)6,7-dimethoxyquinazoline [47] (32 mg, 74%) as a white solid (E:Z = 6:1). HPLC (eluted
with: 70% ACN, 20% H2O, 10% NH4HCO3 at 15 mL/min) was used to isolate a small
amount of the cis and trans isomers. 1H NMR (CDCl3), δ 8.68, s, 1H, H2; 7.70, s, 1H, H2';
7.62-7.60, m, 1H, H6'; 7.46, d, J = 14 Hz, 1H, Ar-CH=CH-I (trans); 7.43, d, J = 5.0 Hz,
1H, Ar-CH=CH-I (cis); 7.37, t, J = 8.0 Hz, 1H, H5'; 7.28, s, 1H, H5; 7.17, bs, 1H, NH;
7.10, d, J = 8.0 Hz, 1H, H4'; 7.03, s, 1H, H8; 6.89, d, J = 14 Hz, 1H, Ar-CH=CH-I (trans);
6.63, d, J = 5.0 Hz, 1H, Ar-CH=CH-I (cis); 4.03, 2x s, 6H, 2x OMe. MS ESI+ m/z 434 (M+,
100%). HRMS ESI+ Trans (C18H17N3O2I) calculated mass 434.0366, found 434.0374. Cis
(C18H17N3O2I) calculated mass 434.0366, found 434.0341.
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7.3.6 4-Amino-N-(3'-hydroxyphenyl)-6,7-dimethoxyquinazoline [68]
A mixture of 4-chloro-6,7-dimethoxyquinazoline [67] (1.46 g,
OH 6.50 mmol) and 3-hydroxyaniline (1.08 g, 9.88 mmol) in

HN
O
O

N

anhydrous DMF (70 mL) was heated at 80 °C under N2 for 1 hr.

N

After cooling to room temperature the precipitate was collected by vacuum filtration and
washed

with

ethyl

acetate

to

give

4-amino-N-(3'-hydroxyphenyl)-6,7-dimethoxy

quinazoline [68] (1.51 g, 78%) as a pale yellow solid. Mp 265-267 °C. 1H NMR, δ 11.23, s,
1H, OH; 9.73, bs, 1H, NH; 8.80, s, 1H, H2; 8.28, s, 1H, H5; 7.25, d, J = 8.0 Hz, 1H, H5';
7.23, s, 1H, H8; 7.13, s, 1H, H2'; 7.09, d, J = 8.0 Hz, 1H, H4'; 6.74, d, J = 8.0 Hz, 1H, H6';
4.01, s, 3H, OMe; 3.99, s, 3H, OMe. 13C NMR, δ 158.1, C4; 157.7, C2; 156.2, C7; 150.2,
C6; 148.5, C8a; 137.7, C3'; 135.5, C1'; 129.3, C5'; 115.5, C6'; 113.5, C4'; 112.0, C2';
107.2, C4a; 104.0, C8; 99.7, C5; 56.9, OMe; 56.4, OMe. MS ESI+ m/z 298 (M+, 100%).
HRMS ESI+ (C16H16N3O3) calculated mass 298.1192, found 298.1205.

7.3.7 4-Amino-N-(3'-(2-hydroxyethoxy)phenyl)-6,7-dimethoxy
quinazoline [69]
To
HN
O
O

O

a

mixture

of

4-amino-N-(3'-hydroxyphenyl)-6,7-

OH

dimethoxyquinazoline [68] (150 mg, 0.52 mmol) and K2CO3

N
N

(210 mg, 1.56 mmol) in anhydrous acetone (10 mL) was

added 2-bromoethanol (71 mg, 0.041 mL, 0.57 mmol). The mixture was heated at reflux for
48 hr. After cooling to room temperature, acetone was removed by evaporation and the
residue was suspended in water and made neutral using HCl. The precipitate was collected
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by vacuum filtration and washed with water and ether. The resulting crude product was
chromatographed on a normal silica column (50% ethyl acetate in petroleum ether with
gradient elution up to 10% methanol in ethyl acetate) to yield 4-amino-7-(2-fluoroethoxy)N-(3'-bromophenyl)-6-methoxyquinazoline [69] as an off white solid (77 mg, 43%). Mp
206-208 °C. 1H NMR, δ 9.49, s, 1H, NH; 8.50, s, 1H, H2; 7.99, dd, J = 2.0, 2.0 Hz, 1H,
H2'; 7.92-7.89, m, 1H, H4'; 7.83, s, 1H, H8; 7.41, dd, J = 8.0, 8.0 Hz, 1H, H5'; 7.22-7.20,
m, 2H, H6' and H5; 4.19, s, 1H, OH; 3.97, s, 3H, OMe; 3.94, s, 3H, OMe. 13C NMR, δ
156.1, C4; 154.3, C2; 152.7, C7; 149.0, C6; 147.0, C8a; 139.8, C3'; 128.9, C1'; 126.3, C5';
124.7, C6'; 122.5, C4'; 121.7, C2'; 108.9, C4a; 107.2, C8; 101.8, C5; 83.5, HOCH2CH2O;
80.5, HOCH2CH2O; 56.2, OMe; 55.8, OMe. MS ESI- m/z 340 (M-, 100%), 113 (77%).
HRMS ESI+ (C18H16N3O2) calculated mass 342.1454, found 342.1459.

7.3.8 4-Amino-N-(3'-bromophenyl)-6,7-dimethoxyquinazoline [13]131 ♣
A mixture of 4-chloro-6,7-dimethoxyquinazoline [67] (0.41 g, 1.83
HN
O
O

Br

mmol) and 3-bromoaniline (0.35 mL, 3.21 mmol) in anhydrous

N
N

DMF (20 mL) was heated at 80 °C under N2 for 1 hr. After cooling

to room temperature the precipitate was collected by vacuum filtration and washed with
ethyl acetate to give 4-amino-N-(3'-bromophenyl)-6,7-dimethoxyquinazoline as a white
solid [13] (0.14 g, 21%), which was spectroscopically identical to that reported in
literature.140 1H NMR, δ 8.87, s, 1H, H2; 8.40, s, 1H, H5; 8.02, s, 1H, H2'; 7.79-7.77, m,

♣

Synthesis of [13] has been reported.131,140 The method used here differs slightly from that reported in the
literature and has not been optimised.

158

1H, H6'; 7.50-7.48, m, 1H, H4'; 7.43, dd, J = 8.0, 8.0 Hz, 1H, H5'; 7.36, s, 1H, H8; 4.02, s,
3H, OMe; 3.98, s, 3H, OMe.

7.3.9 4-Amino-N-(3'-chlorophenyl)-6,7-dimethoxyquinazoline [42]
A mixture of 4-chloro-6,7-dimethoxyquinazoline [67] (0.193 g,
HN
O
O

Cl 0.859 mmol) and 3-chloroaniline (0.14 mL, 0.170 g, 1.33 mmol) in
N

N

anhydrous DMF (10 mL) was heated at 80 °C under N2 for 1.5 hr.

After cooling to room temperature the precipitate was collected by vacuum filtration and
washed with ethyl acetate to give 4-amino-N-(3'-chlorophenyl)-6,7-dimethoxy quinazoline
[42] (0.221 g, 81%) as a white solid. Mp 230-239 °C (Lit 230-235 °C)9. 1H NMR, δ 8.88, s,
1H, H2; 8.39, s, 1H, H5; 7.91, s, 1H, H2'; 7.73, d, J = 8.0 Hz, 1H, H6'; 7.51, dd, J = 8.0,
8.0 Hz, 1H, H5'; 7.38-7.36, m, 2H, H8 and H4'; 4.03, s, 3H, OMe; 4.00, s, 3H, OMe. 13C
NMR, δ 158.1, C4; 156.4, C2; 150.3, C7; 148.9, C6; 138.6, C8a; 132.8, C1'; 130.3, C3' and
C5'; 125.9, C4'; 124.3, C2'; 123.1, C6'; 107.4, C4a; 103.9, C8; 100.0, C5; 57.0, OMe; 56.5,
OMe. MS ESI- m/z 316 (M-Cl35, 100%), 318 (M-Cl37, 67%). HRMS ESI+ (C16H15N3O2Cl)
calculated mass 316.0853, found 316.0864.

7.4 Radiochemical Synthesis
The following iodine and fluorine radiochemical derivatives were synthesised from the
stannane [48] and tosylate precursors [26], [27] prepared in Section 7.2.
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7.4.1 4-Amino-N-(3'-[123I]iodoethenylphenyl)-6,7-dimethoxy
quinazoline [30]
To
I

HN
O

N

O

a

solution

of

4-amino-N-(3'-tributylstannyl

123

ethenylphenyl)-6,7-dimethoxyquinazoline [48] (0.25 mg) in
ethanol (200 μl) was added 15 mCi (100 μl) of sodium

N

[123I]iodide, chloramine-T solution (100 μl, 2 mg/ml) and 0.1 M HCl (100 μl). The reaction
mixture was shaken and left to react for 5 min before quenching with Na2S2O5 solution
(100 μl, 50 mg/ml) and neutralising with NaHCO3 solution (100 μl, 50 mg/ml). The
reaction mixture was then purified by reverse phase HPLC using 45% acetonitrile: 55% 0.1
M ammonium acetate as the eluent at a flow rate of 3 mL/min. Under these conditions the
radiolabelled product, 4-amino-N-(3'-[123I]iodoethenylphenyl)-6,7-dimethoxyquinazoline
[30] eluted at retention times of 18 and 24 minutes for the

cis and trans isomers

respectively, giving an overall radiochemical yield of 71% (E:Z = 8:1). Specific activity
was greater than 2500 Ci/mmol (92 GBq/mmol) – limit of detection.

7.4.2 4-Amino-7-(2-[18F]fluoroethoxy)-N-(3'-bromophenyl)-6methoxyquinazoline [26]
Multiple methods were used for the labeling of [39]. General
HN
O
O

experimentals are given below, followed by all reaction details

N

18

F

Br

N

in Table 7.1 including solvent, base and temperature variations

and corresponding yields. The identity of the labeled compound was confirmed by injection
with the standard compound [36] (50 μl) on HPLC using the same conditions.
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Table 7.1: Reaction conditions and radiochemical yields for the synthesis of [26]
Method
1
2
3a
3b
4a
4b
4c
4d

Precursor
> Product
[39] > [26]
[39] > [26]

Rxn
Solvent
ACN
DMF

K2CO3
K2CO3

Temp
(°C)
100
150

[39] > [26]

DMA

K2C2O4

150

[39] > [26]

DMA

K2C2O4

160

Base

Collected Yield (% RCY)
5 min
10 min 15 min
0
1.5
2.9
3.3
3.7
30
28
22
33.66
31.22
15.78
25.1
24.2
23.1
24.2
15.6
8
9
3
9
8
10

Method 1 An aqueous H[18F] fluoride solution (22.5 mCi, 400 μl) was added to a 10 mL
round bottom vial containing a solution of K2.2.2 (ACN) and K2CO3 (H2O). The solvent was
evaporated under a stream of nitrogen at 100 °C under vacuum. This azeotropic drying was
performed three times with anhydrous ACN (3 x 1 mL). The tosylate precursor [39] (2 mg)
was dissolved in ACN (0.5 mL) and added to the dried K2.2.2.K2CO3.KF complex. The
reaction mixture was heated at 100 °C for 15 min. Aliquots were taken from the reaction
mixture (100 μl) at 5 and 15 min intervals and combined with H2O (300 μl) before being
injected onto the HPLC (eluted with: 75% ACN 25% NH4HCO3 (10 mM, pH8) at 10
mL/min). Very low to nil radiochemical yields (RCY) of [26] were obtained for both time
points under these conditions (See Table 7.1).

Method 2 As stated in Method 1, except dimethylformamide (DMF) was used as the
solvent and the reaction temperature was 150 °C.

Method 3 An aqueous H[18F] fluoride solution (8.1 mCi, 100 μl) was added to a 10-mL
round bottom vial containing a solution of K2.2.2 (ACN) and K2C2O4 sol (H2O). The solvent
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was evaporated under a stream of nitrogen at 95 °C under vacuum. This azeotropic drying
was performed three times with anhydrous ACN (3 x 1 mL). The tosylate precursor [39] (2
mg) was dissolved in DMA (0.5 mL) and added to the dried K2.2.2.K2C2O4.KF complex.
The reaction mixture was heated at 150 °C for 15 min. Aliquots were taken from the
reaction mixture (100 μl) at 5, 10 and 15 min intervals and combined with H2O (300 μl)
before being injected onto the HPLC (eluted with: 75% ACN 25% NH4HCO3 (10 mM,
pH8) at 10 mL/min). Yields for [26] were between 30-34% RCY (slightly lower at 15 min
time point), which greatly improved on other methods used (Table 7.1).

Method 4 As stated in Method 3, except the reaction temperature was 160 °C.

Specific activity for the radiofluorination reactions ranged from 1500-3100 Ci/mmol (55115 GBq/mmol) depending on the source and availability of [18F]fluorine.

7.4.3 4-Amino-7-(2-[18F]fluoroethoxy)-N-(3'-chlorophenyl)-6methoxyquinazoline [27]
Multiple methods were used for the labeling of [40]. General
HN
O

N

18

F

O

Cl experimentals are given below, followed by all reaction details

N

in Table 7.2 including solvent, base and temperature variations

and corresponding yields. The identity of the labeled compound was confirmed by injection
with the standard compound [37] (50 μl) on HPLC using the same conditions, RT at 10.6
mins.
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Table 7.2: Reaction conditions and radiochemical yields for the synthesis of [27]
Method
1a
1b
2
3a
3b
3c
4a
4b
4c
5a
5b
5c
5d

Precursor
> Product

Rxn
Solvent

Base

Temp
(°C)

[40] > [27]

DMF

K2CO3

150

[40] > [27]

DMF

K2C2O4

150

[40] > [27]

DMA

K2CO3

160

[40] > [27]

DMA

K2C2O4

150

[40] > [27]

DMA

K2C2O4

160

Collected Yield (% RCY)
5 min
10 min 15 min
4.6
4.4
5.8
0
25.2
35
35
41
13.5
14
15.5
11.7
7.8
5
36.9
28.7
27.6
25.2
36.9
28.7
27.7
38.2
34.6
32.6
29
29
18.7
24.8
12.5

Method 1 An aqueous H[18F] fluoride solution (17.4 mCi, 300 μl) was added to a 10 mL
round bottom vial containing a solution of K2.2.2 (ACN) and K2CO3 (H2O). The solvent was
evaporated under a stream of nitrogen at 100 °C under vacuum. This azeotropic drying was
performed three times with anhydrous ACN (3 x 1 mL). The tosylate precursor [40] (2 mg)
was dissolved in DMF (0.5 mL) and added to the dried K2.2.2.K2CO3.KF complex. The
reaction mixture was heated at 150 °C for 15 min. Aliquots were taken from the reaction
mixture (100 μl) at 5, 10 and 15 min intervals and combined with H2O (300 μl) before
being injected onto the HPLC (eluted with: 75% ACN 25% NH4HCO3 (10 mM, pH8) at 10
mL/min). Under these conditions, poor results were obtained for the synthesis of [27] with
only 0-6% RCY.

Method 2 As stated in Method 1, except potassium oxalate (K2C2O4) was used as the base.
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Method 3 An aqueous H[18F] fluoride solution (17.4 mCi, 300 μl) was added to a 10-mL
round bottom vial containing a solution of K2.2.2 (ACN) and K2CO3 (H2O). The solvent was
evaporated under a stream of nitrogen at 100 °C under vacuum. This azeotropic drying was
performed three times with anhydrous ACN (3 x 1 mL). The tosylate precursor [40] (2 mg)
was dissolved in DMA (0.5 mL) and added to the dried K2.2.2.K2CO3.KF complex. The
reaction mixture was heated at 160 °C for 15 min. Aliquots were taken from the reaction
mixture (100 μl) at 5, 10 and 15 min intervals and combined with H2O (300 μl) before
being injected onto the HPLC (eluted with: 75% ACN 25% NH4HCO3 (10 mM, pH8) at 10
mL/min). Yields of [27] much higher compared with previous reaction using DMF at a
slightly lower temp (see Method 1 – Table 7.2).

Method 4 As stated in Method 3, except potassium oxalate (K2C2O4) was used as the base
and the reaction temperature was 150 °C.

Method 5 An aqueous H[18F] fluoride solution (31.1 mCi, 400 μl) was added to a 10 mL
round bottom vial containing a solution of K2.2.2 (ACN) and K2C2O4 (H2O). The solvent
was evaporated under a stream of nitrogen at 100 °C under vacuum. This azeotropic drying
was performed three times with anhydrous ACN (3 x 1 mL). The tosylate precursor [40] (2
mg) was dissolved in DMA (0.5 mL) and added to the dried K2.2.2.K2C2O4.KF complex.
The reaction mixture was heated at 160 °C for 15 min. Aliquots were taken from the
reaction mixture (100 μl) at 5, 10 and 15 min intervals and combined with H2O (300 μl)
before being injected onto the HPLC (eluted with: 75% ACN 25% NH4HCO3 (10 mM,
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pH8) at 10 mL/min). Higher yields were obtained when K2C2O4 was used as the base
instead of K2CO3, producing [27] at 30-38% RCY.

Specific activity for the radiofluorination reactions ranged from 1500-3100 Ci/mmol (55115 GBq/mmol) depending on the source and availability of [18F]fluorine.

7.5 Biological Evaluation
The radiopharmaceuticals synthesised in Section 7.4 and their equivalent standards (Section
7.3) underwent in vivo and in vitro evaluation. All experimental procedures were performed
in compliance with the NHMRC Australian Code of Practice for the care and use of
animals for scientific purposes. Details of these studies are outlined in the following
sections.

7.5.1 Rat Tumour Development for Iodine-123 in vivo Studies
The 13762 MAT cell line was established from a transplantable rat ascites tumour derived
from a solid mammary adenocarcinoma. The cells were grown aseptically in the laboratory
and harvested just prior to injection. After washing and counting, the cells were
resuspended in phosphate buffered saline.

Female Fischer-344 rats were purchased from Animal Resources Centre, Western
Australia. The rats were anaesthetised using isoflurane via inhalation from an MIDGET 3
anaesthetic apparatus with vapouriser. They were then shaved on the left shoulder and
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injected into the sub-scapular region with 1x106 13762 MAT cells in 100 μL volume per
rat. After injection rats were returned to their cage and observed until they recover from
anaesthesia. The tumour was allowed to develop for 13-14 days before imaging and
biodistribution studies. During tumour development rats were observed daily, weighed
twice a week to monitor any change in body weight and the tumour measured. Throughout
the experimental period the rats were housed under constant environmental conditions and
were allowed free access to food and water.

7.5.2 Iodine-123 Imaging Studies
On the day of imaging, 100 μl of the radiotracer [30] was injected into the lateral tail vein
which had been warmed in 40 °C water for one minute. The radiotracer activity for imaging
was 100-200 μCi (3.7-7.4 MBq) in 100 μl saline. The activity was selected to maximise the
activity in the tumour while trying to minimise the activity in the liver and other target
organs. Planar imaging was performed on a GE Starcam Imaging System.

Anaesthesia was induced and maintained via inhalation of isofluorane (as in Section 7.5.1).
After the rat was anaesthestised it was then positioned on the Gamma Camera and an image
accumulated. For tumour imaging, anaesthesia was established for periods of 20 min to 1
hour over a 48 hour period. During this time rats were monitored continuously for the
pattern and depth of respiration and the colour of mucus membranes, ears, muzzle and
footpads were noted. Depth of anaesthesia was assessed by pedal reflex (pinching the
interdigital skin). Rats were insulated to minimise heat loss by wrapping in "bubble
packing". Eyes were kept moist with ophthalmic lubricant (Lacry-lube). Between imaging
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and for recovery the rat was placed in a cage on a heating pad in a quiet area. Rats were
humanely sacrificed via CO2 administration after image acquisition was complete. The
acquisition times for each of the rat images are outlined in Table 7.3:

Table 7.3: Rat Imaging Acquisition Times for trans [30]


 




 




 







   

 


 

 
 
 


 

 
 
 


 

 
 
 

 
 































7.5.3 Biodistribution Studies
The in vivo biodistribution studies were conducted in Female Fischer-344 rats that had been
transplanted with 13762 MAT mammary adenocarcinoma derived tumours on the left
shoulder as outlined in Section 7.5.2. Twenty eight rats (weighing between 155-200 g each)
were used, 20 for the trans [30] studies and 8 for the cis [30]. Each rat was injected with
180-200 μCi of the radiolabelled compound [30], via the tail vein after placing the tail in
warm water. At time points of 15 min, 1, 3, 6 and 24 h post injection, 4 rats were sacrificed
by CO2 administration. The rats were weighed before the removal and weighing of 16
organs, including liver, spleen, kidney, muscle, skin, lungs, heart, blood, bladder, stomach,
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GIT, tail, brain, thyroid, pancreas, thymus and the tumour. An automated gamma counter
was used to measure the amount of radioactivity in each organ and the percent injected
dose (%ID) was calculated against a diluted solution of the initial injected dose. The weight
of each tissue or organ excised was also accounted to give the relative density of
radioactivity for each organ (%ID/g).

7.5.4 In Vitro Testing
To determine the in vitro affinity and selectivity of the target compounds synthesized
testing was carried out at Caliper Life Sciences, USA. Initial screening of the
radiopharmaceutical standards [36], [37], [42], [43], [47] tested the percent inhibition in a
radioligand EGF binding assay.

Subsequent testing of [36] and [37] evaluated enzyme activity in seven different kinases
including EGFR, Flt1 (VEGFR1), KDR (VEGFR2), FGFR1, PDGFRa, IGF1R and Akt1.
Results were given as percent inhibition at concentrations of 10-5 and 10-7 M. Since both
derivatives [36] and [37] provided almost 100% inhibition of the EGFR kinase at each
concentration, IC50 values were also determined. The IC50 was calculated by evaluating and
graphing 10-12 inhibition values between concentrations of 10-5 and 10-11 M, then the value
required to achieve 50% inhibition could be measured from the graph.



Initial screening was conducted at Novascreen, which has changed to Caliper LS in more recent years.145
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7.6 Computer-Aided Drug Design Methods
Analysis of the EGF and VEGF receptor structure and binding interactions through
computer-aided methods are outlined below.

7.6.1 General Comments
The three-dimensional X-ray crystal structures (1M14, 1M17, 1XKK, 1Y6A and 1Y6B)
and their atomic co-ordinates were obtained from the RCSB Protein Data Bank. The
BUILDER module of InsightII® was used to construct and manipulate enzyme structures,
then docking simulations were carried out with the AutoDock 3.0.5 suite. Experiments
using InsightII® and AutoDock164,172 were performed on Silicon Graphics O2 workstations
(MIPS R12000, 270 MHz processor with 384 Mb RAM).

Visualisation and analysis of docking simulation results were performed using Accelrys DS
ViewerPro and DS Visualizer173 on PC. ProFlex, a program developed in-house, was used
to calculate difference distance matrices (DDMs) for different X-ray crystal structures of
EGFR and VEGFR using either Cα atoms or all atoms. This evaluation also determined the
best crystal structure candidates, 1M17 (EGFR) and 1Y6B (VEGFR), for use in docking
experiments.

Clustal W structure analysis was carried out according to the EBI tools instructions.ƒ
Briefly, the EGFR and VEGFR sequences to be aligned had to be submitted in one of the
following valid formats (GCG, FASTA, EMBL, GenBank, PIR, NBRF, PHYLIP or
ƒ

Clustal W 2.0 now available, however previous version 1.83 was used in this project) 174
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UniProtKB/Swiss-Prot). The UniProtKB/TrEMBL database provided the EGFR (P00533)
and VEGFR2 (P35968) sequences.175,176 Once these sequences had been uploaded to the
webform,177 the job was submitted using the default settings including slow, but accurate
alignment.

7.6.2 Preparation of Ligands and RTKs for AutoDock Experiments
The EGF and VEGF RTKs used in docking experiments were prepared from X-ray crystal
structures (pdb files) by deleting bound ligands and any irrelevant water molecules ie those
not situated within the key binding area. The ligands were either sourced from their X-ray
crystal structures or built and modified using the BUILDER module of InsightII® by
deleting atoms from an already existing ligand structure.

A forcefield was applied to the prepared ligands, and the potential of each atom assigned
(using the FF → Potentials menu in InsightII®). After checking the assigned potentials of
the ligand (Molecule → Label), these were compared to expected atom type potentials in
the Discover 2.9/95.0/3.0.0 Forcefields Simulations User Guide, Part 1. Minimisation of the
ligands were performed (Optimise tab) to determine their lowest energy conformation and
then saved as either a mol2 or pdb file.

7.6.3 AutoDock Experiments using AutoDock Tools
AutoDock Tools (ADT) provides a user interface for the preparation and docking of ligands
to X-ray crystal structures of receptors/enzymes. To open AutoDock Tools a unix shell was
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used with the command line: adt. Conversion of the receptor/enzyme pdb to a pdbqs file via
the addition of Kollman charges and solvation parameters is required for Autodock as
outlined in the ADT tutorial. However, contrary to the tutorial instructions, both of the
Kollman charges and solvation parameters needed to be added manually. Each ligand was
prepared according to the procedure in the ADT tutorial with the ligand being saved as a
pdbq file. Once written as a pdbq, the ligand was deleted, and the pdbq reloaded in the
window.

7.6.4 AutoDock and AutoGrid Parameters
The receptor/enzyme (pdbqs) was uploaded to the same window as the ligand (pdbq) and a
grid positioning file (gpf) was prepared following the procedure outlined in the ADT
tutorial. The AutoGrid coordinates for the structures used in docking experiments were
centered at: ϒ
1M17 (21.697, 0.303, 52.093);
1Y6B (-0.41, 29.192, 18.754);
A grid spacing of 0.375 Å and 50 x 50 x 50 grid points were used, incorporating a total
volume of 18.75 x 18.75 x 18.75 Å3. Electrostatic grid maps were subsequently generated
for each atom type in the ligand using the auxillary program AutoGrid3, and used as a
reference for the docking simulations. Initially, problems were encountered during the
generation of atom maps for some ligands, as they exceeded the maximum number of atom
types. AutoGrid and AutoDock were only set up for 6 atom types eg Carbon, Aromatic,

ϒ

The grid was often set to 'center on ligand' in docking experiments, but only when these centre co-ordinates
corresponded to those given above (within ~1 grid point) for the receptor structure involved in docking.

171

Hydrogen, Nitrogen, Oxygen and Sulphur OR a Halogen (X). Most RTK ligands used in
these docking experiments contained multiple halogens or both sulphur and a halogen.
Therefore, a method for increasing the number of atom types for AutoGrid and AutoDock
was eventually sourced: Within the autocomm.h source code, '#define ATOM_MAPS' was
changed from 6 to 14, before recompiling both AutoGrid and AutoDock. After this, all test
ligands could be successfully docked without error.

Docked conformations were generated using the Lamarckian genetic algorithm (LGA).
Global optimisation began with a population of 50 individuals and a maximum of 1 x 106
energy evaluations. A maximum of 27000 generations were produced with a total 250
docking runs (ga runs) performed. The remaining parameters were maintained at AutoDock
3.0.5 defaults, with the elitism value (number of top individuals that automatically
survived) set to 1. The average of the worst energy was calculated over a window of 10
previous generations and the rate of crossover was 0.8. The rate at which random gene
mutation occurred was 0.02, the mean of Cauchy distribution for gene mutation was zero,
and the variance of Cauchy distribution for gene mutation was 1.0. The local search (LS)
employed the pseudo-Soils Wets method, with a maximum of 300 iterations and 50 LS
runs. The maximum number of consecutive successes or failures before halving or doubling
the local step size (ρ) was four. The Soils and Wets parameter defining the initial variance
and size of the local space to be sampled was 1.0, and the termination criterion was 0.01.
The probability of any particular phenotype being subjected to a local search was 0.06.
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For the dock options, the platform independent library was utilised as the random number
generator. The energy parameter for the external grid energy was 1000.0 kcal mol-1, the
maximum allowable initial energy was 0.0 kcal mol-1, the maximum number of retries was
1000, and the internal electrostatic energy was not calculated. The step size parameter for
translation was 2.0 Å per step, and the quaternion and torsion were both set at 50° per step.
The root-mean-squared deviation (RMSD) was set at either 1.5 Å or 2.0 Å for all ligands
docked.

7.6.5 Post-Docking Analysis of EGFR and VEGFR binding sites
On completion of the docking experiments, cluster analysis was conducted with ADT
(Analyse → Clusterings → Show Clusterings). The RMSD was set to 1.0 Å since the
ligands used were all relatively small molecules. Within the highest populated clusters the
lowest energy conformations were saved as a pdf, to be used for analysis and visualisation
of the surface docking experiments with DS Viewer Pro or DS Visualizer.173 Ligandreceptor interactions were determined manually, with the exception of hydrogen bonding
which was calculated up to 3.5 Å. Solid surfaces were represented as solvent accessible
surfaces with a probe radius of 1.4 Å.
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Appendix

Compound No
[36]
[37]
[42]
[43]
[47]

% Inhibition EGF at 10-5 (Average, N=2)
-46.33
-42.51
-46.18
-45.02
-43.32

Appendix 1: EGF Binding Assay. Preliminary in vitro testing of compounds [36], [37], [42], [43] and [47]
which only measured extracellular binding, not intracellular kinase activity of EGFR. Assay performed by
Novascreen.

Appendix 2: Proflex Sequence Alignment of EGFR vs VEGFR. Darkest shading = exact residue match,
Lighter shades = similar amino acid residues in alignment. Note: common HRDLAARN section in catalytic
loop was not aligned using this method (Row 4, Residues 140-151).
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Appendix 3: Calibration of VEGFR docking using 1Y6B and oxazole 46 [71]. For this receptor all water
molecules were removed while preparing the crystal structure for docking, as they were not significant to
binding.
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CLUSTERING HISTOGRAM for [36]
_____|___________|_____|___________|_____|____:____|____:____|____:____|____:___
Clus | Lowest | Run | Mean
| Num | Histogram
-ter | Docked | | Docked | in |
Rank | Energy | | Energy | Clus| 5 10 15 20 25 30 35
_____|___________|_____|___________|_____|____:____|____:____|____:____|____:___
1 | -9.79 | 127 | -9.74 | 4 |****
2|

-9.57 | 175 |

-9.57 | 1 |*

3|

-9.38 | 66 |

-9.38 | 1 |*

4|

-9.34 | 42 |

-9.19 | 64 |****************************************************************

5 | -9.29 | 117 | -9.19 | 147
|*****************************************************************************************************************************
**********************
6|

-9.27 | 53 |

-9.27 | 1 |*

7|

-9.25 | 21 |

-9.25 | 1 |*

8|

-9.24 | 70 |

-9.24 | 1 |*

9|

-9.23 | 97 |

-9.09 | 14 |**************

10 |

-9.11 | 233 |

-9.11 | 1 |*

11 |

-9.10 | 96 |

-9.05 | 7 |*******

12 |

-9.06 | 232 |

-9.03 | 2 |**

13 |

-8.95 | 120 |

-8.95 | 1 |*

14 |

-8.95 | 46 |

-8.95 | 1 |*

15 |

-8.89 | 151 |

-8.89 | 1 |*

16 |

-8.89 | 31 |

-8.89 | 1 |*

17 |

-8.86 | 90 |

-8.86 | 1 |*

18 |

-8.83 | 181 |

-8.83 | 1 |*

Appendix 4: Example of Docking Results a) [36] docked into EGFR.
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CLUSTERING HISTOGRAM for [47]
_____|___________|_____|___________|_____|____:____|____:____|____:____|____:___
Clus | Lowest | Run | Mean
| Num | Histogram
-ter | Docked | | Docked | in |
Rank | Energy | | Energy | Clus| 5 10 15 20 25 30 35
_____|___________|_____|___________|_____|____:____|____:____|____:____|____:___
1 | -8.63 | 54 | -8.63 | 1 |*
2 | -8.60 | 169 | -8.43 | 129
|*****************************************************************************************************************************
****
3|

-8.55 | 38 |

-8.53 | 2 |**

4|

-8.51 | 65 |

-8.33 | 22 |**********************

5|

-8.48 | 12 |

-8.38 | 6 |******

6|

-8.45 | 59 |

-8.35 | 5 |*****

7|

-8.43 | 170 |

-8.43 | 1 |*

8|

-8.41 | 209 |

-8.24 | 4 |****

9|

-8.35 | 94 |

-8.04 | 8 |********

10 |

-8.32 | 39 |

-8.32 | 1 |*

11 |

-8.30 | 53 |

-8.09 | 4 |****

12 |

-8.24 | 139 |

-8.16 | 4 |****

13 |

-8.24 | 74 |

-8.24 | 1 |*

14 |

-8.23 | 89 |

-8.19 | 2 |**

15 |

-8.21 | 93 |

-8.06 | 8 |********

16 |

-8.19 | 133 |

-8.09 | 3 |***

17 |

-8.19 | 73 |

-7.94 | 3 |***

18 |

-8.18 | 148 |

-8.11 | 6 |******

19 |

-8.17 | 234 |

-8.10 | 3 |***

20 |

-8.11 | 232 |

-8.11 | 1 |*

21 |

-8.09 | 195 |

-7.99 | 2 |**

22 |

-8.06 | 160 |

-8.06 | 1 |*

23 |

-8.05 | 19 |

-8.05 | 2 |**

24 |

-8.04 | 141 |

-8.04 | 1 |*

25 |

-8.00 | 71 |

-7.94 | 4 |****

26 |

-7.99 | 156 |

-7.84 | 2 |**

27 |

-7.98 | 68 |

-7.88 | 3 |***
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28 |

-7.95 | 218 |

-7.89 | 2 |**

29 |

-7.92 | 173 |

-7.92 | 1 |*

30 |

-7.87 | 104 |

-7.87 | 1 |*

31 |

-7.77 | 200 |

-7.77 | 1 |*

32 |

-7.75 | 187 |

-7.75 | 1 |*

33 |

-7.74 | 184 |

-7.74 | 1 |*

34 |

-7.71 | 145 |

-7.71 | 1 |*

35 |

-7.69 | 162 |

-7.69 | 1 |*

36 |

-7.68 | 143 |

-7.68 | 1 |*

37 |

-7.67 | 128 |

-7.67 | 1 |*

38 |

-7.61 | 222 |

-7.61 | 1 |*

39 |

-7.60 | 56 |

-7.60 | 1 |*

40 |

-7.53 | 111 |

-7.53 | 1 |*

41 |

-7.48 | 177 |

-7.48 | 1 |*

42 |

-7.48 | 80 |

-7.48 | 1 |*

43 |

-7.37 | 100 |

-7.37 | 1 |*

44 |

-7.32 | 217 |

-7.32 | 1 |*

45 |

-7.15 | 57 |

-7.15 | 1 |*

46 |

-6.78 | 171 |

-6.78 | 1 |*

47 |

-6.64 | 144 |

-6.64 | 1 |*

Appendix 4: Example of Docking Results b) [47] docked into VEGFR.
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